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Summary 
Type I hypersensitivities are mediated by the IgE antibody.  The effector functions and synthesis 
of IgE result from interactions with a network of proteins that include a high affinity (Fc RIα) 
and a low affinity (CD23, Fc RII) Fc receptor in conjunction with the B lymphocyte receptor, 
CD21.  CD23 is a multifunctional type II transmembrane protein that binds its known ligands 
through its ectodomain either as a membrane-bound or soluble receptor generated in vivo by 
specific proteolytic cleavages.  IgE production is primarily regulated by interactions between 
IgE, CD23 and CD21.  Despite its importance for development of strategies to limit 
hypersensitivity, precise information about the molecular interactions remains limited.  During 
this study, I engineered, expressed and purified from bacteria three soluble human CD23 
fragments that are normally formed in vivo and shed from the cell surface (1) derCD23, amino 
acids 156-298 (2) sCD23, amino acids 150-321 and (3) the entire ectodomain, exCD23, amino 
acids 48-321 to examine the comparative binding of recombinant human CD21 SCR 1-2 and 
native human IgE to these fragments.  Gel filtration HPLC revealed that derCD23 and sCD23 
were monomeric whereas exCD23 assembled as a heterogeneous mixture that included trimers 
and monomers.  At the concentrations utilized, CD23 fragments sCD23 and exCD23 bound 
CD21 with similar affinity, whereas interaction between derCD23 and CD21 was minimal when 
analyzed by surface plasmon resonance (SPR) spectroscopy.  These findings suggest that 
penultimate “tail” amino acids between 298 and 321 stabilize CD21 attachment, although it 
cannot be ruled out, the region between Met 
150
 and Ser 
156
 may also play a role in binding CD21 
SCR 1-2.  In contrast, there is a progressive increment in the affinity of soluble fragments 
(exCD23>sCD23>derCD23) for IgE, upon increasing length of the proximal CD23 “stalk” 
domain.  
These findings highlight the differences in both the structural basis and affinity of the three 
physiological fragments of human CD23 for the ligands CD21 and IgE and underscore the 
complexity of CD23-mediated regulatory networks.    
It was found that B-cells only make up ~5% of the PBMC population, and that these cells were 
able to be activated, via STAT-6 phosphorylation, to enter class switch recombination (CSR) by 
the addition of switch factors (IL-4 and anti-CD40).   
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Titration experiments dictated that 25 ng/mL of CD23 was the most efficient concentration to 
up-regulate IgE synthesis in PBMCs; furthermore, soluble CD23 proteins were incubated with 
PBMCs in the presence and absence of CD21 SCR 1-2 to investigate the effect that these 
recombinant proteins have on IgE synthesis.    
Results showed that the influence of recombinant proteins (both CD23 and CD21) on IgE 
synthesis was slight.  It was shown that while derCD23 had no significant effect, monomeric 
sCD23 down-regulated, and the mixture of monomeric and oligomeric exCD23 up-regulated IgE 
synthesis.  On addition of CD21 SCR 1-2 to the cells switched and treated with soluble CD23, it 
was found that in both cases for sCD23 and exCD23, IgE synthesis was increased, while for 
derCD23, there was no noticeable difference in IgE synthesis.  This confirmed previous data 
showing the lack of binding between derCD23 and CD21 SCR 1-2. 
The exact binding site for CD21 on the CD23 molecule is unknown, and incompletely 
represented in the NMR and crystal structures.  It is thought that CD21 binds to the C-terminal 
tail section, not present in derCD23.  It is therefore likely that only a negative-feedback 
mechanism operates with derCD23 to regulate IgE synthesis.  Further investigation of the 
binding of CD23 fragments to SCR 5-8 of CD21 and the effect of this on IgE synthesis may lead 
to a potential therapeutic role for derCD23 in the treatment of allergic disease.  Data accumulated 
in this study suggests that investigating the modulation of oligomeric state and thus the activity 
of soluble CD23 fragments may be important in the construction of new regulators of IgE 
synthesis. 
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1. Chapter 1:  Literature review 
The world is being seized by an allergic epidemic.  Allergy is not just a condition or a set of 
symptoms that make you sneeze and itch, but a disease that could stop you breathing altogether. 
It is often not appreciated how serious it can be.  The morbidity associated with atopy is high and 
it requires large quantities of costly medication which relieve only the symptoms and have no 
effect on the underlying immune disorder (Smith et al., 1997).  Atopic diseases such as asthma, 
rhinitis, eczema, and food allergies have increased in most industrialized countries of the world 
over the last 20 years (Miescher and Vogel, 2002).  Where 50 years ago 1 in 30 were affected, it 
is said that now 1 in 3 people in the population suffers from allergies (Gould and Sutton, 2008) 
and that 20% of the population worldwide is susceptible to atopic disease (Romagnani, 1997).    
The reason for this increase is not known; it is one of modern medicine‟s greatest puzzles, 
although diverse hypotheses have been suggested.  
Forty years ago, scientists thought the answer to atopy lay almost 3000 km from any other land 
mass.  Tristan da Cunha is the most remote inhabited island in the world, where half of its 301 
residents suffer from asthma, giving it the highest prevalence of the disease anywhere in the 
world (Zamel, 1995).  Air pollution is non-existent on the island as there is no industry and the 
winds are so strong that the air is pristine and pure.  Therefore, the high prevalence of asthma 
must be at least partially, genetic.  Genealogy tests done by Zamel (2005) showed that the level 
of inbreeding is so high that all the islanders are cousins, in some instances 50 times over.  
Because of the size of the population, Zamel (1995) isolated a particular gene, known as ESE3.  
This gene is involved in deposition of collagen in the airways, and if the gene is disrupted, the 
airway walls are thickened and constricted, making it more difficult to breathe.  Although the 
discovery in Tristan da Cunha is exceptional, it does not explain the allergy explosion in the rest 
of the world.  Central to our understanding of allergic disease is the dissection of the chronology 
of events, as there is a general acknowledgment that most atopic disorders originate in childhood, 
and when a child inherits a certain characteristic, it may or may not result in susceptibility to 
allergic disorders (Miescher and Vogel, 2002).  However, the striking increase in atopy cannot 
simply be attributed to the improved diagnostic techniques of today or the increased awareness 
of the general public.  After birth there are increased external influences that must be taken into 
account for cause and effect phenomena to try and explain the epidemic of allergy.   
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Outdoor air pollution at levels occurring in many urban areas around the world has substantial 
adverse effects on health in general, and a growing number of studies also show that children 
living in environments near traffic have increased risks of new-onset asthma and asthma related 
symptoms.  Criteria pollutants include ozone, nitrogen oxides such as nitrogen dioxide, and 
respired particulate matter (Gilliland, 2009).  These particles can be inhaled, and are deposited in 
the lungs, coated with metals and other toxic chemicals, and can then reside in the lung and 
produce adverse effects.  In a study to directly assess the impact of particulate air pollution, it 
was found that diesel exhaust increased the allergic response of allergen 20-fold.  The emerging 
data shows air pollution does indeed cause asthma and allergy as well as exacerbating it once 
you already have those conditions (Gilliland, 2009).   
Netherton syndrome is a rare autosomal recessive genodermatosis characterized by chronic skin 
inflammation, resulting in scaling and exfoliation, predisposing patients to life-threatening 
infections, sepsis and dehydration.  Mutations of both copies of the Spink5 gene, which encodes 
the serine protease inhibitor lymphoepithelial Kazal-type-related inhibitor (LEKTI) have been 
identified as causative (Chavanas et al., 2000).  Patients with Netherton syndrome are also at risk 
to a wide range of allergies and are highly allergic.  This finding led to a recent study linking 
allergy and the skin barrier (Namazi, 2007), which may shed light on why allergies are on the 
rise in the developed world.  From a time 50 or 60 years ago when we had a bath maybe once a 
week, our current population baths almost daily, using various products, some very strong 
detergents and rough exfoliating agents.  These hygiene habits can result in damage to the skin 
barrier and increased exposure to allergens.          
From investigations on the island of Barbados where the rate of increase in allergies is most 
extreme (~1000-fold during the 1990s) Kathleen Barnes believes that the modern home 
contributes a variety of factors, such as indoor carpeting and better upholstered furniture which 
increase exposure to allergens such as dust mites.  Barnes goes on to explain that “allergies are 
the price we pay for our modernization over time” (Barnes and Marsh, 1998).   
It is said that there is an imbalance of evolutionary function of immunoglobulin E (IgE) with 
modern lifestyle when looking back into our ancient past that perhaps holds the answer.  In 
certain parts of rural Africa there was no asthma or allergic disease at all and when those same 
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people modernised or moved out of rural Africa into the urban setting, asthma and allergic 
disease appeared suddenly.  IgE is thought to have evolved in mammals as the first line of 
defence against parasites (Thornton et al., 2003), but the benefit of this defence is largely 
overshadowed by the cost.  IgE is the antibody in our immune system that is specifically 
involved in allergic disease and asthma, but it did not evolve because of asthma and allergies.  It 
initially had a protective mechanism against parasitic worms that caused diseases like ascaris and 
schistosomiasis.  In rural Africa, which was endemic for these parasites, the local populations 
produce high IgE levels, even once removed from their environment.  What evolved to protect us 
in one type of environment has now become a liability (Harris et al., 1978). 
In summary, atopic disease consists of multi-factorial determinants influencing its development.  
Current thinking tries to relate genetic predisposition, and cause and effect, to environmental 
changes and habits related to different lifestyles resulting in either enhancement or protection 
from allergic disease, as illustrated in figure 1.   
 
Figure 1:  Allergic sensitization and positive feedback.  The interaction of genes and environmental factors 
determine the risk of allergic sensitization (Gould and Sutton, 2008).  This figure shows some of the genes in 
which polymorphisms are directly involved in the synthesis or effector functions of IgE.  Equally, there are many 
environmental factors involved in allergy.  These include the exposure to allergens, the way  in which food is 
processed (Maleki et al., 2000), elevated pH of the stomach contents of the foetus and young babies, or caused 
by antacid medications in adults, atmospheric pollution (Diaz-Sanchez et al., 1994), respiratory syncytial virus 
and rhinovirus infections during infancy, infections generating superallergenic enterotoxins, and the activity of 
autoantibodies.   
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The immune system, although principally protective, often is the cause of human disease, called 
hypersensitivities.  The Gell and Coombs classification delineates 4 types of hypersensitivity 
reaction.  Hypersensitivity disorders often involve more than one type though (Gell and Coombs, 
1963). 
Type I hypersensitivity, or allergy, is the clinical manifestation of an immune response against 
foreign molecules commonly known as allergens, which are potent inducers of IgE synthesis 
(Gould and Sutton, 2008; Holgate and Polosa, 2008).  Type I reactions underlie atopic disorders 
(e.g. allergic asthma).   
Type II reactions result when antibody binds to cellular or tissue antigens or to a molecule 
coupled to a cell or tissue.  The antigen-antibody complex activates cells that participate in 
antibody-dependent cell-mediated cytotoxicity [e.g. Natural Killer (NK) cells, eosinophils, 
macrophages], complement, or both (Black, 1999).  Type II reactions include hyper-acute graft 
rejection of an organ transplant. 
Type III reactions cause acute inflammation in response to circulating antigen-antibody immune 
complexes deposited in vessels or tissue.  These complexes can activate the complement system 
or bind to and activate certain immune cells, resulting in release of inflammatory mediators.  
Type III disorders include serum sickness and rheumatoid arthritis (Rajan, 2003).      
Type IV reactions are T cell-mediated.  There are 4 subtypes based on the T-cell subpopulation 
involved: IVa, type 1 helper T-cells; IVb, type 2 helper T-cells; IVc, cytotoxic T-cells; and IVd, 
IL-8-secreting T-cells.  These cells, sensitized after contact with a specific antigen, are activated 
by re-exposure to the antigen; they damage tissue by direct toxic effects through release of 
cytokines, which activate eosinophils, monocytes and macrophages, neutrophils, or killer cells 
depending on type (Rajan, 2003).  Disorders involving type IV reaction include contact 
dermatitis (e.g. poison ivy). 
Allergic reactions consist of a series of events that start with recognition of the native allergen 
structure by antigen presenting cells, such as dendritic cells (DC), and culminate in IgE antibody 
production, mast cell sensitization and triggering (figure 2).  It is, as yet, unknown whether there 
is any molecular similarity between various antigens; however, it is difficult to imagine how 
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such relatively diverse biochemical activities could all lead to the polarization of T helper (Th) 
cells towards Th2 subtype cells and subsequent IgE synthesis. 
Seasonal allergies are believed to share a unique mechanism of disease which involves the 
binding of IgE antibodies to surface receptors present on a wide variety of cells, most 
importantly mast cells and eosinophils (figure 2).  An allergic reaction is initiated when antigen 
crosslinks IgE antibodies bound to their high-affinity Fc receptor (FcεRI) on tissue mast cells or 
blood basophils.  The immediate reaction, taking effect within minutes of allergen provocation, 
results in the release of mediators that lead to symptoms characteristic of the target organ.  A 
late-phase response associated with the influx of T-cells, monocytes, and eosinophils may ensue 
some hours later (Gould et al., 2003).  Hayfever, asthma, reactions to food, and eczema are the 
most common allergic responses caused by mast cell activation in mucosal tissues of, 
respectively, the nose, lung, gut and skin.  Blood basophils are the IgE effector cells in the rare, 
but more dangerous, manifestations of systemic anaphylaxis (Gould et al., 2003). 
These type I hypersensitivity reactions include weal and flare eruptions of the skin and sneezing, 
rhinorrhoea and conjunctival irritations.  More serious conditions such as asthma and 
anaphylaxis are believed to share a similar pathogenesis (Corry and Kheradmand, 1999). 
 
Figure 2:  The classic pathway for the allergic cascade.  Allergen recognition and processing by antigen 
presenting cells leads to Th2 polarization, IL-4 production and subsequent switching to IgE synthesis by B-cells.  
The binding of secreted IgE to mast cells and eosinophils via specific Fc receptors (i.e. FcεRI) and subsequent 
cross linking of receptor-bound IgE by allergen triggers the release of mediators and the onset of allergy.  Taken 
from Corry and Kheradmand (1999).   
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1.1 IgE and its receptors 
IgE occurs only in mammals and elicits a range of cellular responses to antigens, culminating in 
anatomical and physiological changes which exclude parasites from the body.  IgE has been 
implicated in allergic diseases, in specific bacterial, fungal and parasitic infections, graft-versus-
host diseases and in a few primary immunodeficiency syndromes (Gould et al., 2003).  IgE plays 
an important role in the allergic response.  An allergic reaction is however, not a „normal‟ 
immune reaction, it is the oversensitivity of IgE against potentially non-harmful antigens, 
allergens (Sutton and Gould, 1993).     
IgE is the least abundant antibody class in serum, and its concentration reflects the number of 
circulating B-cells committed to IgE synthesis (Gould et al., 2003).  However, in certain parasitic 
diseases and in the hyper-IgE syndrome, serum IgE concentrations may be up to three orders of 
magnitude higher than normal without signs of allergic disease.  In some individuals with hay 
fever or asthma IgE antibodies are detectable only in secretions from the target organ (Gould et 
al., 2003).  IgE concentrations in the circulation may reach over 10 times the normal level in 
“atopic” individuals, who have an increased risk of developing allergies.  Allergen specific IgE 
antibody concentrations are generally more closely correlated with symptoms and may be over 
1000 times higher than the minimal level of detection found in the majority of healthy subjects.  
IgE is characterized by ε heavy-chains, which contain one variable H-domain (VH) and four 
constant-domains (Cε 1-4), therefore an additional C-domain in comparison to IgG (figure 3). 
 
Figure 3: The domain structures of IgE and IgG.  Schematic representation of the polypeptide and domain 
structures of human IgE and IgG1.  Illustrated are inter- and intra-domain disulfide bridges and the sites for N-
linked glycosylation.  Taken from Gould and Sutton (2008). 
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Initially, it was thought that the „extra‟ Cε2 domain pair might simply act as a spacer between the 
antigen-binding fragment (Fab) „arms‟ and the Cε3-Cε4 part of the crystallisable fragment (Fc) 
region, but further studies determined that the distance between the N-and C-termini of the 
molecule was less than half that expected for an extended Y-shaped structure.  When the crystal 
structure of the complete IgE-Fc, including the Cε2 domains (figure 4), was determined  (Zheng 
et al., 1991), the molecule was found to be even more acutely bent than had been anticipated, 
with the Cε2 domains folded back and making extensive contact with the Cε3 domains, and even 
touching the Cε4 domains (Wan et al., 2002).  Cε2 in IgE is a critical determinant in its 
distinctive physical properties and isotype-specific functions (Gould et al., 2003).  Comparison 
of crystal structures of Fcε3-4 alone and in complex with its high affinity receptor FcεRIα 
(Zheng et al., 1991) show that the Cε3 domains can adopt „closed‟ or „open‟ conformations by 
rotating relative to Cε4 (figure 4).  These structural features of IgE-Fc must also apply to the 
membrane form of the IgE molecule, which together with the signalling chains Igα and Igβ 
constitutes the receptor for antigen on B-cells committed to IgE synthesis (Vangelista et al., 
2005). 
 
Figure 4:  The structures of IgE-Fc fragments. (a,b) Two views of the complete IgE-Fc (uncomplexed) molecule, 
including the Cε2 domains *Protein DataBank (PDB) ID: 1O0V+.  The two ε‑chains are coloured purple and green, 
and the two points of connection to the Fab regions can be seen most clearly in a and b respectively, indicating 
the extent of the bend in the IgE molecule.  (c) The structure of the Fcε3‑4 fragment (uncomplexed) showing the 
two Cε3 domains in the ‘closed’ conformation (PDB ID: 1FP5). (d) The structure of the Fcε3‑4 fragment taken 
from the crystal structure of the complex of Fcε3-4 and the FcεRI α-chain, showing the Cε3 domains in the ‘open’ 
conformation (PDB ID: 1F6A).  Taken from Gould and Sutton, (2008) 
P a g e  | 26 
 
Although the serum concentration of IgE is low in comparison to other antibodies, its action is 
powerfully amplified by the activities of the receptors to which it binds (Sutton and Gould, 
1993).  It has emerged that IgE acts as part of a protein network (Gould et al., 2003), which 
includes the two principal receptors, Fc RI (the high affinity IgE receptor) and Fc RII (the low 
affinity IgE receptor, also called CD23), as well as the IgE- and FcεRI-binding protein galectin-
3.    
1.1.1 The high affinity IgE receptor FcεRI 
The high affinity IgE receptor on skin mast cells and blood basophils, FcεRI, is responsible for 
immediate hypersensitivity reactions.  IgE binds to cells bearing FcεRI with such a high affinity 
(Ka ~ 10
10
 M
-1
), that they are permanently coated with IgE, and thus sensitized for rapid 
activation when challenged with allergen.  This activation, triggered by aggregation of as few as 
two receptor molecules by multivalent allergen, leads to release of molecules that promote an 
immediate inflammatory response.  Moreover, the expression of these high-affinity receptors is 
probably up-regulated by IgE itself (Grimbacher et al., 2002).  Therefore, the concentration of 
circulating IgE does not reflect its true activity.   
FcεRI is expressed as an αβγ2 tetramer on mast cells and basophils, and as an αγ2 trimer on 
human antigen presenting cells (APCs), monocytes, eosinophils, platelets and smooth-muscle 
cells (Kinet, 2007).  The two extracellular domains of the α-chain (sFcεRIα) contain the IgE 
binding function, whereas the signalling motifs are located in the intracellular sequence of the β- 
and γ-chains.  Although the quaternary arrangement of the chains is not known, X-ray analysis of 
sFcεRIα in several different crystal forms have revealed that the two domains are folded back on 
each other exposing a hydrophobic „ridge‟ that was found to be the IgE binding site (Garman et 
al., 2000).  Part of the ridge is formed by the FG‟ loop of the α2 domain, a segment that 
strikingly is the only region to exhibit conformational variation among the different unliganded 
sFcεRIα structures (figure 5).  In D2 these strands are longer and the FG loop projects above the 
D2 domain surface.  The C‟ strands also differ between the two domains.  In D2 a series of 
aromatic residues (Y
120
 and Y
131) form a hydrophobic core that pushes the C‟ strand and loop 
away from the C-strand, altering the local conformation of this region.  The FG loop and CC‟ 
strands of D2 form part of the binding site for IgE (Garman et al., 2000).  
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Figure 5:  Ribbon diagram of Fc RIα showing the positions of the disulfides and the FG loop in domain 2 (D2) that 
is implicated in receptor specificity. Taken from Garman et al., (2000).  
1.1.2 The low affinity IgE receptor (FcεRII / CD23) 
1.1.2.1 Characteristics and structure 
The low affinity IgE receptor, FcεRII (or CD23) is found on several cell types, including B-cells, 
T-cells, NK cells, eosinophils, platelets, macrophages, follicular dendritic cells (FDC), 
Langerhans cells, a subset of thymic epithelial cells, Epstein-Barr virus (EBV)-containing 
nasopharyngeal carcinoma cells (Delespesse et al., 1991), as well as a variety of haematopoietic 
cell lines (Conrad, 1990).   
CD23 has multiple functions dependent on which ligand it is bound to.  Besides its function as an 
IgE receptor, CD23 also acts as B-cell growth factor and promotes proliferation of IgE-specific 
plasmablasts, thus elevating IgE levels.  On inflammatory cells, (monocytes/macrophages, 
eosinophils and platelets) CD23 has been shown to be involved in IgE-dependent cytotoxicity 
against parasites (Delespesse et al., 1991) and phagocytosis of IgE-coated particles.  CD23 acts 
in synergy with the complement receptors (CR) for C3bi (also called CD11b) in an IgE-
independent manner to release IL-1, IL-6, and TNF-α, and generate superoxides (Gould and 
Sutton, 2008).   
Molecularly, human CD23 is a single chain glycoprotein of 321 amino acids that is 45 kDa in 
size.  It is encoded by a single-copy gene that contains 11 exons and spans 13 kb found on 
chromosome 19 (Conrad, 1990).  Unlike FcεRI and other FcR CD23 is not a member of the Ig 
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superfamily.  CD23 is a type II integral membrane protein and a member of the C-type (calcium-
dependent) lectin family, thus making it a unique Fc receptor.  Being a C-type lectin CD23 is 
related to several adhesion molecules and carbohydrate pattern recognition receptors (Gould et 
al., 2003).  The N-terminal cytoplasmic domain is followed by the transmembrane region, a stalk 
region (Beavil et al., 1995; Chen et al., 2002; Dierks et al., 1993), and a short neck region that is 
found ahead of  the C-type lectin domain (Wurzburg et al., 2006).  Beyond the lectin domain, in 
the human, but not the murine form, there is a stretch of about 30 residues (a tail) whose function 
is not yet fully known (figure 6).   
Two forms of CD23 are commonly found, CD23a and CD23b.  The two isoforms result from 
alternative transcription initiation sites and differ only in the initial 6-7 N-terminal cytoplasmic 
amino acids (Conrad and Huff, 2000).  In mice, CD23a is expressed on both B-cells and FDC, 
whereas CD23b is found on gut epithelial cells (Yu et al., 2003) and FDC (Sukumar et al., 
2006).  In humans, the expression of CD23a is limited to B lymphocytes, whereas that of CD23b 
is less restricted, with expression on a variety of haematopoietic cells, including monocytes, 
eosinophils, and Langerhans cells (Conrad and Huff, 2000).  Given the cellular distribution of 
the two CD23 isoforms, most of the above functions must be ascribed to CD23b (Delespesse, 
1992).  This prediction is supported by transfection experiments showing that CD23b mediates 
phagocytosis of IgE-coated particles where CD23a mediates endocytosis of soluble IgE 
complexes (Kikutani et al., 1986).   
Beavil et al., (1995) noticed a periodic seven-amino acid repeat throughout the length of the stalk 
region of CD23.  Almost every seventh position contains a leucine or other hydrophobic amino 
acid, suggesting that CD23 could form an α-helical coiled coil.  This would imply that CD23 
would be expressed as a dimer or trimer (Dierks et al., 1993).  Modelling and cross-linking data 
suggested that CD23 would form a trimer, instead of a dimer, which is normally seen with 
proteins containing leucine zippers (Beavil et al., 1995).  The trimer model is supported by the 
NMR structure (Hibbert et al., 2005) of the lectin domain of CD23.  Although the affinity of a 
single lectin head for IgE-Fc is low (Ka ~ 10
6
 - 10
7 
M
-1
), the avidity effect achieved with the 
trimer leads to an affinity (Ka ~ 10
9
 - 10
10 
M
-1) approaching that of FcεRI.  Oligomerization of 
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CD23 would allow the lectin domains to come into close proximity of each other and cooperate 
in binding one IgE molecule each, resulting in high avidity binding.     
 
Figure 6: The two-dimensional schematic representation of human CD23.  The double lines indicate α helix, 
arrows indicate β sheet and single lines indicate loops. (1) The C-type lectin domain, (2) The cytoplasmic amino 
acid sequence, (3) the leucine zipper, (4) proteolytic cleavage sites are coloured purple, and the sizes of the 
released soluble fractions are indicated, (5) The reverse RGD sequence and (6) the RGD binding inhibitory 
peptide (Kijimoto-Ochiai, 2002).  
1.1.2.2 Regulation of CD23 expression 
CD23 surface levels can be increased by two mechanisms: cytokine-induced primarily by 
interleukin (IL) -4 and -13, and IgE dependent inhibition of catabolism.   
The expression of CD23 is tightly regulated in a cell-specific manner.  IL-4 is the most potent 
inducer of CD23 expression, as it acts on all cell types that are capable of expressing this 
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molecule.  Freshly isolated normal B-cells express a small amount of the type A isoform of 
CD23 and, after incubation, in the absence of a stimulant, they rapidly lose both CD23 protein 
and mRNA, indicating that the expression of CD23 on normal resting B-cells is not constitutive 
(Delespesse, 1992).  When cultured in the presence of IL-4 resting B-cells express substantial 
amounts of CD23a and b.  This enhancing effect of IL-4 on B-cells is inhibited by interferon 
gamma (IFN-γ); interferon alpha (IFN-α), transforming growth factor beta (TGF-β) and 
glucocorticoids.  IL-2 was reported to upregulate CD23 on activated but not on resting B-cells.  
Several B-cell activation signals markedly increase the IL-4-induced expression of CD23; these 
signals may be delivered by contact-dependent interactions with T-cells, or by the engagement of 
either soluble immunoglobulin (sIg), or cluster of differentiation 40 (CD40) or CD72.  Yet, in the 
absence of IL-4 and IL-2, activated B-cells do not express more CD23 than resting B-cells and 
this indicates that CD23 is not a true B-cell activation marker (Delespesse, 1992).  
Lipopolysaccharide (LPS) can substantially exaggerate the response to IL-4 (Richards and Katz, 
1990) and also activates nuclear factor (NF)-κB (Tolnay et al., 2002).  
The regulation of CD23 expression on monocytes is different from that on B-cells.  For example, 
freshly isolated normal monocytes do not express CD23 and, in contrast to B-cells, IFN-γ does 
not suppress but rather enhances CD23 expression on monocytes. Interestingly, 1,25 dihydroxy-
vitamin D3 inhibits CD23 expression on IL-4 stimulated monocytes without affecting the 
expression of either the type A or B CD23 isoforms by highly-purified B-cells.  The regulation 
of CD23 on T-cells appears to be similar to that on B-cells, while on Langerhans cells, 
eosinophils and platelets CD23 seems to be regulated in the same way as on monocytes 
(Delespesse et al., 1992).        
CD23 is initially expressed as a membrane-bound molecule but is cleaved from the cell surface 
by a membrane-anchored metalloprotease (Conrad, 2007).  The principal endogenous protease 
that releases soluble CD23 has been identified as a disintegrin and metalloproteinase (ADAM) 
10 (Weskamp et al., 2006).  Consequently, smaller soluble fragments of CD23 (sCD23) are 
generated of various sizes (37, 33, 29, 25 and 16 kDa) all of which have been shown to contain 
the lectin domain (figure 6).  Coincidentally, the 16 kDa fragment is no different from the 
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fragment formed after cleavage of CD23 with Der pI, the cysteine proteinase allergen from 
faecal pellets of the house dust mite Dermatophagoides pteronyssinus (Wan et al., 2002).   
All these soluble CD23 fragments are found in the circulation of normal human subjects and are 
found to retain binding with IgE, albeit with a lower affinity than that of the full-length, 
membrane-bound form.  Fragments that also contain stalk sequences form trimers in a 
concentration-dependent manner or upon IgE binding, whereas those lacking any stalk region are 
monomeric (McCloskey et al., 2007).  These fragments also differ in their trimerization 
tendencies depending on the length of the residual stalk (Schulz et al., 1997).  It has also been 
found that soluble CD23 monomers inhibit and oligomers stimulate IgE synthesis in human B-
cells (McCloskey et al., 2007). 
Not only does oligomerization of soluble CD23 molecules increase binding affinity, but it has 
also been shown by way of domain deletion mutants, that the IgE-binding activity could be 
increased by adding to the length of stalk present (Chen et al., 2002), and that this oligomerised 
complex increases in stability as the length of the stalk region of sCD23 increases (Chen et al., 
2003). 
1.1.2.3 CD23 as a ligand for IgE 
The CD23 binding site on IgE has been mapped to the outer side of the Cε3 domain (Vercelli et 
al., 1989).  The site for CD23 has not been precisely mapped, but it is known that it falls in this 
Cε3 region, distinct from the FcεRI site (Sayers et al., 204).   
NMR analysis of CD23 (Hibbert et al., 2005) located binding sites for IgE on the lectin head 
itself (figure 7) using monomeric Cε3 as ligand.  Deletion analysis of the native stalk has 
implicated a region near the lectin domain (the “neck”) as necessary for the high-affinity 
interaction between IgE and CD23 (Chen et al., 2002).  This region appears to be less tightly 
associated, potentially allowing for some flexibility in orienting the lectin domains to bind to 
IgE, enabling the high-affinity interaction (Kilmon et al., 2001).  Changes in CD23 
oligomerization also play a role in the decreased binding seen at physiological temperatures. 
Kilmon et al., (2004) have found that trimeric CD23 is pre-assembled on the cell surface in the 
absence of ligand.  They observed that under physiological conditions CD23 is partially 
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dissociated; only the upper portion of the molecule, including the lectin domain, dissociates.  
They have also determined that the stalk region is not required for association into trimers.  Only 
the transmembrane and cytoplasmic regions are required for this association.  The suggestion is 
that the role of the stalk may be to direct the correct orientation of the lectin heads needed for 
high affinity binding to IgE. 
In addition to promoting oligomerization, however, the stalk region most likely has other 
functions, since a peptide at the base of the stalk region has been implicated in binding to major 
histocompatibility (MHC) class II molecules (Kijimoto-Ochiai, 2002).  This finding was 
confirmed by saturation binding analysis (Conrad and Huff, 2000), which showed that CD23 
binds IgE with a dual affinity, explained by multipoint interaction of two CD23 lectin domains 
with distinct regions of Cε3 domain of IgE, whereas low-affinity binding is represented by the 
interaction of a single lectin domain with the ligand.  Definitive proof of this would be validated 
by analysis of the CD23/IgE crystal structure, which is currently unresolved.  
   
Figure 7:  The CD23 trimer and the architecture of ligand interaction sites.  (A) An overhead view of the 
postulated CD23 trimer.  For each monomer, the backbone ribbons are shown in grey.  The surfaces are coloured 
according to electrostatic charge.  Side chains for residues that are part of the IgE interaction site are displayed 
and coloured in green.  (B) Cartoon representations (top and side views).  The two oligomerization sites are blue 
and red, respectively, the IgE interaction site is green, the CD21 binding site is cyan, and the calcium binding site 
is yellow.  Taken from Hibbert et al., (2005). 
C-type lectins bind carbohydrate in a calcium-dependent manner by direct ligation of two of the 
saccharide hydroxyls to the lectin bound calcium ion (Wurzburg et al., 2006).  CD23 binds to 
some of its ligands in a lectin-like manner by binding to their carbohydrates in a calcium-
dependent way.  However, CD23 binds to IgE in a non-lectin-like manner, as it can bind to 
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deglycosylated IgE (Vercelli et al., 1989), indicating that IgE binding is mediated by protein-
protein contacts.  While CD23 binds to IgE in a carbohydrate-independent manner, the binding is 
still calcium dependent (Richards and Katz, 1990). 
Wurzburg et al., (2006) have solved the crystal structures of the soluble C-terminal fragment of 
CD23 in the presence and absence of calcium.  Calcium binding is observed at the principal 
binding site, but not at an auxiliary site, in contrast to the conclusion from the NMR study of 
CD23 (Hibbert et al., 2005).  In the crystal structure of the apo form, the principal calcium 
binding site is occupied by an arginine from a neighbouring loop, while in the calcium bound 
form, this arginine and the surrounding loop residues are disordered.  Differences in the CD23 
structure associated with calcium binding overlap with regions previously identified as important 
for IgE-Fc interactions (Bettler et al., 1989).  What now is evident is a domain with considerable 
plasticity. 
1.2 CD23 interactions with other ligands 
The functions of CD23 (both in the secreted form and on membranes of immune cells) are 
extended by several co-receptors apart from IgE.   These co-receptors comprise of the vitronectin 
receptor, αMβ2-integrin (otherwise known as CD11b/CD18 or CR3), αxβ2-integrin (CD11c/CD18 
or CR4), as well as the CR2, known as CD21 (Hibbert et al., 2005).   
1.2.1 Interaction of CD23 with the vitronectin receptor 
The vitronectin receptor (αVβ3) is an omnipresent receptor that interacts with several ligands, 
such as vitronectin, fibronectin, osteopontin, and metalloproteinase MMP-2, and because of this 
binding diversity, this integrin takes part in cell migration, tumour invasion, bone resorption, 
angiogenesis, and immune responsiveness (Gladson and Cheresh, 1994).  During inflammation, 
circulating human monocytes are able to leave the blood by attaching to, and migrating through, 
endothelial and subendothelial matrices to the site of injury.  The vitronectin receptor, expressed 
on endothelial cells, is involved in the transendothelial migration process (Brown and Lindberg, 
1996).   
 sCD23 levels are elevated in various chronic inflammatory disorders.  sCD23 and CD23 ligation 
can trigger monokine release by human monocytes (Bonnefoy et al., 1997) and it has also been 
reported that the vitronectin receptor associated with CD47 on monocytes mediates 
P a g e  | 34 
 
proinflammatory cytokine synthesis via interaction with CD23 (Hermann et al., 1999). The 
region of CD23 involved in the interaction with vitronectin has been located, and is distinct from 
the IgE and CD21 binding sites but is close to the stalk region.  
1.2.2 Interaction of CD23 with CD11b and CD11c 
It has also been shown that CD23 binds to the CD11b/CD18 and CD11c/CD18 β2 integrins 
expressed by monocytes and neutrophils (Bajorath and Aruffo, 1996).  The integrin family 
consists of heterodimeric membrane-bound glycoproteins that mediate homotypic and 
heterotypic cell-cell adhesion, as well as cell-matrix interactions in a broad range of biologic 
functions.  β2 integrins play an important role in the production of IL-1β in human monocytes 
stimulated by direct contact with activated T lymphocytes.  The leukocyte-specific β2 integrin 
subfamily includes LFA-1 (CR1), Mac-1 (CR3), and p150,95 (CR4), each consisting of an 
association of an α chain (CD11a, CD11b, or CD11c) and a common β chain (CD18) (Rezzonico 
et al., 2000).  
 
CD11b, the α-chain of Mac-1 is the complement type 3 receptor (CR3) and has been 
demonstrated to be physically associated with urokinase-type plasminogen activator receptor 
(uPAR, CD87), with CD14, and with the crystallisable fragment gamma class receptor IIb 
(FcγRIIb) (Aubry et al., 1994).  CD11b/CD18 is expressed on mature neutrophils, monocytes 
and NK cells.  It also binds to intercellular-leukocyte adhesion molecule (ICAM)-1, as well as to 
several soluble ligands, including the complement fragment iC3b, fibrinogen, coagulation factor 
X, and LPS (Rezzonico et al., 2000). CD11c, the α-chain of p150/95, is the complement type 4 
receptor (CR4) and is also physically associated with uPAR (Aubry et al., 1994).  CD11c/CD18 
is found on a variety of cells such as monocytes, macrophages, granulocytes, some T and B 
lymphocytes, and dendritic cells.  CD11c/CD18 has been shown to bind iC3b, fibrinogen, LPS 
and like the other leukocyte integrins, it is involved in the adhesion of monocytes to the 
endothelium (Rezzonico et al., 2000).  
 
CD23 appears to identify an epitope on CD11b and CD11c close or identical to that for factor X; 
and only this ligand inhibited monocyte binding to CD23-coated liposomes without affecting 
surface expression of CD11b or CD11c on monocytes (Bonnefoy et al., 1997).  The interaction 
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between CD23 and CD11b/c is thought to trigger the production of inflammatory cytokines such 
as IL-1β, IL-6 and TNF-α.  These findings implicate CD23 in a number of chronic inflammatory 
diseases.  Thus, CD23 may be an attractive target for the treatment of chronic inflammatory 
diseases.  The CD23-β2 integrin interactions are “lectin-like” in that CD23 recognizes specific 
carbohydrate structures expressed on CD11b/c, respectively (Bajorath and Aruffo, 1996) as it 
was found that EDTA decreased CD23 binding to monocytes by chelation of Ca
2+
 whereas 
addition of Ca
2+
, resulted in a dose dependent increase of CD23 binding to monocytes (Bonnefoy 
et al., 1997). It must also be noted that the reverse RGD sequence of CD23, a common 
recognition site for integrin receptors, was not found to be involved in the interaction with 
CD11b and CD11c (Bonnefoy et al., 1997). 
 
It has also been shown that the extracellular signal-related kinase (ERK) 1/2 and p38/stress 
activated protein kinase (SAPK) 2 pathways are essential for the stimulation of IL-1β production 
induced by the direct engagement of the β2 integrin α chains of CD11b and CD11c, either with 
mAbs or their functional ligand sCD23 in monocytes.  This activation of monocytes through β2 
integrins may be relevant to physiologic and pathologic conditions involving cell-cell 
interactions or other pathologic situations in which sCD23 levels are increased (Rezzonico et al., 
2000). 
 
The functional significance of CD23 binding to CD11b/c was demonstrated by triggering CD11b 
and CD11c on monocytes with either recombinant CD23 or anti-CD11b/c mAbs which caused a 
marked increase in nitrite (NO2
-
) oxidative products (hydrogen peroxide) and proinflammatory 
cytokines.  Furthermore, CD23 elicits an increase in the production of IL-1α, IL-1β, IFN-γ, IL-6 
and TNFα.  These CD23-mediated activities are inhibited by Fab fragments of mAbs to CD11b, 
CD11c and CD23.  Together, these results suggest that CD11b and CD11c are functional 
receptors for CD23, and that CD23 is a proinflammatory mediator.  A potential mechanism of 
action of anti-CD23 antibody could be by blocking the interaction between CD23 and CD11b/c, 
which would decrease the release of proinflammatory cytokines that are known to participate in 
the inflammatory process (Bonnefoy et al., 1997).   
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1.2.3 Interaction of CD23 with Complement receptor 2 (CD21) 
CD23 has also been shown to bind to CD21, also known as complement receptor 2 (Aubry et al., 
1994).   
The complement system (illustrated in figure 8) has the potential to be extremely damaging to 
host tissues; therefore its activation must be tightly regulated.  Complement control proteins, 
which are present at a higher concentration in the blood plasma than complement proteins 
themselves, serve to regulate activation of complement (Goldman and Prabhakar, 1996).  
 
Figure 8:  Overview of Complement activation and function. All three pathways that activate the complement 
cascade converge at the formation of a C3 convertase. This complex cleaves C3 into components C3a and C3b, 
ultimately leading to pathogen opsonisation, release of inflammatory mediators, and formation of terminal 
complement components that lyse pathogens.  Taken from Janeway et al., (2005).  
CD21 is a member of the regulators of complement activity (RCA) family, distinguished by the 
presence of short complement regulator (SCR) domains (also known as short consensus repeat, 
Sushi or complement control protein domains).  CD21 is a type 1 membrane glycoprotein with a 
molecular mass of ~ 145 kDa.  The protein has a large extracellular portion (Ling et al., 1998) 
that contains 15 – 16 SCR domains depending on alternative splicing (figure 9), each of about 60 
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amino acids, a transmembrane region, and a short cytoplasmic tail (Gilbert et al., 2006).  It is 
principally found on mature B-cells, FDC, epithelial cells, and some T-cells.  CD21 is a receptor 
that plays an integral role in the immune system (Holers, 2004).  In 1989, mutation studies 
showed that both the SCR 1-2 domains are required for the binding of C3 cleavage fragments 
(C3d, C3dg and iC3b) and the Epstein-Barr virus (EBV) coat glycoprotein gp350/220 (Lowell et 
al., 1989).  The spectrum of disease that can be directly linked to EBV infection has dramatically 
increased since the 1964 discovery of the virus in tumour cells from children with Burkitt‟s 
lymphoma (Epstein et al., 1964).  It has also been shown that the EBV-binding site on CD21 is 
involved in CD23 binding, and IL-4-induced IgE and IgG4 production by human B-cells 
(Henchoz-Lecoanet et al., 1996).  Signal transduction is mediated by a CD21/CD19 signalling 
complex brought into proximity with the B cell receptor (BCR) through a C3d-antigen bridge 
(Dempsey et al., 1996). 
 
Figure 9:  A schematic diagram of CD21 showing the 15 SCR domains.  The position of the 16th domain in the 
alternatively spliced form of CD21 is indicated by the broken ellipse labelled 10a.  The long homologous repeats 
(LHR) are indicated in bracketed ranges, in which SCR 15 does not fit the pattern.  The binding sites for four sets 
of ligands are shown by horizontal arrows.  The number of residues in each of the 14 inter-SCR linkers is shown 
between each pair of domains.  The 11 predicted N-linked glycosylation sites are marked by ψ symbols. 
Underneath, the 15 SCR sequences of CD21 are aligned.  Each SCR sequence is numbered at its start and end, 
counting from residue 1 at the start of the signal peptide (not included) (SWISSPROT entry P20023). The 
sequence from residue 972 onwards is not included. Conserved Cys and Trp residues are highlighted in red, and 
the linker sequences are highlighted in green.  The N-linked glycosylation sites are underlined.  Taken from 
Gilbert et al., (2006). 
SCR 1 and 2 are joined by an eight-residue linker.  The crystal structure of CD21 SCR 1-2, both 
alone and in complex with C3d, showed the two SCR domains to be in a closed V-shape (Prota 
et al., 2002; Szakonyi et al., 2001) (figure 10).  In contrast, the solution structure of SCR 1-2 
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shows the free form is a far more open shape, showing a high degree of flexibility in the linker 
between SCR 1 and 2. 
 
Figure 10:  Structure and conformation of CD21 SCR1–2. (A) Ribbon drawing of the crystallized protein, with 
strands labelled.  Disulfide bonds and NAG residues are shown in yellow and orange, respectively. (B) Interface 
between domains SCR1 and SCR2. Amino acids that participate in the contact are shown in green. Hydrogen 
bonds and salt bridges are represented with dashed lines. A comparison with the structure of C3d-liganded CD21 
SCR1–2 (gray) reveals substantial interdomain flexibility despite extensive interface contacts.  Taken from Prota 
et al., (2002) 
Gilbert et al., (2006) have shown that CD21 is, on average, semi-extended in solution and that it 
has a flexible structure that is able to fold back, therefore facilitating ligand interactions 
occurring across SCR domains that are separated in the linear CD21 sequence.  Ultimately, 
scattering data showed the best fit for the data was obtained with SCR 1-2 folded back towards 
SCR 4-6, and with a further slight turn around SCR 11-13 (figure 11).  The appearance of the 
model is suggestive of a “fish-hook” (Gilbert et al., 2006).  The length was determined from 
scattering to be 38 nm (Gilbert et al., 2006).   
SCR 1-2 also contains binding sites for the low-affinity IgE receptor, CD23, and IFN-α.  
Importantly a further binding site for CD23 occurs in the SCR 5-8 domains that is dependent 
upon the N-linked oligosaccharides within SCR 5-8 domains (Gilbert et al., 2006).  
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Figure 11:  Views of the overall best-fit model for CD21 SCR 1-15 in comparison with its ligands, C3d, CD23 and 
IFN-α.  Ovalbumin is a model antigen when conjugated with 4-hydroxy-3-nitrophenol (NP), and its crystal 
structure is shown for comparison.  The ligands are based on crystal and NMR structures with the following PDB 
codes 1ghq, 1t8d and 1rh2, and that for ovalbumin has the PDB code 1ova. The IgM-S monomer model from 
solution scattering and the IgE-Fc fragment from X-ray crystallography (PDB code 1ls0) are shown face-on for 
comparison (green), in which the Fab and Fc fragments and the Cε2 and Cμ2 domains are labelled. The scale bar 
corresponds to the average length of one SCR domain.  Taken from Gilbert et al., (2006) 
CD21 also has a role in generation of immunological memory, Ig class switching and tolerance 
(Carayannopoulos et al., 2002).  Thus, examining the role of CD21 in innate and adaptive 
immunity is also a concept for understanding this critical interface between our evolutionarily 
ancient mechanisms of recognition of pathogens and our more recently evolved lymphocyte 
subsets with their own means of controlling self and non-self recognition and setting tolerance 
thresholds. 
NMR analysis of derCD23 (Hibbert et al., 2005) located the binding site for CD21 SCR 1-2 on 
the C-terminal tail (residues E294, G295, S296, and E298).  Conspicuously, both the NMR and 
crystal structures of CD23 show an incompletely represented site for CD21 as the full C-terminal 
tail was not present in the construct used in the NMR study, and although present in the X-ray 
analysis, it was not visible in the structure.  This leads to speculation of a flexible region.  
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However, the IgE and CD21 binding sites on CD23 are clearly distinct from each other.  This is 
consistent with previous site-direct mutagenesis studies (Mossalayi et al., 1992). 
Hibbert et al., (2005) also found that both CD21 and IgE can bind CD23 simultaneously, and 
proposed a trimolecular complex model, which envisions the lectin heads of trimeric CD23 
uniting, and therefore bringing the three CD21 binding sites (at the tail region) close together 
associated around the top of the stalk region and leaving the IgE binding sites positioned around 
the periphery (refer to figure 7). 
It is important to remember that binding of CD23 to CD21 also involves SCR 5-8, and the 
flexibility of CD21 could clearly allow extensive multi-point attachments to the CD23 trimer 
complex, possibly involving both the lectin head and C-terminal tail.   
1.3 Regulation of IgE expression 
The finding that IL-4 simultaneously induces IgE and CD23 lends support to the hypothesis that 
CD23 plays a role in the regulation of IgE synthesis.  In addition to its IgE regulatory role, CD23 
can enhance antigen processing and presentation, resulting in increased production of antigen-
specific IgG, IgM, and IgE in response to IgE-antigen complexes (Conrad, 2007).     
Allergen-IgE complexes bound in the mucosa to CD23 that is expressed by allergen-activated B- 
cells can facilitate antigen presentation to T-cells (Carlsson et al., 2007).  The process of antigen 
presentation by way of CD23 is termed facilitated antigen presentation (FAP).  The interaction 
between CD23 and the MHC II receptor, human leukocyte antigen receptor (HLA-DR), in the 
cell membrane is involved in trafficking of allergen-IgE-CD23 complexes to endosomes.  Here 
the allergen-derived peptides are loaded onto HLA-DR molecules for presentation at the B-cell 
surface to T-cells (Gould and Sutton, 2008).   
Antigen presentation through the membrane-bound BCR involves the interaction of B-cells with 
Th cells, which is limited by the number of associated B-cells.  However, antigen presentation 
through secreted IgE via FAP may overcome this limitation as all antigen-activated B-cells are 
able to present a variety of peptides, even from totally unrelated allergens, to cognate T-cells, 
regardless of the specificity of the B cell‟s own antigen receptor.  This is a probable scenario for 
“epitope spreading” which is the process by which an antibody response to one epitope on an 
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antigen leads to the production of antibodies specific for other epitopes on the same antigen, or 
for epitopes on entirely unrelated antigens.  This results from internalization of whole antigen 
and subsequent display of a range of peptides derived from that antigen, leading to the generation 
of T-cells with different epitope specificities.  Simultaneous processing of two unrelated antigens 
by an antigen-presenting cell can lead to the production of antibodies directed against both 
antigens (Mudde et al., 1995).  Furthermore, whereas FAP enhances the presentation of allergens 
recognized by pre-existing IgE molecules, it suppresses that of other antigens and therefore 
serves as a positive-feedback system to enhance allergic sensitization.  This is clinically serious, 
as monospecific allergies often deteriorate into polyspecific allergies.   
The microenvironment of mucosal tissues favours the synthesis of IgE at the expense of IgG.  
The expression of IgE requires heavy-chain switching from IgM, often by way of IgG, to IgE by 
somatic recombination of the germline genes in B-cells.  Class switching is linked to cell 
division, and the IgE switch requires more cycles than the switch to IgG.  Cells may drop out at 
any stage of this process by terminal differentiation of the B-cells into immunoglobulin-secreting 
plasma cells or by apoptosis.  Local conditions in the mucosal tissues of allergic individuals 
evidently favour class switching to IgE, and the rate at which it is synthesized and secreted can 
be calculated to overcome the loss of bound antibody from the mast cells.  This mechanism 
serves as an explanation as to why allergic reactions are confined to particular target organs 
(Gould et al., 2003) 
1.3.1 Class switch recombination 
The ability of B-cells to express immunoglobulins with identical antigen specificity but different 
effector functions results from their capacity to undergo class switch recombination (CSR) 
(Monticeli et al., 2001).  The expression of IgE requires CSR of the variable (VDJ) region, 
initially linked to the constant (C) region of another antibody class (Cµ or Cγ) to Cε, in the 
immunoglobulin heavy-chain locus (Gould and Sutton, 2008).   
This process involves repetitive switch (S) regions located 5‟ of each constant heavy chain (CH) 
gene except Cδ, and consists of an intrachromosomal DNA recombination event that results in 
the juxtaposition of different downstream CH genes to the expressed VDJ gene (figure 12).  The 
S region involved in recombination is not targeted at random, but rather, CSR appears to be 
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directed by Th cell-derived cytokines, in conjunction with the regulation of B cell proliferation 
and differentiation (Vercelli et al., 1989).  Molecular analysis has shown that cytokine-dependent 
induction of CSR to a particular CH gene almost invariably correlates with the transcriptional 
activation of the same gene in germline (GL) configuration.  GL or S transcripts initiating from 
TATAA-less promoters, a few kilobases upstream of the S region, proceed through short non-
coding exons (IH exons), the S regions and CH exons, and are polyadenylated near the normal 
poly (A) site for mature IgH mRNAs.  The IH exon is then spliced to the normal acceptor site in 
the first exon of the CH gene (Vercelli, 2001) (figure 12).    
Switch circles (SCs) are the by-products of CSR.  A single SC is generated from genomic DNA 
following each switch recombination event in a B cell.  Because the circle DNA is not replicated 
at cell division, it is diluted out in the proliferating B-cell population.  Circle transcripts (CTs) 
revealing class switching from IgM, IgG1, IgG3 and IgG4 to IgE were observed in nasal biopsies 
from allergic patients, but absent from controls (Takhar et al., 2007) suggesting that allergen 
drives class switching to IgE in the respiratory mucosa in allergic rhinitis.  It has subsequently 
been shown (Gould, 2006) that switching to IgE can occur in the respiratory mucosa in the 
absence of cellular traffic from remote sites.      
CSR was thought to occur only in the germinal centres of lymphoid tissues.  (Kleinjan et al., 
2000) provided the first direct evidence for local IgE synthesis, illustrating that approximately 
4% of B-cells and 12-19% of plasma cells expressed IgE in patients with rhinitis, compared to 
1% and no expression, respectively in a group of normal subjects.  Therefore, it is clear that IgE-
expressing B-cells and plasma cells accumulate in the respiratory mucosa in patients with 
allergic inflammation even in healthy controls.  CSR to IgE is induced by the cytokines IL-4 or 
IL-13 secreted by Th2 cells, as well as CD40 ligand (CD40L) expression.   
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Figure 12:  Mechanism of class-switch recombination to IgE. Immunoglobulin heavy-chain constant-region genes 
(here Cµ, Cγ, C  and Cα), which determine antibody class, are arranged in tandem in the germline configuration 
downstream of the expressed variable regions (VH or VDJ) and upstream of the 30- enhancer (E) in the human Ig 
heavy-chain locus on chromosome 14.  Each heavy-chain germline gene comprises an intervening (I) exon 
(narrow rectangles) with its IH promoter, a GC-rich tandem repeat, called a switch (S) region (ovals), containing 
potential DNA breakpoints, and the constant-region exons (broad rectangles). IL-4 and IL-13 stimulate  germline 
gene transcription. Transcription of the  germline gene leads, through splicing, to  germline gene transcripts 
(GLTs). GLTs contain stop codons in all three reading frames, precluding translation into protein; however, the 
GLTs are needed for CSR. CSR occurs by deletional rearrangement with break points in the two participating S 
regions (zig-zag arrows). During recombination, for example from IgM to IgE, the broken ends of Sµ and S  join 
to form a hybrid S junction to express -chain mRNA and protein. A by-product of this reaction is the looped-out 
and deleted intervening sequence, the ends of which are joined to form a reciprocal hybrid S junction.  The 
extrachromosomal circular DNA molecule, known as a switch circle (SC), is not replicated during cell division, 
and can be lost following B-cell proliferation. SCs contain the I  promoter upstream of the targeted S  region, 
the S –Sµ hybrid junction and Cµ, allowing the expression of multiple switch circle transcripts (CTs). Owing to 
the rapid decay of CTs in the B-cell population, they are convenient markers for ongoing or recent CSR from IgM 
to IgE. The presence of CTs is an irrefutable sign of the irreversible process of CSR.  Taken from Gould (2006). 
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CD40, expressed in various cell types, including B-cells, dendritic cells, FDC, and macrophages, 
is a member of the tumour necrosis factor receptor (TNFR) superfamily (Banchereau et al., 
1994).  After initiation of IL-4/IL-13 induction of germline Cε transcription, IgE isotype 
switching is subsequently induced by CD40 ligation with its ligand (CD154) or agonistic anti-
CD40 antibodies.  Although germline Cε transcription is not inducible in general by CD40 
ligation alone, CD40-mediated signalling upregulates IL-4 or IL-13 driven germline Cε 
transcription and it is required for DNA recombination events.  However, the intracellular 
signalling pathways used by CD40 remain poorly understood.  The cytoplasmic domain, lacking 
any transduction signalling into B-cells, interacts with four members of TNF-receptor associated 
factor (TRAF) proteins.  The most reproducible signalling events documented in B-cells 
following CD40 engagement is the activation of NF-κB, the mitogen activated kinase (MAPK) 
p38 (Jabara and Geha, 2005) and c-Jun N-terminal kinase (JNK).  The importance of the 
involvement of these transcription factors in IgE production is demonstrated by defective IgE 
class switching in NF-κB knockout mice (Jabara and Geha, 2005). 
 
CD40 ligation activates NF-κB, MAPK p38 and JNK and causes immunoglobulin CSR in B-
cells.  The role of JNK activation in CD40-mediated isotype switching remains relatively 
unknown, but Jabara and Geha (2005) found that SP600125, an inhibitor for JNK drastically 
inhibited JNK phosphorylation but had little effect on CD40-mediated p38 phosphorylation and 
expression of the NF-κB dependent genes c-Myc and bcl-xL. SP600125 inhibited IgE synthesis 
by approximately 88% but had no effect on B-cell proliferation and survival in response to anti-
CD40 and IL-4 or on upregulation of CD23, CD54, and CD86 in response to CD40 ligation.  
Analysis of molecular events involved in IgE class switching revealed that SP600125 had no 
effect on the expression of C  germline and activation-induced cytidine deaminase (AID) 
transcripts.  In contrast, SP600125 severely reduced Sµ-S  switch recombination and expression 
of mature  transcripts.  Jabara and Geha (2005) therefore demonstrated that JNK activation is 
essential for CD40-mediated CSR to IgE and suggest that JNK is important for AID activity in 
B-cells. 
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Trimeric membrane CD40L is expressed transiently on activated T-cells.  CD40L activates B-
cells through the CD40 receptor.  Engagement of CD40 may override the suppressive effects of 
interferons and TGF-β on the IL-4-induced CD23 expression (figure 13), clearly indicating that 
regulation of CD23 expression on the B cell is complex and tight (Basaki et al., 2002).  CD40 
ligation upregulates CD23, CD54 and CD86 gene expression in B-cells (Banchereau et al., 1994) 
and JNK activation is implicated in the upregulation of CD86. 
 
Prior to induction of CD23 mRNA or CSR by IL-4 or IL-13, the B-cells require activation of 
Janus kinases (JAK) and signal transducers and activators of transcription (STAT)-6 DNA 
binding activity.  STAT6 is a critical component in one of two pathways that mediate signalling 
from the IL-4 receptor.  Through STAT6, IL-4 regulates MHC class II, CD23 and IL-4Rα 
expression, B cell isotype switching, and Th cell differentiation to the Th2 phenotype (Nelson et 
al., 2002).  Thus, STAT6 plays a pivotal role in allergic conditions such as asthma, rhinitis, and a 
variety of immune disorders such as type 1 diabetes, arthritis and enterocolitis.  The targeted 
disruption of the Stat6 gene in mice has shown that it is required for the IL-4-dependent 
expression of CD23 (Haque et al., 1997).   
 
Cytokine signalling induces phosphorylation of JAKs that associate with cytokine receptors and 
phosphorylate tyrosines in their cytoplasmic domains, which act as docking sites to recruit 
various STATs that undergo JAK-mediated tyrosine phosphorylation, dimerization and 
activation (Geha et al., 2003).   
 
IL-21 activates STAT1, STAT3 and STAT5 (Avery et al., 2008) and it has also been shown that 
in addition to STAT6, STAT3 is also activated by IL-4 and IL-13, dependent on expression of 
IL-13Rα1.  Tyrosine residues located at the C-terminus of IL-13Rα1 are necessary for STAT3 
activation (Arinobu et al., 2000).  Avery et al., (2008) have also shown that STAT3 is required 
for IL-21 to induce high quantities of IgE induced by costimulation of human B-cells with 
CD40L and IL-4. 
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Figure 13:  Molecular control of the IgE response.  The stimulatory effect is indicated by an arrow, while an 
inhibitory effect is indicated by perpendicular lines.  Antigen presented through MHC class II molecules to the T-
cell receptor (TCR) can be either stimulatory or inhibitory depending on the nature of the antigen and other 
factors.  Although many cytokines affect IgE production IFN-γ is probably the most important negative regulator 
while IL-4 and IL-13, are the most potent inducers.  Although many transcription factors are involved, Stat6, and 
NF-κB, through CD40, directly promote IgE production by initiating epsilon transcript synthesis and class 
switching.  Taken from Corry and Kheradmand (1999).  
The Jak-STAT pathways include activation of Jak-1, Jak-3, and Tyk-2 by IL-4, and Jak-1 and 
Tyk-2 by IL-13 in haematopoietic cells, followed by activation of STAT6 (Arinobu et al., 2000), 
which explains the similar biological activities of IL-4 and IL-13.  It has been confirmed that 
STAT6 has a central role in the signal transduction of IL-4 and IL-13, including IgE synthesis 
(Mitsuyasu et al., 1999), Th2 differentiation (Kaplan et al., 1996), proliferation of B-cells and T-
cells, and deactivation of monocytes (Arinobu et al., 2000). 
1.4 IgE Homeostasis 
Evidence of IgE secretion as a strictly regulated process is that IgE comprises less than 0.0001% 
of all serum Ig (Avery et al., 2008).  The concentration of IgE in the serum of healthy individuals 
is 10
4
 times less than that of IgG (Tu et al., 2005).  The process of mast-cell and APC 
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recruitment and IgE production in the mucosal tissues is central to the functions of IgE, and no 
less so in guarding against anaphylaxis.  In allergy and asthma the population of B-cells and 
plasma cells in the respiratory tract mucosa are heavily biased towards the production of IgE.    
As we have described, both IgE synthesis and its effector functions appear to be largely 
confined, but not limited to the mucosa.  The concentrations of IgE in the circulation are 
maintained at a low level, normally 0.1 µg/mL, and may only be increased by about 10-fold in 
allergic individuals (Tu et al., 2005). 
The interactions of CD23 and CD21 are pivotal in IgE regulation (Aubry et al., 1994).  
Ironically, CD23 engages in both the up- and down-regulation of IgE synthesis, thereby 
constituting a two-way switch in IgE homeostasis.  On one hand, cross-linking CD23 at the cell 
surface by IgE delivers a negative feedback for IgE production and inhibits the release of sCD23.  
On the other hand, sCD23 fragments that retain a part of the stalk region, important in mediating 
oligomerization of the protein (Kelly et al., 1998) promote continuing IgE production by at least 
two mechanisms: (i) sCD23 directly stimulates IgE production by triggering CD21, and (ii) 
sCD23, by its ability to trap IgE in the medium, prevents negative feedback through membrane-
bound CD23 (Munoz et al., 1998). 
The exact mechanism by which CD23 fulfils a role in IgE regulation is under intense debate.  
There are two current proposed models.  The first theory is a model which proposes a 
trimolecular complex (Hibbert et al., 2005).  This theory reports CD23 stimulation of IgE 
synthesis at low IgE concentrations and suppression of IgE synthesis at high IgE concentrations.  
It is proposed that soluble CD23, cleaved from the membrane, thereby lacking protection by IgE, 
stimulates upregulation of IgE synthesis by the co-ligation of membrane IgE and CD21 (figure 
14a).  This proposal directly relates to co-ligation of BCR and CD21 by which C3 attaches to 
antigen and stimulates the immune response (Fearon and Carroll, 2000).  This trimolecular 
complex of CD21-CD23-IgE could then act as a signalling platform for the proliferation and 
differentiation of the B-cells into IgE-secreting plasma cells.  Protection of membrane CD23 by 
IgE binding prevents the release of soluble CD23 to initiate stimulation of IgE production (figure 
14a).  In addition, the co-ligation of membrane CD23 and membrane IgE by allergen-IgE 
complexes results in negative signalling for IgE synthesis.   
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The second theory proposes one-to-one binding of IgE and membrane CD23.  It is of the same 
opinion that high levels of IgE stabilize membrane CD23, preventing its proteolysis and 
inhibiting IgE synthesis.  An increase in CD23 cleavage, however, would enhance IgE synthesis 
(figure 14b). 
In principle, these theories are congruent where upregulation of IgE synthesis is involved.  
Although a mechanism for CD23‟s negative feedback inhibition of IgE production is unknown, 
(Conrad, 2007) argues against the trimolecular model due to the lack of phenotype of sCD23 in 
mice and lack of evidence for interaction between sCD23 and CD21, as murine CD23 lacks the 
amino acids on the C-terminal tail apparently responsible for CD21 binding.  It is therefore likely 
that only a negative-feedback mechanism operates in mice, whereas both positive and negative-
feedback mechanisms operate in the human system, which may explain why humans, and not 
mice, suffer from allergy (Gould and Sutton, 2008).       
(Hibbert et al., 2005) suggest that sCD23 would initially up-regulate IgE synthesis by co-ligation 
of membrane IgE and CD21, but as IgE concentrations enter the range in which binding to 
membrane CD23 becomes critical, IgE synthesis would be abruptly terminated, precluding the 
accumulation of dangerous levels of IgE.  Common sense dictates that there are other, as yet 
unidentified signalling molecules associated with CD23 to carry out the negative regulation of 
IgE.  What is however evident is that stabilization of cell-surface CD23 would be beneficial in 
controlling IgE synthesis.      
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(a)  
(b)  
Figure 14:  Mechanisms of IgE regulation by CD23. (a) Positive and negative regulation of IgE synthesis by human 
CD23.  In this model, positive regulation of IgE synthesis is a result of the co-ligation of membrane IgE and CD21 
on a human B cell committed to IgE synthesis by soluble CD23 released from membrane-bound CD23.  IgE 
synthesis is thereby upregulated via synergistic signalling between the membrane IgE–Igα–Igβ complex and the 
CD21–CD19 complex.  Soluble CD23 trimerises in a concentration-dependent manner and on IgE binding, as 
shown here (Hibbert et al., 2005). Negative regulation of IgE synthesis occurs by the co-ligation of IgE and CD23 
on the membrane by allergen–IgE complexes.  Competition between CD21 and CD23 for membrane IgE thus 
leads to homeostasis. (b) In this scheme, IgE binding to mouse membrane CD23 trimers (which lack the C-
terminal tails that in human CD23 bind CD21) interferes with the upregulation of IgE class switching induced by 
IL-4 and CD40L.  As CD23 trimers are unstable in the B-cell membrane, their unraveling allows ADAM10 to cleave 
the stalk region, releasing soluble CD23. This cleavage of membrane CD23 allows IgE synthesis to proceed by 
default. The binding of IgE, or certain CD23-specific IgG antibodies that bind to the lectin head domain, stabilize 
the trimer and thereby enhance negative signalling. Although the negative signalling pathway of CD23 is 
unknown, IL-4 and CD40L act through STAT6 and NF-κB, respectively, to stimulate Cε germline gene transcription 
and class switching to IgE.  Taken from Gould and Sutton (2008).  
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1.5 IgE disease, primary immunodeficiency disorders and therapy 
Uncontrolled IgE synthesis can cause immunopathologies, such as allergy.  IgE levels are 
extremely high in some human genetic diseases, and it is associated with several primary 
immunodeficiency disorders (PID).  Examples of these are the hyper-IgE syndrome (HIES), 
Wiskott-Aldrich syndrome (WAS), Omenn syndrome (OS), Comel-Netherton syndrome (NS), 
thymic hyperplasia syndromes (Grimbacher et al., 2002) and immune dysregulations, 
polyendocrinopathy, enteropathy and X-linked syndrome (Geha et al., 2003).   
It is possible that CD23 provides a link between allergic atopy and these primary immune 
deficiencies.  Both groups share some clinical symptoms, such as an increase in serum IgE and 
soluble CD23 levels, and are characterised by an imbalance in Th1/Th2 cells.  The 
pathophysiology by which excessive production of IgE might adversely affect host defence is not 
known.  One hypothesis is that with an underlying partial T cell deficiency, patients may have 
increased Th2 cells or cytokines, or a deficiency of Th1 type cells or cytokines, driving B-cells to 
isotype-switch for IgE production via IL-4.  This might explain both the infection susceptibility 
and the augmented production of IgE associated with PID (Grimbacher et al., 2002). 
It is difficult to define IgE deficiency, based on the already low levels of IgE in serum; and the 
biological need for IgE antibodies is still debated.  Excessive IgE production is, however, the 
root of several diseases; such as atopic eczema/dermatitis syndrome (AEDS), where IgE levels 
can be as high as 10 000 IU/mL.  In DiGeorge syndrome, meta-analysis of small cohorts 
revealed elevated serum IgE in over 30% of patients (Grimbacher et al., 2002). 
 
HIES is a rare primary immunodeficiency characterized by recurrent staphylococcal skin 
abscesses, pneumonias with pneumatocele formation, extreme elevations of serum IgE, 
eosinophilia, and distinct abnormalities of the connective tissue, skeleton, and dentition.  Most 
cases are sporadic.  However, there have been reports of autosomal dominant kindreds and 
autosomal recessive inheritance in consanguineous families.  Eczema, abscesses, pneumonia, 
mucocutaneous candidiasis, elevated serum IgE, and eosinophilia are the most common features 
of immunodeficiency and immune dysregulation in HIES patients.  Upper-respiratory infections, 
including sinusitis, bronchitis, otitis media, otitis externa and mastoiditis, are frequent in HIES 
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and a clinical hallmark of HIES is recurrent pneumonia.  These are only a few of the frequently 
found characteristics of this disease (Grimbacher et al., 2002).   
 
In HIES, IgE levels of more than 10 000 IU/mL are characteristic and levels of > 50 000 IU/mL 
have been reported.  However, serum IgE levels are not static.  Substantial fluctuations in serum 
IgE concentrations have been noted over time without any obvious change in clinical 
presentation.  With increasing age, IgE levels may fall below 2000 IU/mL, but these individuals 
tend to retain their susceptibility to infection (Grimbacher et al., 2002).   
 
The underlying cause of HIES is still unknown.  Many studies have focused on the immune 
aspects of the disease, such as detection of eosinophilia in blood, sputum, and abscesses, 
defective granulocyte chemotaxis, abnormal T lymphocyte subsets, defective antibody 
production, and decreased production of, or responsiveness to cytokines such as IL-4 and IFN-γ.  
However, cytokine and proliferative responses in vitro to the mitogens phytohaemagglutinin 
(PHA), concanavalin A (ConA), and pokeweed mitogen (PWM) have been essentially normal 
(Grimbacher et al., 2002).   
 
Data suggest that the abnormality of IgE in HIES lies in the regulation of IgE synthesis.  Yet, it 
has also been shown that IgE catabolism is defective in HIES, which may contribute to the 
elevation.  IFN-γ specifically inhibits the IgE-enhancing activity of Th-cell-line supernatants and 
inhibits the effect of IL-4 on cell proliferation and induction of DNA synthesis.  Although both 
IFN-γ and IL-12 reduced IgE synthesis, neither cytokine could shut it off totally in HIES cells in 
vitro.  Interestingly, addition of IL-8 or blockade of IL-6 and TNF-α completely inhibited IgE 
production in HIES cells in vitro (Grimbacher et al., 2002).        
 
New and investigational compounds aimed at modulating the effects of IgE offer promise for 
controlling symptoms and preventing disease progression.  Suppression of IgE and/or IgE 
synthesis is likely to be an important strategy for these therapeutic interventions (Stokes and 
Casale, 2004).  Bronchodilators are used for symptomatic relief in asthma, but have no effect on 
the underlying inflammatory process.  Inhaled β2-adrenergic agonists are safe and highly 
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effective bronchodilators and it has proved impossible to find other classes of drug that are 
better.  Corticosteroids are the most effective treatment currently available for atopic diseases.  
Antihistamines also have a long history in the treatment of atopic diseases, while anaphylactic 
shock is treated with epinephrine.  However, all these therapies treat only the symptoms of the 
disease and not the cause; they are efficient toward short term relief or have systemic side effects 
that limit the dose that can be given over long periods (Barnes, 1999).   
 
Thus far, more research has been devoted to therapy rather than prevention of allergic diseases, 
and strategies to modulate IgE synthesis include the use of agents to block necessary 
transcription factors for IgE production or agents that will induce transcription factors that will 
inhibit IgE synthesis.  Other strategies include agents that either block the effect or synthesis of 
essential IgE promoting cytokines.  Finally, monoclonal anti-CD23 antibodies might also prove 
to be effective for the treatment of allergic respiratory diseases by their ability to inhibit IgE 
synthesis.  Another strategy that has proven effective in modulating the effects of IgE is the use 
of anti-IgE monoclonal antibodies.  New and investigational compounds aimed at modulating the 
effects of IgE offer promise for controlling symptoms and preventing disease progression and  
suppression of IgE and/or IgE synthesis is likely to be an important strategy for these therapeutic 
interventions (Stokes and Casale, 2004).   
Mast cell-stabilizing agents have been used and are well known for treating allergic disease 
(Chang and Shiung, 2006).  In developing mast cell-stabilizing therapeutic agents, an immediate 
question is whether mast cells can be stabilized without compromising their beneficial or 
protective functions (Boyce, 2003).  Mast cells have mostly been studied for their role in 
inflammation, but many studies have established their beneficial roles in innate and acquired 
immunity against bacteria, parasites, and other infectious organisms and in various sentinel and 
homeostatic functions (Boyce, 2003).  Many therapeutic targets down-regulate FcεRI, and 
subsequently inactivate mast cells.  An ordinary anti-IgE antibody can bind to IgE molecules 
already bound by FcεRI on basophils and mast cells, but there is always the risk that even a 
humanized antibody could induce sever anaphylaxis in an injected person.  However, the 
therapeutic anti-IgE, Omalizumab, binds human IgE with a high affinity and not to any other 
protein in the blood and interstitial fluid.  It binds to mIgE on B-cells and does not bind IgE 
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already bound by FcεRI on basophils and mast cells, nor to CD23 (figure 15) (Chang and 
Shiung, 2006).   
It has been some time that an antibody against IgE‟s FcεRI binding site has been discussed, but 
only recently has this antibody been brought about in Omalizumab.  Omalizumab effectively 
neutralizes IgE, and may even cause apoptosis of committed B-cells by crosslinking membrane 
IgE (figure 15) (Chang and Shiung, 2006).  This antibody is proving to be useful to a wide range 
of allergic disorders, but the expense of producing it makes it far beyond reach for most 
applications.  An alternative attractive option would be to design a small molecule inhibitor of 
the IgE-FcεRI interaction, to bind IgE or FcεRI in an inactive conformation.   
The intended pharmacologic purpose of anti-IgE, as it was initially developed, was to reduce IgE 
concentrations in the blood and tissue and to decrease IgE synthesis in B-cells (Chang and 
Shiung, 2006).  Aside from the concern that anti-IgE may compromise certain immune functions, 
anti-IgE has been reported to be well tolerated and causes relatively few serious adverse effects 
(Strunk and Bloomberg, 2006).  The various symptoms of discomfort, such as fever, headache, 
injection site rashes, are common for a subcutaneous injectable, and for an antibody drug, since 
the rates of these complications were similar in patients receiving anti-IgE treatment or placebo. 
There have been a few cases of anaphylactic reactions among patients with very sensitive 
disposition and complex, multiple diseases.  Anti-IgE may still benefit those highly sensitive 
patients, but caution must be taken while administering the drug (Dreyfus and Randolph, 2006). 
There has been no report of immune complex diseases or serum sickness disease.  Omalizumab 
was found not to induce antibody response against itself.  Recently though, a possible link has 
been made between the use of Omalizumab (medically called „Xolair‟) and adverse 
cardiovascular events (Osterweil, 2009).  
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Figure 15:  Targets for immunomodulation of IgE-mediated effects.  Cytokines from Th1 lymphocytes decrease 
the production of IgE.  T-bet stimulates the development of Th1 lymphocytes.  IL-12 and IFN-γ are associated 
with the Th1 phenotype and may be administered by plasmids containing their DNA.  IgE production is driven by 
IL-4 and IL-13 and is reduced by therapy targeting these cytokines.  The transcription factor GATA-3 promotes 
the production of Th2 lymphocytes, and this effect is inhibited with peroxisome proliferator-activated receptor 
(PPAR) agonist treatment.  Suplatast tosilate inhibits the synthesis of IL-4 and IL-5.  Anti-CD23 monoclonal 
antibodies inhibit IgE synthesis, whereas Omalizumab binds with free IgE, decreasing IgE levels and decreasing 
the expression of IgE receptors. Taken from Stokes and Casale (2004).   
1.5.1 CD23 as a therapeutic target 
While current therapy is leaning towards cure, rather than prevention, CD23 appears to be a 
promising target for understanding the sensitization phase of allergic disease, especially in 
children.  As indicated, it is evident that CD23 plays a role in the development of atopy, and 
could play a role as a therapeutic target in children at risk (Gould and Sutton, 2008). 
CD23 has also been targeted using an antibody, Lumiliximab, which is a primatized, IgG1, anti-
CD23 mAb consisting of primate variable regions and human constant regions.  This mAb has 
been shown to block IgE released from B-cells in vitro.  It is also proposed that, in addition to 
reducing IgE synthesis, this antibody may play a role in modulating APCs and allergen focusing 
and presentation to T-cells, thereby decreasing Th2 cell responses.  The inhibition of CD23 
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proteolysis could be a promising therapeutic approach.  These CD23-specific IgG antibodies 
have indeed shown an inhibition of IgE synthesis.  Lumiliximab has shown promise in Phase I 
clinical trials for asthma and most recently entered into Phase II clinical trials for chronic 
lymphatic leukaemia (CLL).  Inhibitors of CD23 signalling pathways have proven effective in 
rodent models of food allergy.  Whether these, or indeed Omalizumab, could be safely 
administered for children is something that has not yet been tested (Gould and Sutton, 2008).   
The fact that both CD23 and CD21 exist as soluble proteins in circulation provides opportunities 
to investigate their potential functions within the immune system, while also providing potential 
therapeutic targets.  The experimental design and aim of this project is to compare the response 
of PBMCs, isolated from normal, atopic and HIES patients, to various forms of CD23 in terms of 
their IgE regulating ability.  CD21 binding domains have also been used to antagonize the up-
regulation of IgE synthesis by sCD23.  Since various forms of CD23 bind to IgE, and possibly 
also CD21 with different affinities (Chen et al., 2002), the effect various CD23 forms have on 
IgE regulation, in conjunction with CD21 may be quite different.   
As our understanding of the network of interactions between IgE and its receptors improves, new 
opportunities for therapeutic intervention emerge.  It is therefore believed that an increased 
knowledge concerning the role of CD23 and CD21 in IgE regulation and use of CD23 as a 
therapeutic agent against allergies will be gained upon investigation of cytokine functions of 
recombinant human CD23 and its role in potential cell culture models. 
Studies of existing therapies suggest that an alternative therapy would be to develop protocols to 
elevate CD23 levels before B cell activation in view of the reduced IgE levels seen (Payet et al., 
1999).  Because it decreased serum IgE levels and hence addresses the cause of atopy more 
directly than existing therapy, CD23 has been proposed as an immune therapy for atopy (Kilmon 
et al., 2001).  The viability of this therapy needs further investigation because of known cytokine 
functions of soluble CD23 that promote inflammation.   
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2 Chapter 2:  Hypothesis and Experimental approach 
2.1 Problem Identification 
CD23 fragments are found in the circulation of normal human subjects.  Elevated concentrations 
of circulating soluble fragments are commonly associated with inflammatory or 
lymphoproliferative diseases.  It has been shown that antibodies to CD23 alleviate these disease 
conditions.  An investigation of the immunomodulatory functions of recombinantly produced 
CD23 and CD21, and characterization of the protein-protein interactions between these receptors 
is needed if the mechanisms of IgE homeostasis are to be understood and agents for intervening 
in this process developed.  The information can be used in further development of a potential 
application of the soluble forms of these receptor proteins in various models of immune therapy 
and to help understand the mechanism by which CD23 regulates IgE synthesis.    
2.2 Hypothesis 
Our hypothesis is that soluble forms of CD23 will bind CD21 and IgE with varying affinities 
depending on their size.  Further, the binding affinity of CD23 for IgE and CD21 relates to the 
secretion of IgE from B lymphocytes.  We propose investigating the theory of trimolecular 
complex formation between soluble CD23, CD21 and IgE causing IgE upregulation.   
The objectives, therefore, for this study are: 
1. Cloning, expression and purification of three forms of biologically active, recombinant 
soluble CD23. 
2. Cloning, expression and purification of the biologically active recombinant co-receptor, 
CD21, as well as SCR domains 1-2 and 5-8. 
3. Characterization of the recombinant proteins to ensure purity, biological activity, correct 
folding and ligand binding analysis.   
4. Optimising primary PBMCs as model for investigation of IgE homeostasis.   
5. Investigation of the cell response for immunomodulatory and effector functions induced 
by recombinant proteins. 
P a g e  | 57 
 
2.3 Experimental approach 
2.3.1  CD23 
2.3.1.1  Cloning and Molecular biology 
The polymerase chain reaction (PCR) was used to amplify coding regions for derCD23, sCD23 
and exCD23 from a pET22b bacterial expression vector containing cDNA of human CD23 
ectodomain.  Thereafter these coding regions were subcloned into bacterial expression vectors 
(pET28), as well as a shuttle vector (pTriEx 7 Ek/LIC) for bacterial, insect and mammalian cell 
expression.   
2.3.1.2  Expression 
All three CD23-encoding plasmids were isolated from E. coli DH5α cells and transformed into 
expression strains.  derCD23 and exCD23 were transformed into E. coli Rosetta DE3 cells, while 
it was found that sCD23 was best expressed from the E. coli Bl21 DE3 strain.  The proteins were 
all expressed with a hexahistidine tag either N-terminal (derCD23 and exCD23) or both C- and 
N-terminal (sCD23).     
2.3.1.3  Purification 
Inclusion bodies were isolated and recombinant CD23 proteins refolded by rapid dilution.  
Proteins were purified by two rounds of gel filtration chromatography and purified proteins were 
confirmed by N-terminal sequencing.  Endotoxin was removed to enable the use of these 
proteins in cell culture. 
2.3.2  CD21 
2.3.2.1  Cloning and molecular biology 
The polymerase chain reaction was used to amplify the coding regions of CD21 SCR 1-2, SCR 
5-8, and SCR 1-15, from the human CD21 cDNA contained within a Bluescript BillNEO (LTR-
SV NEO) plasmid.  Thereafter all CD21 coding regions were subcloned into pIEx 10 Ek/LIC 
vectors for expression by insect cells.   
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2.3.2.2  Transformation into Sf21 insect cells 
Following plasmid DNA preparation intended for transfection of eukaryotic cells, the 
Spodoptera-derived insect cells, Sf21 were used for transfection and subsequent expression of 
the CD21 proteins. 
2.3.2.3 Glycosylated CD21 SCR 1-2 protein and IgE 
CD21 SCR 1-2 was kindly donated by Joyce Fingeroth (Harvard University, Boston).  This form 
of CD21 SCR 1-2 is expressed in yeast.  IgE (from human myeloma) was purchased from 
Meridian Biosciences, USA. 
2.3.3 Protein interactions 
Protein modelling was performed in order to visualize and illustrate binding of IgE and CD21 as 
ligands to various forms of soluble CD23.  Molecular weight determination and analysis of 
oligomer content within the CD23 protein samples were determined by gel filtration HPLC.  
Comparative binding of soluble fragments (derCD23, sCD23, exCD23) of recombinant human 
soluble CD23 to CD21 SCR 1-2 and native IgE was performed by immobilising these proteins 
on a stable chip surface and performing surface plasmon resonance spectroscopy.  
2.3.4 The effect of CD23 and CD23-CD21 interactions on IgE secretion 
PBMCs were isolated from individuals with varying levels of allergenicity (the study was 
approved by the NMMU Human ethics committee, project reference H08-Sci-BCM-001).  These 
PBMCs were stimulated with IL-4 and anti-CD40 (determined to be the most suitable 
stimulants) to induce IgE isotype class switching of B-cells to produce IgE.  This was verified by 
phospho-STAT-6 analysis using flow cytometry.  IgE stimulation and secretion from PBMCs 
was monitored by incubation with recombinant soluble CD23 proteins (derCD23, sCD23 and 
exCD23) in the presence and absence of CD21 SCR 1-2 at predetermined optimum 
concentrations.  IgE levels were quantified by ELISA following incubation with proteins for 14 
days.  The role of co-receptor, CD21, was also investigated by interference and down-regulation 
of the gene by transfection with CD21 siRNA.      
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3 Chapter 3:  Construction of human soluble CD23 proteins 
3.1 Introduction 
There are many hosts available that have the capability of producing recombinant proteins, such 
as eukaryotic cell culture, insect, yeast and bacterial expression systems.  However, the 
development of bacterial expression systems, notably those in Escherichia coli, allow for large 
amounts of proteins from cloned genes (Misawa and Kumagai, 1999).  
 
The production of genetically engineered proteins requires the cloning of the desired fragment of 
deoxyribonucleic acid (DNA) into a vector that will express the protein.  This vector can then be 
used to transform a host.   
 
The pET System (Novagen) is reported to be the most powerful system yet developed for the 
cloning and expression of recombinant proteins in E. coli.  Target genes are cloned in pET 
plasmids under control of strong bacteriophage T7 transcription and translation signals; 
expression is induced by providing a source of T7 RNA polymerase in the host cell.  When T7 
RNA polymerase is fully induced, almost all of the cell‟s resources are converted to expression 
of the target gene.  This results in a yield of more than half of the total protein concentration 
being that of the desired protein after a few hours of induction.  The pET vector system is also 
able to maintain the target genes in a transcriptionally inactive state if not induced (Studier, 
1991).   
 
Within this system, there are two general categories of vectors available: transcription vectors 
and translation vectors.  Transcription vectors are designed for expression of target genes that 
already carry their own prokaryotic ribosome binding site and AUG start codon. Translation 
vectors contain the highly efficient ribosome binding site from the phage T7 major capsid protein 
and are used for the expression of target genes without their own ribosomal binding site.  The 
translation vector names are distinguished from the transcription vector names by the addition of 
a letter suffix following the name, e.g., pET-23a(+), which denotes the reading frame relative to 
the BamH I cloning site recognition sequence, GGATCC.  All vectors with the suffix “a” express 
from the GGA triplet, all vectors with the suffix “b” express from the GAT triplet, and all 
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vectors with the suffix “c” express from the ATC triplet of the BamH I recognition sequence.  
Vectors with a “d” suffix also express from the “c” frame, but contain an upstream Nco I cloning 
site in place of the Nde I site in that series for insertion of target genes directly into the AUG start 
codon.  All pET translation vectors have translation stop codons in all three reading frames 
following the cloning regions in addition to a downstream T7 transcription terminator (Studier 
and Moffatt, 1986)  
 
After plasmids are established in a non-expression host, they are most often transformed into a 
host bearing the T7 RNA polymerase gene (λDE3 lysogen) for expression of target proteins. 
This is a lambda derivative that has the phage 21 immunity region, and has a DNA fragment 
containing the lacI gene, the lacUV5 promoter and the T7 RNA polymerase coding region.  Once 
the DE3 lysogen has formed, the only promoter that is able to direct the transcription of the T7 
RNA polymerase gene is the lacUV5 promoter that is induced by isopropyl-β-D-
thiogalactopyranoside (IPTG).  By adding IPTG, the lysogen induces T7 RNA polymerase 
production, which then transcribes the target DNA in the plasmid (Studier, 1991). 
The pET System uniquely provides a choice of three types of expression hosts that suppress 
basal transcription to varying degrees.  For more stringent control, hosts carrying either pLysS or 
pLysE are available.  The pLys plasmids encode T7 lysozyme, which is a natural inhibitor of T7 
RNA polymerase, and thus reduces its ability to transcribe target genes in uninduced cells.  
pLysS hosts produce low amounts of T7 lysozyme, while pLysE hosts produce much more 
enzyme and, therefore, represent the most stringent control available in λDE3 lysogens.  The 
pET System also provides a choice of expression host backgrounds, all available as λDE3 
lysogens.  The most widely used host is BL21, which has the advantage of being deficient in the 
proteases encoded by both lon and ompT genes.  The pET vectors often also carry an antibiotic 
resistance gene to enable easy identification of positively transformed host cells.  This makes the 
pET vector system suitable for the cloning and expression of recombinant proteins (Studier, 
1991). 
Novagen has also introduced two derivatives of BL21 designed for special purposes (Studier, 
1991).  Rosetta host strains are BL21 derivatives designed to enhance the expression of 
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eukaryotic genes that contain codons rarely used in E. coli.  These strains supply tRNA genes for 
AGG (Arg), AGA (Arg), AUA (Ile), CUA (Leu), CCC (Pro) and GGA (Gly) on a Col-E1 
compatible chloramphenicol-resistant plasmid.  Thus the Rosetta strains provide for "universal" 
translation which is otherwise limited by the codon usage of E. coli.  Transcription of the tRNA 
genes is driven by their native promoters.  In Rosetta (DE3)pLysS and Rosetta(DE3)pLacI, the 
rare tRNA genes are present on the same plasmids that carry the T7 lysozyme and lac repressor 
genes, respectively (EMD Biosciences, 2004).  The NovaBlue strain is a convenient host for 
initial cloning of target DNA into the Ek/LIC vector series due to its high transformation 
efficiency and the high yields and excellent plasmid DNA that results from recA endA mutations 
(Brinkmann et al., 1989). 
A characteristic of using E. coli for recombinant protein expression is the production of inclusion 
bodies.  These insoluble and inactive aggregates are dense, amorphous protein deposits that can 
be found in the cytoplasmic and periplasmic space of bacteria.  A disadvantage of inclusion body 
production is that they have to be renatured and purified.  There are, however, advantages in the 
production of recombinant proteins in inclusion bodies, as often the recombinant protein is 
unstable if produced in the E. coli cytoplasm due to proteolysis and may also prove toxic to the 
host cell, thereby affecting the expression levels of the protein.  The relatively high density of the 
inclusion bodies also facilitates their isolation from the other cellular proteins by centrifugation 
to yield highly concentrated and relatively pure protein (Burgess, 1991). 
Some purification strategies optimize production of insoluble inclusion bodies in the cytoplasm. 
Inclusion bodies are extracted and solubilised; then the target protein is refolded in vitro. This 
procedure usually produces the highest yields of initial protein mass and protects against 
proteolytic degradation in the host cell.  However, the efficiency of refolding into active protein 
varies significantly with the individual protein and can be quite low (Burgess, 1991).  The first 
step towards a successful refold is the purification of the inclusion bodies from impurities by 
washing with a detergent.  Triton X-100, deoxycholate or low molar concentration of chaotrophs 
are usually used for this purpose.  Next, the purified inclusion bodies must be solubilised by 
strong denaturants such as 6 M guanidinium hydrochloride (Gdn-HCl), or 8 M urea.  Gdn-HCl is 
preferable to urea as it is a rather strong chaotroph, which may allow solubilisation of extremely 
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aggregated inclusion bodies that are resistant to solubilisation by urea.  Urea solutions may also 
contain isocyanate, leading to carbamylation of free amino groups of the polypeptide, especially 
upon long-term incubation at alkaline pH values.  In the case of cysteine-containing proteins, the 
isolated inclusion bodies usually contain non-native intramolecular and intermolecular disulfide 
bonds, which reduce the solubility of the inclusion bodies in the absence of reducing agents such 
as dithiothreitol (DTT), dithioerythritol, glutathione (GSH), cysteine, cystamine, or β-
mercaptoethanol.  Addition of these thiol reagents in combination with chaotrophs allows 
reduction of the disulfide bonds by thiol-disulfide exchange (Misawa and Kumagai, 1999).   
To obtain the correctly folded proteins after solubilisation of the inclusion bodies, excess 
denaturants and reducing thiol reagent have to be removed, and the reduced proteins transferred 
to oxidizing conditions.  Renaturation of solubilised inclusion bodies is initiated by removal of 
the denaturant by either dilution or dialysis.  The efficiency of renaturation depends on the 
competition between correct folding and aggregation.  To slow down the aggregation process, 
refolding is usually performed at low protein concentrations, within the range 10-100 µg/mL.  
Furthermore, the renaturation conditions must be carefully optimized with regard to external 
parameters such as temperature, pH, and ionic strength for each individual protein (Misawa and 
Kumagai, 1999). 
 
If a target protein contains disulfide bonds, the renaturation buffer has to be supplemented with a 
redox system.  Addition of a mixture of the reduced (RSH) and oxidized (RSSR) forms of low 
molecular weight thiol reagents such as glutathione, cysteine, or cystamine (molar ratios of 
reduced to oxidized compounds 5 : 1 to 10 : 1, respectively) usually provides the appropriate 
redox potential to allow formation and reshuffling of disulfides.  These systems increase both the 
rate and yield of renaturation/reoxidation by facilitating rapid reshuffling of incorrect disulfide 
bonds (Misawa and Kumagai, 1999).  
 
In order to accelerate thiol-disulfide exchange, the pH of the renaturation buffer should be at the 
upper limit that still allows the protein to form its native structure.  In order to prevent fortuitous 
oxidation of thiols by molecular oxygen, which is catalyzed by trace amounts of metal ions, 
EDTA should be added to the buffer solutions.  In addition to the control of parameters such as 
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temperature, pH, or redox conditions, the presence of low molecular weight compounds  in the 
renaturation buffer may have a marked effect on the yield of renaturation (Misawa and Kumagai, 
1999).  
3.2 Materials 
The pET22b-sCD23 vector was obtained from Dr Peter Sondermann (Max Planck Institute for 
Biochemistry, Martinsried, Germany).  This vector contained the CD23 ectodomain coding 
region from which derCD23, sCD23 and exCD23 coding regions were amplified.  The pET28b-
derCD23His, p28sCD23His, and p28exCD23 vectors were obtained from Gerhardt Boukes, 
Brodie Daniels, and Lauren Ferreira (NMMU, South Africa), respectively.  The LIC vectors, 
pET28b and E. coli Rosetta cells were obtained from Novagen (Madison, Wisconsin).  
Restriction enzymes, IPTG, lysozyme, PVDF membrane, and BSA were from Roche 
(Mannheim, Germany).  The QIAquick PCR purification kit, QIAquick plasmid isolation kit, as 
well as a QIAquick gel extraction kit were obtained from QIAGEN (Hilden, Germany).  E. coli 
DH5α cells were obtained from Invitrogen GmbH (Karlsruhe, Germany).  Automated DNA 
sequencing was performed by the DNA sequencing facility at the Central Analytical Facility, 
University of Stellenbosch.  All FPLC chromatography columns were obtained from Amersham-
Pharmacia Biosciences AB (Uppsula, Sweden).  Amicon Ultra-15 5k centrifugal filters were 
obtained from Millipore (Cork, Ireland).  Protein sequencing, according to the method of 
Muramoto et al., (1993), was performed at Tohoku University, Graduate School of Life 
Sciences, Japan.  Detoxi-GelTM Endotoxin Removal Gel was obtained from Pierce (Rockford, 
USA).  Limulus amebocyte lysate (LAL) endochrome
TM
 test kit was obtained from Charles 
Rivers Endosafe (Maryland, USA).  All other reagents were of analytical grade. 
3.3 Expression and purification of CD23 
3.3.1  Expression Vectors 
Expression vectors for derCD23, sCD23 and exCD23 were available in the FcR laboratory in the 
Department of Biochemistry and Microbiology at NMMU.  These vectors were constructed and 
kindly donated by Gerhardt Boukes (Boukes, 2005), Brodie Daniels (unpublished), and Lauren 
Ferreira (Ferreira, 2007), respectively.  The derCD23 vector encodes Ser
156
 – Glu298, sCD23 
P a g e  | 64 
 
encodes Met
150
 – Ser321, and exCD23 encodes Met48 – Ser321, shown schematically in figure 16.  
All three CD23 coding regions were fused to a poly-His tag. 
 
Figure 16:  The CD23 constructs.  (A) Schematic structure of CD23 with IgE binding site (IgEBC) and CD21 binding 
site (CD21BC) shown.  (B) Linear scale diagrams showing full length CD23 and the soluble constructs:  derCD23 
(Ser 
156
 – Glu 
298
), sCD23 (Met 
150
 – Ser
 321
) and exCD23 (Asp
48
- Ser
321
), engineered for this study.  CT, cytoplasmic 
tail; TM, transmembrane region; CTLD, C-type lectin-like domain. 
3.3.2 Test expression of recombinant CD23 
A single colony from an overnight culture of the desired transformed bacteria was used to 
inoculate 5 mL of LB broth containing kanamycin at 15 µg/mL.  If cells were expressed in 
Rosetta DE3 E. coli strain, chloramphenicol (36 µg/mL) was also added to the LB broth.  The 
inoculated 5 mL broth sample was incubated at 37ºC overnight with rotation at 160 rpm on an 
orbital shaker.  A 250 µL aliquot of the overnight culture was used to inoculate 50 mL 
prewarmed LB broth, containing kanamycin and/or chloramphenicol (at concentrations used 
above) as well as 1% (w/v) glucose, followed by incubation at 37ºC with rotation at 160 rpm.  
The absorbance at 600 nm was monitored and at ~0.6 optical density the cells were harvested by 
removing 900 µL to a sterile Eppendorf tube, adding 100 µL of 80% glycerol.  This glycerol 
stock was stored at -80ºC.  Simultaneously, another 500 µL of culture was removed and 
aliquoted into an Eppendorf tube and the cells were pelleted by centrifugation and the medium 
discarded.  The pellet was stored at -20ºC and later electrophoresed on an SDS-PAGE gel.  After 
removal of the 500 µL of culture, protein expression was induced in the remaining 50 mL of 
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culture by adding IPTG to a final concentration of 1 mM.  Growth was further monitored at 600 
nm at 0.5,1, 2, 3, 4 and 16 hours after induction.  At each of these time intervals, another 500 µL 
of sample was removed and the cells pelleted as before, for later use in electrophoresis.  At the 
16 hour interval, after the 500 µL sample had been removed, the remaining cells were harvested 
by centrifugation at 3600 x g for 10 minutes in a 50 mL Falcon tube using an Eppendorf 5804R 
centrifuge fitted with an A-4-44 rotor.  The pellet was resuspended in 10 mL sonification buffer 
(50 mM Tris-HCl, pH 7.8, containing 0.3 M NaCl and 0.2% NaN3) and stored at -80ºC.   
 
Prior to electrophoresis, the pelleted cell samples were loosened by adding 100 x the sample‟s 
600 nm absorbance, in µL, of double-strength Laemmli SDS-PAGE reducing buffer (2 mL 0.5 
M Tris-HCl, pH 6.8, 1.6 mL 80% glycerol, 3.2 mL 10% (w/v) SDS, 0.8 mL β-mercaptoethanol 
and 0.4 mL 0.2% (w/v) bromophenol blue in a final volume of 10 mL).  The samples were 
heated at 95ºC for 30 minutes in order to lyse the cells.  Lysed cell samples of 20 µL each were 
analysed on an SDS-PAGE gel to determine whether expression of the desired protein had 
occurred.   
3.3.3 SDS-PAGE  
SDS-PAGE was performed in 15% acrylamide gels according to the method of (Laemmli, 1970). 
3.3.4  Preparative expression of recombinant protein 
Preparative expression of protein was performed exactly as for test expression, except that 3 x 1 
litre cultures were induced with 1 mM IPTG for the optimal time established by the test 
expressions (3 hours).  Cells were harvested by centrifugation at 5000 x g for 30 minutes at 4ºC 
in a Beckman Avanti-J25 centrifuge.  The cell pellet from 1 L of culture was resuspended in 10 
mL sonification buffer and the cell suspension was stored at -80ºC in 50 mL Falcon tubes.   
3.3.5  Inclusion body isolation 
The cells harvested from preparative expression were thawed, after which lysozyme was added 
to a concentration of 2 mg/mL.  The cell suspension together with the lysozyme was incubated 
for 1 hour at room temperature with constant mixing by slow, end-over-end rotation.  The cell 
suspension became viscous, which proved lysozyme treatment to be successful.  After 
incubation, the cells were transferred to ice.  Keeping a Rosette vial on ice, the cells were 
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sonicated for 4 bursts of 45 seconds each, followed by 2 bursts of 105 seconds, pulsing at a 50% 
duty cycle and 40% power using an HD2200 Sonopuls (Bandelin Electronics GmbH, Berlin, 
Germany) fitted with a UW2200 probe.  The sonicated cells were transferred to a 50 mL 
centrifuge tube and centrifuged at 5000 x g for 30 minutes at 4ºC.  The supernatant was decanted 
and a sample retained for SDS-PAGE analysis.  The pellet was resuspended, on ice, in 15 mL 
inclusion body wash buffer (50 mM Tris-HCl, pH 7.8, containing 0.3 M NaCl, 0.5% LDAO and 
0.2% NaN3) with 5-6 strokes using a Potter-Elvejham homogeniser.  The resuspended inclusion 
bodies were decanted into a clean 50 mL centrifuge tube and the Potter tube rinsed with 4 mL 
inclusion body wash buffer and 4 strokes with the homogeniser.  The washes were pooled and 
centrifuged as before, keeping an aliquot of the wash supernatant for analysis.  The inclusion 
bodies were continuously washed until the majority of E. coli proteins were removed (~8 
washes), the final wash being performed with sonification buffer.  The washed inclusion bodies 
were suspended in 2 mL sonification buffer and stored at 4ºC.     
 
SDS-PAGE analysis was performed on the washed inclusion bodies and supernatant samples in 
order to determine the purity of the inclusion bodies and to determine whether the desired protein 
was not lost during the washing process.  A 2-5 µL aliquot of the washed inclusion bodies was 
added to 15-18 µL of 2x reducing sample buffer, while 10 µL aliquots of the supernatant 
samples were added to 10 µL 2x reducing sample buffer and the samples boiled for 5 minutes 
prior to SDS-PAGE.   
3.3.6  Refolding of protein using the rapid dilution technique 
A protein stock was prepared from the inclusion body preparation by diluting 1 part inclusion 
bodies to 10 parts 6 M guanidinium hydrochloride in 20 mM Tris-HCl, pH 8.0, containing 0.02% 
NaN3, until a final protein concentration of around 2 mg/mL was obtained.  β-mercaptoethanol 
was added to a final concentration of 100 mM.  The protein concentration was determined by 
measuring the absorbance at 280 nm, where an absorbance of 1 ~ 0.8 mg/mL.   
 
The protein stock solution was added to 500 mL refolding buffer (1.5 M arginine, 100 mM Tris, 
150 mM NaCl, 5 mM GSH, 0.5 mM GSSG and 10 mM CaCl2 at pH 8) at 4ºC with constant 
stirring so that a protein concentration of 100 µg/mL was achieved (Daniels et al., 2005).  The 
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redox potential of the solution was monitored until it was below 1 mM free thiols (section 3.3.7).  
The solutions were stirred continuously throughout the duration of the experiment, which was 
carried out at 4ºC for at least 72 hours.   
3.3.7  Measurement of the redox potential 
This method is based on the reaction of the thiol with 5, 5‟-dithiobis (2-nitrobenzoic acid) 
(DTNB) to give the mixed disulfide and 2-nitro-5-thiobenzoic acid (TNB) that can be quantified 
by absorbance at 412 nm (Aitken and Learmonth, 1996). 
 
The redox potential of the refolding buffer was monitored using Ellman‟s reagent (Ellman, 
1959).  In this method, 25 µL of 1 M Tris (pH 8) was mixed with 2 µL 100 mM DTNB (in 
ethanol) and 1-5 µL of the refolding buffer and made up to 500 µL with ddH2O.  The optical 
density was measured at 412 nm using an Ultrospec 2000 (Pharmacia Biotech).  The optical 
density obtained was used to calculate the redox potential, using a molar extinction coefficient of 
13 600 cm
-1
.M
-1
.   
3.3.8 Ultrafiltration 
The refolded CD23 was concentrated under nitrogen gas by ultrafiltration using an Ultrafiltration 
unit (Amicon) fitted with a 0.22 µm Ultracel regenerated cellulose filter with a molecular weight 
cut off of 5000 kDa.  The 500 mL sample was concentrated to 15 mL before loading onto an 
ultra centrifugal filter (Amicon).  The centrifuge tube was equilibrated with TNC purification 
buffer (100 mM Tris, 150 mM NaCl, 10 mM CaCl2 at pH 8) and centrifuged at 4000 x g until a 
volume of 2 mL was obtained. 
3.3.9  Gel-filtration Chromatography 
The concentrated protein was chromatographed on a Superdex 75 (26/60) gel filtration 
chromatography column using an Äkta FPLC (Amersham Pharmacia Biotech).  This was done 
by injecting a 2 mL sample of protein with a flow rate of 2 mL/min with PBS pH 7.4 as eluent.  
The fractions were collected in 5 mL volumes and the relevant peaks pooled together and 
concentrated using ultra centrifugal filters as above.   
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3.3.10  Bicinchoninic acid protein assay 
The bicinchoninic acid (BCA) assay is based on the reduction of Cu
2+
 to Cu
+
 by protein in an 
alkaline medium and the detection of the resulting cuprous cation by bicinchoninic acid (Smith et 
al., 1985). 
 
The working reagent was prepared by mixing 50 parts of reagent A (1 g sodium bicinchoninate, 
2 g Na2CO3, 0.16 g sodium tartrate, 0.4 g NaOH, 0.95 g NaHCO3 in 100 ml ddH2O at pH 11.25) 
with 1 part of reagent B (0.4 g CuSO4•5H2O in 10 mL H2O). After pipetting 10 µL of the protein 
sample into a well in a microtitre plate, 200 µL of the working reagent was added to each well.  
The samples were mixed by shaking on a Multiscan MS microtitre plate reader, covered and 
incubated for 60 minutes at 37ºC.  The absorbance was measured at 540 nm using a Multiscan 
MS microtitre plate reader (Labsystems).  Bovine serum albumin (BSA) was used to calibrate 
the assay.   
3.3.11  Protein sequencing 
The pure protein was electrophoresed using SDS-PAGE. An unstained gel was used for protein 
transfer to PVDF membrane (section 3.3.12) for sequencing of the protein by Prof. Koji 
Muramoto (Tohoku University, Graduate School of Life Sciences, Japan), according to the 
method of (Muramoto et al., 1993). 
3.3.12  Protein transfer 
Proteins that were separated using SDS-PAGE were transferred to an Immobilon PVDF 
membrane for N-terminal amino acid sequencing and Western blotting.  This protein transfer 
was achieved using the Transblot® SD semi-dry electrophoretic transfer cell system (Bio-Rad).   
 
After electrophoresis, the SDS-PAGE gel was placed in transfer buffer (48 mM Tris, 39 mM 
glycine, 20% (v/v) methanol buffer) for 20 minutes to allow for the equilibration of the gel.  A 
piece of Immobilon PVDF membrane the size of the gel was pre-wet in 5-10 mL 100% methanol 
for 2 seconds followed immediately with soaking in 500 mL ddH2O for 5 minutes to remove the 
methanol.  The membrane was equilibrated for 15 minutes in 500 mL transfer buffer.  Five 
pieces of blotting paper were also equilibrated in transfer buffer.   
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The blotting cassette was assembled according to the Bio-Rad instruction manual for the 
Transblot® SD semi-dry electrophoretic cell.  The transfer was carried out for 3 hours at 25 V 
with a constant current of 5 mA/cm
2
. 
 
Once transfer was complete, if the membrane was to be sent for sequencing, it was stained with 
Coomassie Blue (0.1% Coomassie Blue R-250 in 40% methanol, 10% acetic acid) for 10 
minutes and destained with destain solution (40% methanol, 10% acetic acid in ddH2O) for 10 
minutes.   
3.3.13  Endotoxin removal 
The Detoxi-Gel
TM
 Endotoxin Removal Gel support (Pierce, USA) was used to remove 
endotoxins from the purified CD23 protein.  This gel is polymyxin B immobilized on agarose.  
This ligand binds and removes pyrogens from solution.  The polymyxins are a family of 
antibiotics that contain a cationic cyclopeptide with a fatty acid chain.  Polymyxin B can 
neutralize the biological activity of endotoxins by binding to the lipid A portion of bacterial 
lipopolysaccharide (Issekutz, 1983). 
 
The column was packed by suspending the gel as 50% slurry in filter sterilized TNC purification 
buffer made with pyrogen free water.  The slurry was placed in the bottom of a suction filter 
flask along with a magnetic stirrer.  While stirring the slurry, an aspirator was used to create a 
vacuum within the flask.  The solution was degassed for approximately 15 minutes.  The 
appropriately sized column was packed with degassed slurry and the gel allowed to settle for 30 
minutes.  The column was regenerated with 5 column volumes of 1% sodium deoxycholate; 
followed by three to five column volumes of pyrogen-free water to remove the detergent.  The 
column was regenerated before each use, including first time use.  The gel was equilibrated with 
3-5 volumes of a TNC buffer.  The sample was then applied.  Two hundred microlitres of 
pyrogen-free buffer was added to the column, the top and bottom of the column were capped and 
the column allowed to incubate for at least an hour.  The top and bottom caps were removed 
sequentially and pyrogen free TNC buffer was added to elute the sample.   
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The sample was collected by gravity flow by adding aliquots of the same pyrogen free buffer.  
The void volume of the 1 ml column is 0.3-0.5 mL.  This is the volume of solution that was 
collected from the column before the sample had begun to emerge from the column.  Once 
collected, the sample was, once again, passed over the column as explained above. 
3.3.14  Detection and quantification of endotoxins 
The Limulus amebocyte lysate (LAL) endochrome
TM
 test kit (Charles Rivers, USA) was used to 
test the amount of endotoxin present in the protein sample after purification.  This kit is the most 
sensitive and specific means available to detect and measure bacterial endotoxin, a fever-
producing by-product of gram-negative bacteria commonly known as pyrogen.  The basis of the 
test is that endotoxin produces an opacity and gelation in LAL that is easily recognized 
(Hochstein, 1987).  The endpoint chromogenic LAL test method is a simple, reproducible, 
quantitative test that is conducted by mixing ENDOCHROME
TM
 and test specimen and 
monitoring the appearance of yellow colour, the colour intensity of which is directly related to 
endotoxin concentration in the sample.  In principle, the bacterial endotoxin initiates activation 
of a proenzyme in LAL that cleaves a peptide from coagulogen to produce opacity (Levin and 
Bang, 1968).  However, in the presence of a colourless substrate (S-2423) it rapidly catalyzes the 
cleavage of the chromophore, yielding p-nitroaniline (pNA).  The pNA produces the yellow 
colour that is measured spectrophotometrically at 450nm (Jordan and Coomer, 1993).   
All reagents were reconstituted as instructed by the manual.  The microtitre plate method was 
followed.  Fifty µL test sample or standard was added, in quadruplicate, to the microtitre plate.  
The plate was incubated at 37ºC for 5 minutes.  After incubation, 50 µL of LAL solution was 
added and the plate was incubated for a further 18 minutes at 37ºC.  Substrate (100 µL), 
reconstituted with 100 mM Tris-buffer (pH 8) was added and the plate was incubated at 37ºC for 
8 minutes.  Stop solution (100 µL 20% acetic acid) was added and the plate was mixed 
immediately before measuring absorbance at 412nm. 
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3.4 Results and discussion 
3.4.1 Expression vectors 
The expression vector containing the coding region for derCD23, pET28bderCD23His (Ser
156
 - 
Glu
298
) was obtained from (Boukes, 2005), that for sCD23, p28sCD23His (Met
150
 - Ser
321
) was 
obtained from Brodie Daniels (unpublished data) and that for exCD23, p28exCD23 (Asp
48
 - 
Ser
321
) was obtained from (Ferreira, 2007) (figure 17 a, b and c, respectively).  
  
   (a)                     (b)                        
   
   (c) 
Figure 17: Vector maps used for construction of the recombinant plasmids for expression of the CD23 proteins. 
(a) derCD23, (b) sCD23 and (c) exCD23.  The restriction sites used for cloning and the position of the tag and the 
DNA insert relative to the position of the various other sequence landmarks present on the vector are shown. 
p28exCD23 
6165 bp 
lac operator 
lac I 
kan 
sequence 
exCD23 
T7 promoter 
His tag 
thrombin 
f1 origin 
T7 terminator 
Bam H I (199) 
Nde  I (1035) 
p28sCD23His 
5800 bp 
lac operator 
lac I 
kan  
sequence 
sCD23 
T7 promoter 
His tag 
His tag 
thrombin 
f1 origin 
T7 terminator 
Nde  I (670) 
Xho  I (159) 
Nco  I (218) 
Nco I (728) 
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5744 bp 
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T7 promoter 
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thrombin 
f1 origin 
T7 terminator 
Hin d III (174) 
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Nde I (614) 
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Plasmids were verified by DNA sequencing (University of Stellenbosch).  The DNA sequences 
were aligned with the human sequence of CD23 (obtained from Genbank, accession code 
NM002_002) using the ClustalW alignment tool software on the EMBL-EBI webpage, available 
at http://www.ebi.ac.uk/clustalw/index.html.  The alignments gave no errors (Addendum A).  
DNA sequences were translated using ExPASy translate tool, available at 
http://www.expasy.org/tools/dna.html. and aligned with the human CD23 protein sequence 
(obtained from Genbank, accession code NP001_993).  The protein sequences aligned correctly 
and each amino acid correlated positively to the correct reading frame (see Addendum A for 
sequences).  
3.4.2 Expression and purification of CD23 
The recombinant CD23 proteins were expressed in E. coli Bl21 (DE3) (for sCD23) and Rosetta 
(DE3) E. coli cells (for derCD23 and exCD23) after induction with IPTG (1 mM) for 3 hours 
(figure 18).  Figure 18 (a) shows derCD23 as an example of expression pre-induction and post-
induction (0.5-16 hours).  It is evident that the target protein is expressed successfully, at the 
determined molecular weight of ~16 kDa for derCD23, ~25 kDa for sCD23 (figure 18b) and ~37 
kDa for exCD23 (figure 18c) in comparison to migration of the marker.  It is also evident from 
test expression experiments that 3 hours is the optimum time for post-induction expression (lane 
indicated with a star in figure 18 a) as it yields the highest amount of protein and preparative 
expression was therefore carried out accordingly.   
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  (a)                          
  (b)               (c)             
Figure 18: Expression of recombinant CD23 proteins.  (a) derCD23 at various time intervals (0.5 – 16 hours); star 
indicates optimum time for post-induction expression of 3 hours (1) Low Molecular Weight Marker (Sigma) 
showing adjacent molecular weight in Da (2) pre-induction (3) 1/2 hour post induction (4) 1 hour post induction 
(5) 3 hours post induction (6) 16 hours post induction, (b) sCD23 (1) peQ Gold marker II showing adjacent 
molecular weight in Da (2) pre-induction (3) 3 hours post induction, (c) exCD23 (1) peQ Gold marker II (2) pre-
induction (3) 3 hours post induction.  Arrows annotated on the diagrams indicate the respective expressed 
proteins (a) equivalent to ~16 kDa (b) ~25 kDa and (c) ~37 kDa. 
The harvested cells were lysed, sonicated and the inclusion bodies for derCD23, sCD23 and 
exCD23 were isolated by washing 8 times with inclusion body wash buffer (figure 19).  The 
SDS-PAGE analysis verified enrichment of the CD23 recombinant proteins in the inclusion 
bodies, and removal of the majority of contaminating E. coli protein with successive washing.   
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  (a)                    
  (b)                               
  (c)                         
Figure 19:  Reducing SDS-PAGE (15% acrylamide) illustrating isolation of CD23 inclusion bodies. (a) der CD23 (b) 
sCD23 (c) exCD23; (1) Molecular weight marker  (2) wash 1 (3) wash 2 (4) wash 3 (5) wash 4 (6) wash 7 (7) wash 8 
(8) 10 µL of purified inclusion bodies (9) 1 µL of purified inclusion bodies.  Bands of interest are denoted by 
arrows. 
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The first few wash steps illustrate vast amounts of typical E. coli protein as well as excess 
lysozyme (dark band of low molecular weight protein) being washed away.  The latter steps 
show a purer protein (inclusion bodies appeared whiter to the naked eye), whereas the last two 
samples on each gel show purified inclusion bodies at both a high and low concentration.  The 
inclusion body pellet was retained and resuspended in 1 mL sonification buffer.  The 
concentration of the inclusion bodies was determined.  The concentration of derCD23 was 20 
mg/mL, sCD23 was 36 mg/mL and exCD23 was 29 mg/mL.    
After inclusion bodies were purified a large scale refold was performed using 50 mg of protein in 
500 mL of refold buffer.  Refolded CD23 proteins were concentrated to ~2 mL and individually 
purified using Superdex75 (26/60) gel filtration chromatography.  Chromatography was 
performed using TNC buffer (100 mM Tris, 150 mM NaCl, 10 mM CaCl2 and 0.02% NaN3, pH 
8), at a flow rate of 2 mL/min (figure 20).  The chromatograph for each protein (derCD23, 
sCD23 and exCD23) showed the void volume (indicated with a triangle), preceding a single peak 
of purified protein, followed by a shouldered peak (indicated with a star) representing 
glutathione (oxidized and reduced).  The corresponding tubes for the peak representing each 
purified protein were pooled, concentrated and routinely re-chromatographed to ensure the 
highest quality of pure protein.  Molecular weight was confirmed by SDS-PAGE and protein 
concentrations were determined using BCA.  derCD23 yield was 0.81 mg/L culture, sCD23 4.9 
mg/L culture, while exCD23 yielded 0.86 mg/L culture.   
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Figure 20: Purification of refolded CD23 by gel filtration chromatography.  derCD23 (denoted by grey arrow and 
line), sCD23 (denoted by black arrow and line) and exCD23 (denoted by dotted arrow and line).  Void volume 
indicated with a triangle.  Glutathione [oxidized (GSSG)/reduced (GSH)] is indicated with a star. 
The purity of each CD23 protein was verified by N-terminal sequencing (figure 21) and SDS-
PAGE (figure 22).  From the sequencing results, it is evident that each CD23 protein was 
positively verified.  It is apparent sCD23 and exCD23 have lost the N-terminal formyl-
methionine, which is common in expression from E. coli.  It is also apparent that derCD23 has 
been cleaved at the thrombin cleavage site, and therefore also lost the N-terminal hexahistidine 
tag.  As the proteins were purified by gel filtration chromatography and not nickel ion 
chromatography, this did not prove to be a problem. 
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Figure 21:  Aligned sequence for CD23 variants.  Amino acid numbers are provided on right of figure for each 
variant.  The CD23 variants encode exCD23
48 – 321
, sCD23
150 – 321 
and derCD23
156 – 298
.  Sequences were derived 
from translation of DNA-sequenced expression vectors and N-terminal sequencing (red residues); underlined 
sequences are vector-encoded. 
The predicted sizes for pure derCD23, sCD23 and exCD23 are 16, 25 and 37 kDa, respectively.  
Figure 23 shows derCD23 migrating slightly below the 17 kDa marker, sCD23 migrating slightly 
below the 26 kDa marker and exCD23 migrating slightly above the 34 kDa marker, thus 
corresponding well with the banding pattern shown on the gel, therefore showing successful 
purification.     
hCD23            MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERA 60 
exCD23-NHis      -------------------------- GSSHHHHHHSSGLVPRGSHMDTTQSLKQLEERA 34 
sCD23            ------------------------------------------------------------ 
derCD23          ------------------------------------------------------------ 
                                                                              
 
hCD23            ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 120 
exCD23-NHis      ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 94 
sCD23            ------------------------------------------------------------ 
derCD23          ------------------------------------------------------------ 
                                                                              
 
hCD23            SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 180 
exCD23-NHis      SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 154 
SCD23            ----------GSSHHHHHHSSGLVPRGSHMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 31 
derCD23          -------------------------------SHMSSGFVCNTCPEKWINFQRKCYYFGKG 25 
                                                   ************************** 
 
hCD23            TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 240 
exCD23-NHis      TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 214 
sCD23            TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 91 
derCD23          TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 85 
                 ************************************************************ 
 
hCD23            DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 300 
exCD23-NHis      DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 274 
sCD23            DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 151 
derCD23          DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAE-- 143 
                 **********************************************************   
 
hCD23            GPDSRPDPDGRLPTPSAPLHS 321 
exCD23-NHis      GPDSRPDPDGRLPTPSAPLHS 295 
sCD23            GPDSRPDPDGRLPTPSAPLHS 172 
derCD23          --------------------- 
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Figure 22: SDS-PAGE analysis of pure CD23 proteins.  (1) peQGold marker IV (2) derCD23 (3) sCD23 (4) exCD23.   
3.4.3 Removal and quantification of endotoxin 
Humans can develop symptoms when exposed to as little endotoxin as 0.5 ng/kg body weight. 
These symptoms include, but are not limited to, fever, low blood pressure, increased heart rate, 
and low urine output; and even small doses of endotoxin in the bloodstream are often fatal. 
Endotoxins were removed from the proteins by means of affinity chromatography using an 
endotoxin removal kit based on a polymyxin B immobilized support.  After endotoxin removal, 
proteins were tested for residual levels of endotoxin (table 1).  These levels were found to be 
within the specified range previous authors have used for immunological work with recombinant 
protein expressed in E. coli (< 1 ng/mg protein) to consider their effect on human cells and cell 
lines negligible  (Pollock, 2003).  
Table 1: Protein and Endotoxin concentrations of purified recombinant CD23 
Proteins Protein yield before 
endotoxin removal  
(mg/L culture) 
Protein yield after 
endotoxin removal 
(mg/L culture) 
Endotoxin 
concentration 
(pg/mg protein) 
derCD23 0.81 0.47                34.29 
sCD23 4.90 3.55 1.40 
exCD23 0.86 0.69                10.40 
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3.4.4 Conclusions 
The key objectives in this chapter were the purification of recombinant CD23 proteins.  We 
accomplished this using the pET vector bacterial expression system, purifying three variants of 
soluble CD23 fragments, derCD23, sCD23, and exCD23. 
It has previously been reported by Kelly et al., (1998) and others (Bartlett et al., 1995; 
Delespesse et al., 1991; Letellier et al., 1989; Rao et al., 1987) that the creation of soluble CD23 
naturally occurs by proteolytic cleavage within the stalk, resulting in the release of a 37 kDa 
fragment, with subsequent cleavage forming smaller fragments.  Recombinant proteins are also 
likely to be cleaved by endogenous proteases.  Letellier et al., (1989) found that recombinant 
exCD23, expressed in Chinese hamster ovary (CHO) mammalian cells using a modified pSVd-
ER expression plasmid, is not exceptionally stable upon storage, and that degradation into 
smaller CD23 fragments was increased with storage time, even upon addition of protease 
inhibitor cocktail.  Consequently, entirely pure preparations of exCD23 are difficult to construct.  
After purification of the CD23 proteins, I stored them at -80°C in aliquots to avoid freeze/thaw 
cycles.  Proteins were routinely subjected to SDS-PAGE analysis before addition to cell culture 
experiments (chapter 6), which showed intact protein.          
The production of derCD23 and sCD23 was initially attempted by construction of pTriEx 7 
recombinant vectors, designed as shuttle vectors for mammalian, insect, or bacterial expression 
of recombinant proteins (experiments not shown).  The plan was to construct single vectors that 
would allow expression of CD23 in any of the three expression host systems.  The vector maps 
for these constructs are shown in addendum B.  Expression of these vectors in insect cells failed 
(see chapter 4 for a more detailed discussion of the insect expression system).  Despite positive 
sequence correlation of derCD23, expression of derCD23 or sCD23 was not evident even in E. 
coli cells.  Various expression hosts [E. coli Bl21 (DE3), Rosetta (DE3) as well as NovaBlue 
cells], various concentrations of IPTG to induce expression (0.0625 – 1 mM), various detection 
methods for expressed proteins (Coomassie Blue, silver staining, running whole cells, soluble 
and insoluble fractions, as well as Western blotting using antibodies against the HIS tag) were 
attempted but all failed to prove expression of CD23 was evident.  It was thought that cells might 
be expressing the protein prior to IPTG induction, but this was ruled out by electrophoresis of 
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samples taken before and after induction which showed no pre-induction expression.  It was 
therefore concluded that the expressed protein was proving to be toxic to the cells and therefore 
inhibiting growth.  Although addition of 0.5-1% glucose was added to try and prevent toxicity, 
still no protein expression was evident. 
This data is not shown as the bacterial expression system based on pET vectors worked well for 
CD23.  
It has been demonstrated that the pET vector system is highly efficient in swiftly producing 
recombinant protein.  The derCD23 and exCD23 produced in our study are the same proteins 
produced in the same way by Hibbert et al., (2005) and McCloskey et al., (2007).  sCD23 has 
previously been expressed in insect cells (Wurzburg et al., 2006) and in our laboratory in 
bacterial cells (Daniels et al., 2005).  These proteins are the same as those obtained in vivo by 
proteolytic cleavage of the membrane CD23 receptor protein (Beavil et al., 1995).   
The vectors containing the coding regions for derCD23, sCD23 and exCD23 were verified by 
sequencing and transformed into Bl21 and Rosetta DE3 expression strains of E. coli.  CD23 was 
expressed in inclusion bodies, which were shown to be effectively solubilised and successfully 
refolded (refer chapter 5).  Gel exclusion chromatography proved to yield pure proteins, 
authenticated by SDS-PAGE and protein sequencing, for binding studies.  Endotoxin was 
removed to an acceptable level for future cell culture experiments (chapter 6). 
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4 Chapter 4: Construction of human soluble CD21 
4.1 Introduction 
In contrast to the interaction between CD23 and IgE, the interaction between CD23 and CD21 
may need glycosylation of CD21 (Sutton and Gould, 1993) and is thus a more typical lectin 
interaction (Gould and Sutton, 2008; Sutton and Gould, 1993).  The amino acid sequence of 
CD21 has 11 potential sites for N-linked glycosylation (Aubry et al., 1994).  It was therefore 
necessary to use a eukaryotic expression system in order to glycosylate CD21 proteins, which 
would be lacking if expressed through a bacterial expression system. 
Insect cells provide an alternative system for expressing proteins that require certain post-
translational modifications to retain solubility and activity.  The focus on high-throughput (HT) 
expression screening to rapidly identify the appropriate expression system for hundreds or 
thousands of individual targets in parallel has traditionally not involved insect expression 
systems.  The several weeks that are required to create, titre, and maintain viral recombinants 
make conventional baculovirus systems too complex and time-consuming for HT processing.  
For HT purposes, researchers have been limited to cloning open reading frames into bacterial 
expression vectors to make recombinants that are used to direct target protein expression in E. 
coli.  Insect vectors that rely on Autographa californica nuclear polyhedrosis virus (AcNVP) 
immediate early promoters to drive expression need no baculovirus component, so the time 
required from transfection to expression is measured in days, not weeks (Loomis et al., 2003). 
The application of recombinant baculoviruses for the expression of recombinant proteins in 
insect cells was first described in the early 1980s (Pennock et al., 1984; Smith et al., 1983). 
Since these initial reports, the baculovirus insect cell expression system has been extensively 
developed and used for the production of numerous recombinant proteins in insect cells (Kost et 
al., 2000; O'Reilly et al., 1994).   
The Baculovirus Expression Vector System (BEVS) is a eukaryotic system for heterologous 
gene expression.  Baculovirus expression provides correct folding of recombinant protein as well 
as disulfide bond formation, oligomerization and other important post-translational 
modifications.  Consequently the over expressed protein exhibits the proper biological activity 
and function.  The BEVS is based on the introduction of a foreign gene into a nonessential region 
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of the viral genome via homologous recombination with a transfer vector containing the cloned 
gene; an event that occurs in the co-transfected insect cells.  The production of foreign protein is 
then achieved by infection of additional insect cell cultures with the resultant recombinant virus 
(Smith et al., 1983).  
The pIEx Ek/LIC vectors are expression vectors designed for transfection into Spodoptera-
derived insect cells.  Ligation-independent cloning (LIC) was developed for the directional 
cloning of PCR products without the need for restriction enzyme digestion or ligation reactions 
(Aslanidis and de Jong, 1990; Haun et al., 1992).  The Ek/LIC vectors are engineered to express 
the target protein immediately downstream of an enterokinase cleavage site so that all vector-
encoded fusion sequences can be removed from the purified protein.  All Ek/LIC vectors possess 
the same cloning site so that an Ek/LIC-prepared target insert can be annealed into any or all of 
the Ek/LIC vectors in a 5-minute reaction (Aslanidis and de Jong, 1990). 
The LIC method takes advantage of the 3'→5' exonuclease activity of T4 DNA polymerase to 
create very specific 13- or 14-base single-stranded overhangs in the Ek/LIC vector.  PCR 
products with complementary overhangs are created by building appropriate 5' extensions into 
the primers.  The purified PCR product is treated with LIC-qualified T4 DNA polymerase in the 
presence of dATP to generate the specific vector-compatible overhangs.  Cloning is very 
efficient because only the desired product forms during the annealing process.  The annealed 
Ek/LIC vector and insert are transformed into competent E. coli cells.  Covalent bond formation 
at the vector-insert junctions occurs within the cell to yield circular plasmid.  After verification, 
the construct is ready for expression in bacteria or transfection into insect or mammalian cells 
depending on the characteristics of the chosen vector (Haun et al., 1992). 
After recombinants are established in E. coli, plasmids are isolated and transfected into Sf9 or 
Sf21 insect cells for target protein expression.  The vectors employ an optimal combination of 
AcNPV baculovirus-derived transcription elements, the hr5 enhancer and the ie1 immediate 
early promoter. This promoter/enhancer combination recruits endogenous insect cell 
transcription machinery, thus eliminating the need to utilize baculovirus and avoiding the 
cytopathic effects associated with infection.  The pIEx vectors contain the baculovirus p10 
promoter for protein expression in infected insect cells. The p10 promoter is highly active during 
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the very late phase of baculovirus infection, thus it is necessary to prepare a recombinant 
baculovirus, using the pTriEx plasmid as a transfer vector (Guarino and Dong, 1994).   
NovaBlue GigaSingles™ Competent cells (Novagen, Cat. No. 71127) are provided in the 
Ek/LIC Vector Kits and were used for initial cloning with all Ek/LIC Vectors.  NovaBlue is a 
convenient host for initial cloning of target DNA into the Ek/LIC vector due to its high 
transformation efficiency, high yields and excellent plasmid DNA that result from recA endA 
mutations.  After positive clones are identified, plasmid DNA can be isolated for transformation 
into expression hosts, restriction mapping, and sequence analysis.  Plasmid DNA from candidate 
recombinants may also be evaluated using in vitro transcription/translation analysis (Fresno et 
al., 2007). 
Once established and verified the gene will be transfected into an insect cell host.  The most 
commonly used insect host cell lines include the Sf9 and Sf21AE, which are lines originally 
derived from Spodoptera frugiperda pupal ovarian tissue (Vaughn et al., 1977).  This 
transfection will permit harvesting of mature protein by cell lysis which will allow extraction of 
soluble proteins from insect cell monolayer culture or cell pellets.   
Gene transfer is often monitored using ß-galactosidase as the reporter.  The BetaBlue
TM
 Staining 
Kit provides direct visualization of ß-galactosidase expression in isolated cells, tissues or intact 
organisms.  The kit contains solutions of the substrate X-gal (5-bromo-4-chloro-3-indolyl-ß-D-
galactopyranoside) and Reaction Buffer optimized for rapid, sensitive histochemical staining 
with minimal background (Smith et al., 1985).  BetaBlue Staining Kit enables determination of 
transfection efficiencies, assessment of stable cell line generation, and transgene expression in 
tissue slices or whole mounts of transgenic animals.  
4.2 Materials 
The CD21 BillNEO(LTR-SV NEO) vector, containing the human CD21 cDNA was a gift from 
Micheal Holers (University of Colorado Health Sciences Centre, Denver, Colorado, USA) and 
was contained within a Bluescript plasmid from which SCR 1-2, SCR 5-8 and SCR 1-15 were 
amplified and transformed into pIEx 10 vector.  The LIC vectors, Insect GeneJuice® 
Transfection Reagent, CytobusterTM and BacVector® Insect Cell Medium were obtained from 
Novagen (Madison, Wisconsin).  Restriction enzymes, PVDF membrane and BSA were from 
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Roche (Mannheim, Germany).  The QIAquick PCR purification kit, QIAquick plasmid isolation 
kit, as well as a QIAquick gel extraction kit were obtained from QIAGEN (Hilden, Germany).  
TC100 insect cell medium was obtained from Invitrogen, (San Diego, USA).  Sf21 insect cells 
were a gift from Fritz Tied, at the University of Cape Town.  Aurum total RNA fatty and fibrous 
tissue kit and iScriptTM cDNA Synthesis kit were obtained from Bio-Rad (California, USA).  
Agilent RNA 6000 Nano Kit was obtained from Agilent Technologies (Waldbronn, Germany).  
Anti-CD21 [CD21 (HB-5)] mouse monoclonal IgG2a was from Santa Cruz Biotech, (Santa 
Cruz, USA) and anti-mouse IgG2 conjugated to horse radish peroxidase (HRP) from R&D 
(Minneapolis, USA).  Automated DNA sequencing was performed by the DNA sequencing 
facility at the Central Analytical Facility, University of Stellenbosch.  All other reagents were of 
analytical grade. 
4.3 Methods 
4.3.1 Cloning and molecular biology 
4.3.1.1 Agarose gel electrophoresis 
Agarose gel electrophoresis (AGE) was used to verify restriction enzyme (RE) digestion and 
PCR amplification of vectors and PCR products.  AGE was performed using a 1% (w/v) agarose 
gel in Tris-acetate-EDTA buffer (TAE) (242 g Tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 
M EDTA, pH 8) according to Sambrook et al., (1989).  The gel was run at 120 V, 64 mA until 
the tracking dye (containing xylene cyanol and bromothymol blue) reached three quarters of the 
way down the gel.  The gel was removed and viewed on a transilluminator and digital 
photographs were taken using an AlphaImagerTM 3400. 
4.3.1.2 Ultra violet spectrophotometry determination of DNA concentration and      
purity 
An appropriate dilution of the DNA sample was made (usually a 20x dilution by adding 5 µL 
DNA sample to 95 µL ddH2O in a 100 µL microcuvette).  Absorbance readings were recorded at 
260nm and 280nm.  The purity of the DNA sample was determined using the 
OD260nm:OD280nm ratio, where a ratio of 2.00 indicates 100% nucleic acids and no protein 
and ratios less than 2.00 indicate an increasing amount of protein.  Since an OD260nm of 1 
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equals 50 µg/mL double-stranded or 30 µg/mL single-stranded DNA or RNA, the DNA 
concentration was determined by the following two equations (Sambrook et al., 1989): 
 
[DNA] (µg/mL) = OD260 x 50 x dilution factor (for double stranded DNA) 
or 
[DNA/RNA] (µg/mL) = OD260 x 30 x dilution factor (for single stranded DNA) 
4.3.1.3  Restriction digestion 
Restriction digests were performed using between 2 and 5 µL of DNA depending on the 
concentration of the DNA.  The restriction digestion was carried out according to (Sambrook et 
al., 1989).  
4.3.1.4  Small scale plasmid purification 
Plasmid DNA was isolated using a QIAGEN Plasmid Mini Kit according to manufacturer 
instructions.  An overnight culture of the bacterial cells containing the desired plasmid was 
prepared by inoculating 10 mL of Luria-Bertani (LB) broth (10 g Tryptone, 10 g NaCl, 5 g Yeast 
extract, 1 mL 1 M NaOH in 1 L ddH2O), containing antibiotic at prescribed concentrations, with 
a single colony.  This culture was incubated overnight at 37ºC with constant agitation prior to 
plasmid isolation.         
4.3.1.5 Preparation of competent cells 
Competent cells are required for transformations whereby plasmids are inserted into bacterial 
cells to allow replication or expression of the plasmid.  Two types of competent cells exist, 
chemically competent and electro-competent.  Chemically competent cells were prepared 
according to Sambrook et al., (1989) and electro-competent cells according to (Smith et al., 
1990).   
 
For transformation of chemically competent cells 1 µL of plasmid or ligation mix was added to 
cells (50 µL) thawed on ice and gently mixed prior to 5 minutes incubation on ice.  This 
incubation was followed by 30 seconds incubation at 42ºC without mixing, followed by 2 
minutes incubation on ice.  Following incubation 250 µL prewarmed SOC (50 g Bactotryptone, 
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12.5 g yeast extract, 1.46 g NaCl, 0.465 g KCl, 2.5 L ddH2O, 1 mL 2 M MgCl2, 1 mL 2 M 
glucose) medium was added to the mixture and the cells incubated for 1 hour at 37ºC with 
rotation at 225 rpm.  Various aliquots of the cells were spread onto LB plates containing 
antibiotics and the plate incubated overnight at 37ºC (Sambrook et al., 1989). 
 
For transformation of electro-competent cells a 40 µL aliquot of the cell suspension thawed on 
ice was added to 1 µL of plasmid DNA or ligation mix in a pre-chilled Eppendorf tube, keeping 
the cells on ice.  The cells and DNA were gently mixed and transferred to a pre-chilled 1 mm gap 
electroporation cuvette, making sure not to touch the side electrodes on the cuvette.  The cuvette 
was placed in the electroporator and electroporation carried out at 16000 V/cm.  A 960 µL 
aliquot of LB broth was added immediately in order to allow expression of antibiotic resistance 
genes.  The resulting mix was incubated for 1 hour at 37ºC.  Various aliquots of the transformed 
cells were spread onto LB plates containing the selective antibiotic medium and incubated 
overnight at 37ºC.   
4.3.1.6 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify the coding regions of CD21 SCR 1-2, 
which is ~400 bp, SCR 5-8, which is ~750 bp and SCR 1-15, which is ~3200 bp from the human 
CD21 cDNA contained within the Bluescript BillNEO (LTR-SV NEO) plasmid.  The coding 
regions amplified encode Cys
3
-Glu
133
, Cys
256
-Thr
560
, and Cys
3
- Ser
1067 
for CD21 SCR 1-2, SCR 
5-8, and SCR 1-15, respectively.  Thereafter all CD21 coding regions were cloned into pIEx 10 
Ek/LIC vectors for expression by insect cells.   
The desired CD21 coding regions were targeted by a forward and reverse primer, the respective 
sequences were those listed in table 2.  Primers contained appropriate 5‟ extensions in order to 
create complementary overhangs in PCR products to allow LIC to pIEx10 Ek/LIC plasmid. 
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Table 2: LIC primers used to amplify CD21 coding regions 
CD21 
coding 
region 
Forward primer Reverse primer 
(SCR 1-2) 5’(GAC)3AAGATTTCTTGTGGCTCTCCTCCG-3’ 5’(GAG)2AAGCCCGGTCTACTCGAGAGGGAAAAC-3’ 
(SCR 5-8) 5’(GAC)3AAGATTTTTTGCCCATCACCTCCCCCT-3’ 5’(GAG)2AAGCCCGGTCTAGGTGATTTCTTTACAAAG-3’ 
(SCR1-15) 5’(GAC)3AAGATTTCTTGTGGCTCTCCTCCG-3’ 5’(GAG)2AAGCCCGGTTTAGCTGGCTGGGTTGTATGG-3’ 
Figure 23 indicates the human CD21 sequence as well as the homologous regions on the CD21 
gene fragment to which the primers will bind, thus forming the borders of the amplified coding 
sequences.    
PCR was performed according to (Sambrook et al., 1989).  For all CD21 clones, an initial PCR 
was performed with a gradient of annealing temperatures between 51 and 60°C.  Thereafter, PCR 
was performed using the optimum annealing temperature determined.  The PCR reaction mix of 
25 µL, contained  12.6 µL distilled sterile H2O,  2.5 µL Taq buffer (containing 2.5 mM MgCl2), 
0.38 units Taq polymerase, 0.5 µL 10 mM dNTPs, 1 µL  of 100 pmole/µL forward and reverse 
primers each and 2 µL of the respective template containing ~ 2 µg DNA.     
The gradient PCR reactions were carried out with the following parameters: (1) denaturation at 
95°C for 5 minutes followed by (2) 25 cycles of denaturation at 95°C for 1 minute, annealing at 
50-60°C for 1 minute and extension at 72°C for one minute, with the final step being (3) a 10 
minute extension at 72°C.   
The final reaction was carried out with the following parameters: (1) denaturation at 95°C for 3 
minutes followed by (2) 10 cycles of denaturation at 95°C for 45 seconds, annealing at 50°C for 
45 seconds and extension at 72°C for one minute (3) 20 cycles of annealing at 55°C and 
extension at 72°C, with the final step being (4) a 10 minute extension at 72°C and 5 minutes at 
4°C so as to keep the final product cool.  The PCR product was verified using agarose gel 
electrophoresis as an indication of whether the correct size DNA fragment was amplified. 
To verify transformed cells colony PCR was performed by picking a colony from an agar plate 
containing ligation transformants using a pipette tip.  The bacteria were transferred to a 0.5 mL 
tube containing 50 µL of sterile water.  The tube was vortexed to disperse the cells and placed in 
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a boiling water bath to lyse cells for 5 minutes and denature DNases.  The tube was centrifuged 
at 12 000 x g for 1 minute to remove cell debris.  Ten microlitres of the supernatant was 
transferred to a fresh 0.5 mL tube for PCR analysis. 
4.3.1.7 DNA sequencing 
Once the plasmids were isolated and verified by restriction enzyme (RE) digestion, sequence 
analysis was performed using an automated DNA sequencer using the dye terminator sequencing 
method (Sanger, 1981). 
     CACAGCTGCTTGCTGCTCCAGCCTTGCCCTCCCAGAGCTGCCGGACGCTCG  51 
     CGGGTCTCGGAACGCATCCCGCCGCGGGGGCTTCGGCCGTGGCATGGGCGC  102 
                                           -20  M  G  A 
                                              5’(GAC)3AA 
     CGCGGGCCTGCTCGGGGTTTTCTTGGCTCTCGTCGCACCGGGGGTCCTCGG  153 
-17:  A  G  L  L  G  V  F  L  A  L  V  A  P  G  V  L  G 
     GATTTCTTGTGGCTCTCCTCCG-3’   CD21 (SCR 1-2 and 1-15) 
     GATTTCTTGTGGCTCTCCTCCGCCTATCCTAAATGGCCGGATTAGTTATTA  204 
 +1:  M  S  C  G  S  P  P  P  I  L  N  G  R  I  S  Y  Y  
     TTCTACCCCCATTGCTGTTGGTACCGTGATAAGGTACAGTTGTTCAGGTAC  255 
 18:  S  T  P  I  A  V  G  T  V  I  R  Y  S  C  S  G  T  
     CTTCCGCCTCATTGGAGAAAAAAGTCTATTATGCATAACTAAAGACAAAGT  306 
 35:  F  R  L  I  G  E  K  S  L  L  C  I  T  K  D  K  V  
     GGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATTTCAATAAATA  357 
 52:  D  G  T  W  D  K  P  A  P  K  C  E  Y  F  N  K  Y  
     TTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCTC  408 
 69:  S  S  C  P  E  P  I  V  P  G  G  Y  K  I  R  G  S  
     TACACCCTACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTT  459 
 86:  T  P  Y  R  H  G  D  S  V  T  F  A  C  K  T  N  F  
     CTCCATGAACGGAAACAAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGG  510 
103:  S  M  N  G  N  K  S  V  W  C  Q  A  N  N  M  W  G                                 
         3’GTTTTCCCTCTCGAGTAGACCGG 
     GCCGACACGACTACCAACCTGTGTAAGTGTTTTCCCTCTCGAGTGTCCAGC  561 
120:  P  T  R  L  P  T  C  V  S  V  F  *    
     GCTT2(CTC)5’CD21 SCR (1-2) 
………………………………………………                      5’(GAC)3AAGATTTT 
     TGCTGGACAGGGAGTTGCTTGGACCAAAATGCCAGTATGTGAAGAAATTTT 918 
241:        M  G  V  A  W  T  K  M  P  V  C  E  E  I  F  
     TTGCCCATCACCTCCCCCT-3’   CD21 (SCR 5-8) 
     TTGCCCATCACCTCCCCCTATTCTCAATGGAAGACATATAGGCAACTCACT 969 
256:  C  P  S  P  P  P  I  L  N  G  R  H  I  G  N  S  L  
     AGCAAATGTCTCATATGGAAGCATAGTCACTTACACTTGTGACCCGGACCC 1020 
273:  A  N  V  S  Y  G  S  I  V  T  Y  T  C  D  P  D  P  
     AGAGGAAGGAGTGAACTTCATCCTTATTGGAGAGAGCACTCTCCGTTGTAC 1071 
290:  E  E  G  V  N  F  I  L  I  G  E  S  T  L  R  C  T            
     AGTTGATAGTCAGAAGACTGGGACCTGGAGTGGCCCTGCCCCACGCTGTGA 1122 
307:  V  D  S  Q  K  T  G  T  W  S  G  P  A  P  R  C  E          
     ACTTTCTACTTCTGCGGTTCAGTGTCCACATCCCCAGATCCTAAGAGGCCG 1173 
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324:  L  S  T  S  A  V  Q  C  P  H  P  Q  I  L  R  G  R  
     AATGGTATCTGGGCAGAAAGATCGATATACCTATAACGACACTGTGATATT 1224 
341:  M  V  S  G  Q  K  D  R  Y  T  Y  N  D  T  V  I  F  
     TGCTTGCATGTTTGGCTTCACCTTGAAGGGCAGCAAGCAAATCCGATGCAA 1275 
358:  A  C  M  F  G  F  T  L  K  G  S  K  Q  I  R  C  N  
     TGCCCAAGGCACATGGGAGCCATCTGCACCAGTCTGTGAAAAGGAATGCCA 1326 
375:  A  Q  G  T  W  E  P  S  A  P  V  C  E  K  E  C  Q  
     GGCCCCTCCTAACATCCTCAATGGGCAAAAGGAAGATAGACACATGGTCCG 1377 
392:  A  P  P  N  I  L  N  G  Q  K  E  D  R  H  M  V  R  
     CTTTGACCCTGGAACATCTATAAAATATAGCTGTAACCCTGGCTATGTGCT 1428 
409:  F  D  P  G  T  S  I  K  Y  S  C  N  P  G  Y  V  L  
     GGTGGGAGAAGAATCCATACAGTGTACCTCTGAGGGGGTGTGGACACCCCC 1479 
426:  V  G  E  E  S  I  Q  C  T  S  E  G  V  W  T  P  P  
     TGTACCCCAATGCAAAGTGGCAGCGTGTGAAGCTACAGGAAGGCAACTCTT 1530 
443:  V  P  Q  C  K  V  A  A  C  E  A  T  G  R  Q  L  L  
     GACAAAACCCCAGCACCAATTTGTTAGACCAGATGTCAACTCTTCTTGTGG 1581 
460:  T  K  P  Q  H  Q  F  V  R  P  D  V  N  S  S  C  G  
     TGAAGGGTACAAGTTAAGTGGGAGTGTTTATCAGGAGTGTCAAGGCACAAT 1632 
477:  E  G  Y  K  L  S  G  S  V  Y  Q  E  C  Q  G  T  I  
                           CTTTGTAAAGAAATCACCTAGACCGGGCT                                 
     TCCTTGGTTTATGGAGATTCGTCTTTGTAAAGAAATCACCTGCCCACCACC 1683 
494:  P  W  F  M  E  I  R  L  C  K  E  I  L  E  P 
     T2(CTC)5’CD21 (SCR 5-8) 
……………………………………………………… 
2705:  TCTCCTGGAATGTCAATCCTGTACAGCTGTGACCAAGGCTACCTGCTGGTGGGAGAGGCA 
 890:   S  P  G  M  S  I  L  Y  S  C  D  Q  G  Y  L  L  V  G  E  A    
2765:  CTCCTTCTTTGCACACATGAGGGAACCTGGAGCCAACCTGCCCCTCATTGTAAAGAGGTA 
 910:   L  L  L  C  T  H  E  G  T  W  S  Q  P  A  P  H  C  K  E  V  
2825:  AACTGTAGCTCACCAGCAGATATGGATGGAATCCAGAAAGGGCTGGAACCAAGGAAAATG 
 930:   N  C  S  S  P  A  D  M  D  G  I  Q  K  G  L  E  P  R  K  M  
2885:  TATCAGTATGGAGCTGTTGTAACTCTGGAGTGTGAAGATGGGTATATGCTGGAAGGCAGT 
 950:   Y  Q  Y  G  A  V  V  T  L  E  C  E  D  G  Y  M  L  E  G  S  
2945:  CCCCAGAGCCAGTGCCAATCGGATCACCAATGGAACCCTCCCCTGGCGGTTTGCAGATCC 
 970:   P  Q  S  Q  C  Q  S  D  H  Q  W  N  P  P  L  A  V  C  R  S  
3005:  CGTTCACTTGCTCCTGTCCTTTGTGGTATTGCTGCAGGTTTGATACTTCTTACCTTCTTG 
 990:   R  S  L  A  P  V  L  C  G  I  A  A  G  L  I  L  L  T  F  L  
3065:  ATTGTCATTACCTTATACGTGATATCAAAACACAGAGCACGCAATTATTATACAGATACA 
1010:   I  V  I  T  L  Y  V  I  S  K  H  R  A  R  N  Y  Y  T  D  T  
3125:  AGCCAGAAAGAAGCTTTTCATTTAGAAGCACGAGAAGTATATTCTGTTGATCCATACAAC 
                                                      3’  CCATACAAC 
1030:   S  Q  K  E  A  F  H  L  E  A  R  E  V  Y  S  V  D  P  Y  N  
3185:  CCAGCCAGCTGATCAGAAGACAAACTGGTGTGTGCCTCATTGCTTGGAATTCAGCGGAAT 
       CCAGCCAGCTAAACCGGGCTT2(CTC)5’    CD21 (SCR 1-15) 
1050:   P  A  S  -  S  E  D  K  L  V  C  A  S  L  L  G  I  Q  R  N  
 
Figure 23:  DNA and translated protein sequence for human CD21.  Annotated are the annealing positions of 
forward and reverse primers for CD21 (SCR 1-2) in red, (SCR 5-8) in blue, and (SCR 1-15) in green, note that SCR 
1-15 forward primer is the same as that for SCR 1-2 forward primer.  The reverse primer has been inverted.  The 
start (ATG) and stop (TGA) codons are shown in bold text within the CD21 sequence.  Adjacent numbering 
annotates the residue of both cDNA (top) and protein (bottom).   
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4.3.2 Western- and dot-blot procedure 
For Western blotting, semi-dry blotting was performed as described in section 3.3.12.  
Thereafter, the gel was stained (0.1% Coomassie Blue R-250 in 40% methanol, 10% acetic acid) 
for 10 minutes, and destained (40% methanol, 10% acetic acid and 50% distilled water) to 
confirm transfer of proteins to membrane.  For dot blotting, proteins were diluted to 50 ng/µL 
and dotted onto PVDF membrane using a pipette, and the membrane dried at 37°C for 5 minutes.  
After drying, the membrane from either Western blotting or dot-blots was blocked in PBS (pH 
7.4) containing 1% (w/v) BSA and 0.05% Tween-20 for 30 minutes.  In both cases of Western 
and dot blotting, 10 mL anti-CD21 [CD21 (HB-5)] mouse monoclonal IgG2a, diluted (1:200) in 
2% (w/v) fat-free milk powder in TBS containing 0.1% Tween-20 (TBST), was added to the 
membrane and incubated for 1 hour at room temperature.  Incubation was followed by washing 
once for 15 minutes and 3 times for 5 minutes with TBST.  Ten millilitres secondary antibody 
(anti-mouse IgG2-HRP) was diluted (1:5000) in 2% fat-free milk powder in TBST and incubated 
with the membrane for 30 minutes.  Incubation was followed by washing as described above.  
Detection was carried out by adding SIGMAFAST 
TM
 BCIP/NBT (5-Bromo-4-chloro-3-indolyl 
phosphate/nitro blue tetrazolium) pH 9.5 tablets dissolved in 10 mL water to the membrane.  The 
reagent was allowed to incubate until colour developed, where the reaction was stopped by 
adding an excess of ddH2O.             
4.3.3 Protein transfection and expression 
4.3.3.1 Sf21 insect cells 
Sf21 insect cells are derived from the Spodoptera frugiperda cell line and can be grown as semi-
adherent, monolayer cultures in tissue culture flasks, or in suspension as shaker cultures.  Cells 
may be freely transferred between the two culturing methods.  Suspension cultures routinely 
reach densities greater than 1 × 107 cells/mL with greater than 95% viability.  To maintain 
consistency in experimental work, it is important not to passage Sf21 cells indefinitely in culture. 
It is highly recommended to thaw and expand a culture of fresh Sf21 insect cells from a frozen 
stock after the current cell culture has exceeded 20–25 passages. 
Cells were grown in 75cm
2
 flasks in TC-100 insect cell culture medium with the addition of 10% 
foetal calf serum.  Cells were routinely subcultured once reaching 60-70% confluence.  
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Subculturing was performed by simple agitation of the cells using a bent glass Pasteur pipette, 
following which the cells were split at a ratio of between 1:5 and 1:10. 
4.3.3.2 Transfection of Sf21 insect cells 
Exponentially growing Sf21 cells were evenly resuspended and diluted in prewarmed serum-free 
BacVector® Insect cell medium to a density of 4 x 10
5
 cells/mL.  Cells (0.5 mL, therefore 2 x 
10
5
 cells) were added to each well of a 24-well plate and allowed to incubate for 1 hour prior to 
transfection.  For each well to be transfected, 0.4 µg DNA was diluted with 20 µL serum free 
medium.  Slowly, the diluted DNA was added drop-wise to the diluted insect GeneJuice 
Transfection Reagent and mixed immediately by gentle vortexing to avoid precipitation.  The 
GeneJuice/DNA mixture was incubated at room temperature for 15 minutes, thereafter, 160 µL 
of serum-free medium was added to the Insect GeneJuice/DNA transfection mixture.  The cells 
were then incubated for 24 hours at 37°C.  After incubation, the growth medium was aspirated 
from the cells and replaced with transfection mixture (~200 µL).  The cells were incubated at 
28°C for 48 hours in a humidified incubator.  After incubation, cells were harvested for reporter 
assays.   
Staining with the Beta Blue staining kit can begin 72 hours after transfection with high purity 
DNA as well as a construct capable of expressing galactosidase and a negative control 
(containing no DNA).  The X-gal solution was thawed at room temperature and diluted 1:40 in 
BetaBlue Reaction buffer.  The mixture was mixed thoroughly by inversion.  
The medium was aspirated from the cells and the cells were washed twice with PBS.  BetaBlue 
staining solution with X-gal (250 µL) was added to each well in a 24-well plate and incubated at 
37°C for 3 hours.  The cells were viewed with a microscope and photographed. 
4.3.3.3  Total RNA isolation 
The Aurum total RNA fatty and fibrous tissue kit produces high yields of pure total RNA from 
samples that are difficult to disrupt.  Total RNA isolated using the kit is suitable for use in 
various downstream applications, including RT-PCR.   
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The membrane in the Aurum RNA binding mini column selectively binds to mRNA and larger 
rRNAs, while small RNA molecules less than 200 nucleotides are removed.   
Insect cells or Raji cells (cultured as described in section 6.4.1) were pelleted by centrifugation at 
4000 x g for 2 minutes.  PureZOL (1 mL/10
7
 cells) was added directly to the cells.  The cell 
lysate was passed through an 18-gauge needle and syringe several times.  Once disrupted, the 
lysate was incubated at room temperature for 5 minutes to allow the complete dissociation of 
nucleoprotein complexes.  Chloroform (200 µL) was added to each lysate and then covered and 
shaken vigorously for 15 seconds and incubated for 5 minutes at room temperature with periodic 
mixing.  After incubation the sample was centrifuged at 12 000 x g for 15 minutes at 4°C.  The 
aqueous phase was removed to a 2 mL microcentrifuge tube.  An equal volume of 70% ethanol 
was added to the tube and mixed thoroughly by pipetting up and down.  RNA sample (~700 µL) 
was pipetted onto the RNA binding mini column and centrifuged for 60 seconds at 12 000 x g 
(this last step was repeated).  Low stringency wash solution was added (700 µL) to the RNA 
binding column and centrifuged for 30 seconds at 12 000 x g.  Any contaminating genomic DNA 
was removed from the RNA sample by adding 80 µL reconstituted lyophilised DNase I 
(provided in the kit) to each sample.  The DNase I was incubated for 15 minutes at room 
temperature and removed by centrifugation (12 000 x g for 30 seconds).  High stringency wash 
solution (700 µL) was added to the RNA binding column and the column was centrifuged for 30 
seconds at 12 000 x g followed by a repeat wash step with low-stringency wash buffer.  An extra 
centrifugation step (12 000 x g for 2 minutes) was used to remove residual wash solution.  The 
RNA was eluted with prewarmed (70°C) elution solution after incubation (1 minute) by 
centrifugation for 2 minutes at 12 000 x g.  Total RNA isolates were stored at -80°C. 
4.3.3.4 RNA quantification 
RNA was quantified using the Agilent RNA 6000 Nano Assay protocol.  RNA was loaded onto 
the gel and the chip was inserted into the Agilent 2100 Bioanalyzer where it was run and 
calibrated with an RNA ladder (25, 200, 500, 1000, 2000, 4000, 6000 nt).  Samples were 
analyzed with respect to their 18S and 28S rRNA content.   
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4.3.3.5 cDNA synthesis 
The iScript cDNA synthesis kit is a modified Moloney Murine Leukemia Virus (MMLV)-
derived reverse transcriptase, optimized for reliable cDNA synthesis over a wide dynamic range 
of input RNA.  The enzyme is provided preblended with RNase inhibitor.  The reaction was 
prepared by adding 4 µL 5x iScript reaction mix, 1 µL iScript reverse transcriptase, 1 µg RNA 
template and nuclease-free water to make up 20 µL.  The mixture was incubated for 5 minutes at 
25°C, 30 minutes at 42°C and 5 minutes at 85°C.  Upon cDNA synthesis, PCR was followed as 
previously described (section 4.3.1.6).   
4.4 Results and discussion 
4.4.1 Cloning of CD21 coding regions into pIEx 10 plasmid 
The BillNEO (LTR – SV NEO) CD21 vector was transformed into electrocompetent E. coli 
DH5α cells which were consequently grown to enable plasmid isolation (section 4.3.1.4).  
Restriction digestion was performed to verify the presence of the human CD21 gene.  Fragment 
sizes (figure 24) were found to be similar to sizes indicated by Micheal Holers (pers. commun.), 
and thus, the vector was found to be verified positively.    
 
                   
Figure 24:  Restriction digestion of BillNeo vector containing human CD21 cDNA.  1kb Marker (lane 1), digestion 
with BamHI yielding fragments of 5760, 2960 and 2310 bp in lanes 2-4, digestion with HindIII yielding fragments 
of 8110 and 1300 bp in lanes 5 and 6 and digestion with BamHI and HindIII yielding fragments  of 5850, 2590 and 
970 bp (lanes 7-9). 
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PCR was performed to amplify three CD21 coding regions of interest (SCR 1-2, 5-8 and 1-15).  
These fragments were amplified (data not shown) from the BillNEO (LTR – SV NEO) CD21 
plasmid template with primers developed for LIC cloning (table 2) and annealed to the pIEx 10 
Ek/LIC plasmid.  Figure 25 shows vector maps of recombinant pIEx 10 vectors containing CD21 
SCR 1-2 (a), SCR 5-8 (b) and SCR 1-15 (c) coding regions.  After LIC cloning, colony PCR was 
performed to verify clones (figure 25 a(ii), b(ii) and c(ii) for SCR 1-2, SCR 5-8 and SCR 1-15 
respectively).  Expected sizes of inserts were ~400 bp for SCR 1-2, ~750 bp for SCR 5-8 and 
~3200 bp for SCR 1-15.  The sizes calculated from figure 25 were very close to the expected 
sizes, according to migration with the marker.  SCR 1-2 migrated to between the 250 and 500 bp 
marker, SCR 5-8 migrated in line with the 750 bp marker and SCR 1-15 migrated in to between 
the 3000 and 4000 bp marker band.  This illustrates that the vectors contained the correct sized 
fragments.  From gradient PCR reactions, it was found that for all CD21 fragments the optimum 
annealing temperature was 50.8°C.  The recombinant plasmids were isolated and verified by 
DNA sequencing.  DNA sequences were aligned with the human sequence of CD21 (GenBank 
accession code NM_001877).  Apart from minor deletions, insertions and mutations, the 
alignment showed residues to be aligned with the known CD21 sequence, and that the coding 
regions were in frame with the vector start codon.   
SCR 1-2 depicted two double deletions at bp 578 and 591, but upon translation of the DNA, 
these deletions were not shown to affect the protein sequence apart from loosing the N-terminal 
methionine (common for proteins expressed in a bacterial host).   
SCR 5-8 depicted three mutations at bp 1034, 1036 and 1041.  These caused relative mutations 
in the translated protein sequence, but do not shift the reading frame.  Proteins “Glu-Glu” 
become “Asp and Lys” at positions 312 and 313 respectively, while at position 345, 346 and 
347, the run of amino acids changes from “Asn-Phe-Ile” to “Glu-Phe-Ser”.   
SCR 1-15 depicts a mutation at bp 160 and an insertion at bp 168.  These caused relative 
mutations in the translated protein sequence, but do not shift the reading frame.  The first 8 
amino acids show inconsistent alignment, but thereafter, (from Pro 
57
) the protein sequence 
aligns correctly. (See Addendum A for DNA sequencing).   
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(c)(i) (ii)           
      
Figure 25: Expression vectors for CD21 (a) SCR 1-2, (b) SCR 5-8 and (c) SCR 1-15.  Each with respective colony PCR 
of recombinant pIEx10 expression vectors for CD21 coding regions. (a)(ii) SCR 1-2, (b)(ii) SCR 5-8 and (c)(ii) SCR 1-
15, (ii) (1)1kB marker, (2)Colony PCR of pIEx10 expression vector.  
4.4.2 Transfection of Sf21 insect cells 
Transfection of insect cells with recombinant pIEx10-CD21 plasmids appeared to be successful 
(figure 26) based on the colourimetric evidence shown by β-galactosidase expression from the 
transfection control vector.  β-galactosidase expression was monitored using X-gal as a substrate, 
which appears blue when hydrolysed, as clearly seen by the blue appearance of the insect cells 
transfected with the control vector (figure 26b).  This figure shows close to 100% of the cells 
expressing β-galactosidase, which is further evidence of successful transfection of test plasmids. 
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 (a)  
 (b) (c)  
Figure 26: Transfection of insect cells with recombinant pIEX 10-CD21 plasmids. (a) 24-well plate showing wells 
marked by coding region to be expressed, positive control transfection (β-galactosidase) is indicated by the blue 
colour of the cells due to X-gal hydrolysis, where negative control (no DNA added to transfection mix) and 
remaining transfections are clear. (b) Photograph of insect cells transfected with positive control plasmid; (c) 
negative control showing normal untransfected cells (cell sizes are annotated on diagram). 
Following lysis of the transfected cells with Cytobuster
TM
 the lysates, together with lysate from 
Raji cells [well known to naturally express CD21, (Fischer et al., 1999)] were used in a dot blot 
with anti-CD21 (raised against amino acids 21-260 of human CD21) as a detection antibody 
(figure 27).  No evidence of expression of the CD21 domains is evident in the insect cell lysates, 
yet the positive control (Raji cell lysate) shows detection of the presence of human CD21.  
20µm 
20µm 
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Figure 27: Dot blot analysis of CD21 expression by Sf21 insect cells.  (1) negative control, (2 and 3) SCR 1-2, (4 
and 5) SCR 5-8, (6 and 7) SCR 1-15 and (8) Raji cell lysate. 
Insect cell lysates were also electrophoresed using SDS-PAGE.  The expected molecular weights 
were ~19 kDa, ~32 kDa and ~122 kDa for CD21 SCR 1-2 (172 amino acids), SCR 5-8 (292 
amino acids), and SCR 1-15 (1111 amino acids), respectively.  Detection of CD21 protein 
expression by the insect cells via SDS-PAGE, Western blotting (data not shown), and dot 
blotting using an anti-CD21 antibody all failed.  It was decided to isolate RNA from cells and 
perform RT-PCR to determine whether the CD21 mRNA transcripts were present in the insect 
cells.  Total RNA was isolated from fresh cell lysate previously transfected with recombinant 
pIEx 10-CD21 plasmids (encoding CD21 SCR 1-2, 5-8 and 1-15) and quantified using the 
Agilent RNA 6000 nano kit (figure 28).   
Because mRNA comprises only 1-3% of total RNA samples it is not readily detectable even with 
the most sensitive of methods.  Ribosomal RNA, on the other hand, makes up >80% of total 
RNA samples, with the majority of that comprised by the 28S and 18S rRNA species (in 
mammalian systems).  An improved analytical tool (in comparison to AGE and ethidium 
bromide staining) for total RNA analysis is the Agilent 2100 bioanalyzer, which uses a 
combination of microfluidics, capillary electrophoresis, and fluorescence to evaluate both RNA 
concentration and integrity (Palmer and Prediger, 2003).  
Because mammalian 28S and 18S rRNAs are approximately 5 kb and 2 kb in size, the theoretical 
28S:18S ratio is approximately 2:1, long been considered the benchmark for intact RNA.  
Because the RNA6000 assays are non-denaturing, secondary structure of the 28S rRNA results 
in altered migration (note that 28S rRNA does not migrate according to its molecular weight (~5 
kb) but rather migrates ahead of the 4 kb size marker) (Palmer and Prediger, 2003).   
        1          2           3           4            5             6         7            8 
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Figure 28 shows total RNA concentration and integrity analysis using an Agilent system of non-
denaturing conditions.  The gel shows 18S and 28S rRNA within total RNA isolation samples of 
SCR 1-2, SCR 5-8 and SCR 1-15 as well as a positive control isolated from Raji cells.  It is clear 
from the positive control that Raji cells show both 18S and 28S rRNA quantification as two clear 
bands, correlating with the molecular weight of 18S (2 kb) and 28S (5 kb) according to the 
marker (indicated with an arrow).  RNA isolated from insect cells transfected with expression 
vectors for the CD21 fragments have only a weak band of 28S rRNA, although total RNA 
isolation conditions were the same as those for Raji cells.   
                  
Figure 28:  Gel image of Agilent chip data showing isolation of total RNA from Sf21 insect cells.  The first lane 
contains an RNA ladder (25, 200, 500, 1000, 2000, 4000, 6000 nt); Sample 1 and 2 are CD21 SCR 1-2, Sample 4 
and 5 are SCR 5-8, Sample 7 and 8 are SCR 1-15 and Sample 10 and 11 are lysate of Raji cells (positive control).  
Arrows annotate 18S and 28S rRNA bands.  Samples 3, 6, 9 and 12 are loaded with RNAse free water. 
Figure 29 shows profiles representing quantification of RNA within each sample of isolated total 
RNA.  This quantification is represented by fluorescent intensity.  The 18S and 28S rRNA are 
annotated with arrows (solid and broken lines, respectively).  The decreased area of the 28S 
rRNA peak can represent break down of the 28S rRNA, but it has been shown (Palmer and 
Prediger, 2003) even when a sample appears to be fairly degraded based on the 28S rRNA 
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profile, the 18S rRNA and mRNAs may still be fairly intact.  This instability of 28S rRNA may 
result from its size as well as its high degree of secondary and tertiary structure.  In fact, some 
23S and 28S rRNAs contain an AU-rich sequence called a "hidden break" that can result in 
processing of these rRNA species into two smaller RNAs. The molecular mechanism for this 
type of processing is poorly understood but, it is likely that similar structural features may be 
responsible for the "hypersensitivity" of the mammalian 28S rRNA relative to the 18S rRNA 
(Palmer and Prediger, 2003).   
What is evident is that the profile of rRNA from an insect cell is slightly different to that of a 
human, and the 28S rRNA is considerably lower in fluorescent intensity and concentration than 
the 18S rRNA.  Although many transfections and total RNA isolations were performed, a larger 
amount of 28S rRNA was never obtained for RNA isolates from insect cells.  It was therefore 
decided to continue with RT-PCR regardless of this low 28S rRNA intensity, and subsequent 
low 28S:18S ratio.  This was presumed to be normal for a representation of RNA isolated from 
insect cells.   
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Figure 29:  Ribosomal RNA profiles from RNA isolated from Sf21 insect cells transfected with recombinant CD21-
encoding plasmid DNA and lysate from Raji cells (positive control).  Sample 1 and 2 are SCR 1-2, Sample 4 and 5 
are SCR 5-8, Sample 7 and 8 are SCR 1-15 and Sample 10 and 11 are lysate of Raji cells.  These data correlate with 
figure 29.  Arrows indicate 18S (solid) and 28S (broken and red) rRNA. 
Table 3 tabulates the quantification of total RNA isolated from transfected insect cells.  RT-PCR 
and cDNA synthesis required quantification of total RNA as the maximum volume of the cDNA 
reaction recommended for downstream PCR is one-tenth of the reaction volume, and the 
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maximum concentration is 1 µg.  When using larger amounts of input RNA (> 1 µg), the 
reaction would have to be scaled up to ensure optimum synthesis efficiency, which was not 
necessary for any RNA isolates.   
  Table 3: Quantification of total RNA obtained from an Agilent nano chip kit 
RNA Concentration 
(ng/µL) 
SCR 1-2 148  
SCR 5-8 363 
SCR 1-15 378 
Raji cell lysate 376 
 
cDNA was synthesized by RT-PCR and was amplified by PCR to check for transcription 
products in the transfected insect cells.  Positive amplification of CD21 SCR 1-2 and RNA 
isolated from Raji cell lysate (confirmed by amplification using SCR 1-2 primers), as well as a 
positive control for the PCR reaction using isolated recombinant pIEx vectors containing the 
SCR 1-2, 5-8, and 1-15 coding regions was observed (figure 30).  No amplification was observed 
from RNA isolated from cells transfected with expression vectors encoding SCR 5-8 or SCR 1-
15 (lanes 2 and 3).  This shows that transcription was successful in the case of SCR 1-2, but no 
protein (or perhaps undetectable levels of protein) was being translated by the cells.  This could 
be attributed to the insertions, deletions and mutations in DNA (addendum A) causing minor 
variances in translated protein, or a fault in post-translational modification causing an error in 
translation of the protein by the insect cells; alternatively the protein was translated, but was 
being targeted as a “toxic” protein and labelled by the cell for destruction by degradation 
(Frolova et al., 1998).  It has been previously reported that misfolded proteins are targeted for 
degradation by proteases (Frolova et al., 1998).  Whenever possible, secretion is the preferred 
strategy for recombinant protein synthesis (Tan et al., 2002).  Our CD21 coding regions were 
preceded by an IgM signalling sequence in order to promote solubility and transport into the 
medium, but this signalling sequence was possibly not optimum for the genes in question, as 
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each expression system needs specific tailoring to meet the stringent requirements for each 
protein product to ensure correct folding, activity and desired yield (Tan et al., 2002).  It is also 
possible that this signalling sequence could have aided targeting of the recombinant protein for 
digestion by endogenous proteases, as during stressful conditions, proteins may be misfolded and 
targeted for degradation (Swanton and High, 2006).  It is also possible that the production of 
protein was too low to be detected by Western blotting or dot blotting methods performed.   
          
Figure 30:  PCR of cDNA synthesized from RNA isolated from Sf21 insect cells transfected with recombinant pIEx 
10-CD21 plasmids.  CD21 SCR 1-2 (Lane 1), SCR 5-8 (lane 2), SCR 1-15 (lane 3) and Raji cell lysate amplified with 
primers for SCR 1-2 (lane 7).  Lane 8 illustrates a 1kB Marker (Roche) and Lane 4 represents a positive control of 
pIEx 10 vector containing SCR 1-2, amplified with primers for SCR 1-2. Lane 5 represents a positive control of 
pIEx 10 vector containing SCR 5-8 amplified with primers for SCR 5-8 and Lane 6 represents a positive control of 
pIEx 10 vector containing SCR 1-15 amplified with primers for SCR 1-15.  
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Owing to the lack of protein expression by the insect cell system, human CD21 SCR 1-2 protein 
was kindly donated by Joyce Fingeroth (Harvard University, Boston, USA).  For this protein, the 
DNA sequence coding for residues 2–130 of CD21 was amplified by PCR and ligated into the 
vector pPICZ_A (Invitrogen) for expression in Pichia pastoris.  The secreted protein contains a 
C-terminal factor Xa cleavage site followed by a hexahistidine tag.  Subsequent nickel-affinity 
and size-exclusion chromatography steps resulted in pure protein.  The purified CD21 SCR1–
SCR2 protein was extensively glycosylated, with three major glycoforms ranging in molecular 
mass from ~22 kDa to ~35 kDa as well as a nonglycosylated fragment of ~16 kDa (Prota et al., 
2002). 
Protein was found to be intact by SDS-PAGE and Western blotting.  Figure 31 illustrates the 
three forms of SCR 1-2 showing the migration of the fragments relative to the marker, to be 
confirmed as the above mentioned molecular weights (~16, ~22 and ~35 kDa).  Prota et al., 
(2002) mention that CD46, a structurally related protein to CD21, requires glycosylation for its 
interaction with measles virus (Maisner et al., 1996), and in this case, glycosylation is thought to 
help maintain the conformation of the receptor.  Although the interaction of SCR 1-2 and CD23 
does not require glycosylation of CD21 (Asokan et al., 2006; Aubry et al., 1994), of the three 
forms of CD21 (SCR 1-2) provided, CD21 expressed with multiple glycoforms was used for 
further experiments.   
 
Figure 31: Western blot of CD21 SCR 1-2 using anti-CD21. (1) SCR 1-2 deglycosylated (2) SCR 1-2 low glycoforms 
(3) SCR 1-2 all glycoforms. 
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4.4.3 Conclusions 
Previously CD21 has either been isolated from cell culture supernatant (Fremeaux-Bacchi et al., 
1996) of Raji cells or recombinantly produced.  Recombinant CD21 SCR 1-2 has been produced 
by expression in Baculovirus (Guthridge et al., 2001; Szakonyi et al., 2001) or yeast expression 
systems (Prota et al., 2002) and more recently using bacterial expression systems in E. coli 
(Young et al., 2008). 
In this study it is shown that successful cloning of CD21 SCR 1-2, CD21 SCR 5-8, and full 
length CD21 SCR 1-15 was achieved into expression vectors for insect cell expression.  These 
cloned fragments were verified by DNA sequencing and were aligned with the human sequence 
of CD21 (GenBank accession code NM_001877) and the alignment showed that residues aligned 
with the known CD21 sequence (apart from the minor mutations, insertions or deletions 
mentioned previously in section 4.4.1) and that the coding regions were in frame with the vector 
start codon (Addendum A). 
Furthermore, as exemplified by the positive control monitoring β-galactosidase expression using 
X-gal as a substrate, (figure 26b) there is evidence which confirms very high expression of β-
galactosidase, indicating successful transfection of cells with the expression vectors.   
Subsequent total RNA isolation and monitoring of the gene expression for these CD21 fragments 
by cDNA production and RT-PCR proved that CD21 SCR 1-2 was indeed transcribed.  CD21 
SCR 5-8 and SCR 1-15 transcripts were not detected by RT-PCR.  This indicated that 
transcription was successful in the case of SCR 1-2, but no protein (or perhaps undetectable 
levels of protein) was being translated by the cells, possibly due to a fault in post-translational 
modification causing an error in translation of the protein by the insect cells or alternative 
targeting of the protein as a “toxic” protein labelled for destruction by degradation (Frolova et 
al., 1998).  It is also possible that IgM signalling sequence, used in this case, in order to promote 
solubility and transport into the medium, was not optimum for the genes expressed in these 
particular cases.  It is also possible that the production of protein was too low to be detected by 
Western blotting or dot blotting methods performed.   
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Whether the protein was not being expressed at all or the level of expression was too low for 
detection, it seems that this expression system would need more investigation and optimisation 
before production of CD21 fragments at detectable levels would be possible.   
CD21 was thus donated and verified by SDS-PAGE and Western blotting to be intact and 
representative of the correct CD21 SCR 1-2 fragment which contained multiple glycoforms.  
This form of CD21 was used in following experiments described in chapters 5 and 6.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 107 
 
5 Protein interactions and ligand binding 
5.1 Introduction 
Proteins are dynamic molecules whose functions almost invariably depend on interactions with 
other molecules.  These interactions are affected in physiologically important ways by 
sometimes subtle, sometimes striking changes in protein conformation.  One can hardly 
overemphasize the importance of molecular interactions to a protein‟s function, many of which 
involve the reversible binding of other molecules, or ligands.   
All soluble CD23 fragments, shed from the cell surface, retain binding to IgE, and several have 
also been shown to have cytokine activities, stimulating the secretion of IL-1β, TNF-α, and IL-6 
(Armant et al., 1994; Beavil et al., 1995; Daniels et al., 2005; Mossalayi et al., 1997).  We know 
that these fragments also differ in their tendency to form trimers depending on the length of the 
residual stalk (Schulz et al., 1997).  CD23 can also act as an adhesion molecule, interacting with 
CD21, CD18/CD11b and CD18/CD11c (also known as CR2, CR3 and CR4, respectively) and 
the vitronectin receptor (Hibbert et al., 2005).  These interactions control important aspects of 
immune regulation.  Perturbation of such molecular interactions may promote allergy and other 
inflammatory disorders (Bonnefoy et al., 1997).   For example, the dust mite protease Der p I 
cleaves CD23 close to the lectin domain, and the resulting monomeric CD23 (16 kDa) may be a 
factor in the high allergenicity of dust mites (Schulz et al., 1997; Schulz O, 1997)). 
The binding of IgE to both FcεRI and CD23 has been localized to the Cε3 domains, suggesting 
this domain might be an attractive target for structural and functional studies.  The lectin head of 
CD23 is the site of interaction with the Cε3 domain of IgE (Kilmon et al., 2001).  Most C-type 
lectins require Ca
2+
 for ligand binding (Kilmon et al., 2001).  However, calcium is not involved 
directly in CD23-IgE interaction (Hibbert et al., 2005).  Glycosylation of CD23 is also not 
required for IgE binding because the truncated products of human CD23 have no N-
glycosylation sites (Hibbert et al., 2005).  The peptide region of CD23 that interacts with IgE has 
been shown to be near the carboxyl terminus of the lectin head region.  Although IgE is heavily 
glycosylated, CD23 recognizes only protein epitopes in IgE (Gould et al., 2003), which is 
unexpected for a lectin (Gould and Sutton, 2008).   
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CD23 has also been shown to interact with CD21 (Aubry et al., 1992).  This interaction mediates 
most of the CD23 activities on B-cells.  In contrast to IgE, the interaction between CD23 and 
CD21 may require glycosylation of CD21 (Sutton and Gould, 1993).  It has been shown that 
CD21 has two binding sites for CD23, SCR 1-2 and SCR 5-8.  CD23 binds SCR 1-2 via protein-
protein interactions (Aubry et al., 1994).  The crystal structure of domains 1 and 2 of CD21 is 
known (Szakonyi et al., 2001), and the whole molecule adopts an extended, flexible structure 
that is approximately 40 nm long (Gilbert et al., 2006).  Tunicamycin treatment of CD21-
transfected K562 cells strongly inhibited the binding of CD23-liposomes, suggesting that an N-
linked sugar, present on SCRs 5-8, is involved in the CD23-CD21 interaction.  By mutating 
together or individually, the three asparagines present on SCRs 5-8, asparagines Asn
370
 and 
Asn
295
, but not Asn
492
, were shown to be involved critically in the binding of CD23.  
Furthermore, Aubry et al., (1994) mapped the binding sites of a panel of anti-CD21 mAbs and 
found that at least six epitopes can be detected on CD21.  The mAbs that inhibit the most CD23 
binding to CD21 map in SCRs 5-8.  They therefore indicated that SCRs 5-8 represented a novel 
functional domain on the CD21 molecule, and this was the first demonstration of an activity of 
an extracytoplasmic region of the CD21 outside of SCRs 1-4.  Similar to the binding of CD23 
with IgE, the interaction between CD23 and CD21 is calcium dependent.  Importantly, it has 
been found that the CD23-CD21 pairing controls IgE synthesis in an isotype-specific manner 
(Bonnefoy et al., 1997).   
The objective for the experiments described in this chapter were to assess the oligomeric state of 
recombinant soluble CD23 fragments and compare the binding interactions of derCD23, sCD23 
and exCD23 with both IgE and CD21 SCR 1-2 to verify biological activity and to elucidate IgE 
regulation in chapters to follow.  Following biotinylation of CD23 proteins, gel filtration HPLC 
analysis was performed in order to analyse oligomer status.  In order to confirm biological 
activity binding studies were performed between recombinant CD23 and its ligand, IgE and co-
receptor CD21.  This was carried out by surface plasmon resonance (SPR) spectroscopy, using a 
BIAcore T100 instrument. 
Surface plasmon resonance is an optoelectronic phenomenon through which real-time binding of 
ligands to their receptors can be recorded.  Both kinetic data, the on- and off-rate, are determined 
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and from these the equilibrium dissociation constant can be calculated (Rich and Myszka, 2004).  
Surface plasmon resonance based biosensors are being used to define the kinetics of a wide 
variety of macromolecular interactions.  The key advantage of optical biosensors is that they 
allow the real-time analysis of reactions without labelling requirements.  Compared to other 
methods like calorimetry, the biosensor requires much less material, and provides dynamic 
information about complex formations, and measures a much wider range of affinities (Rich and 
Myszka, 2004).  They have been used to characterize a wide variety of interactions, including 
antibody-antigen, ligand-receptor, and proteins with oligonucleotides or carbohydrates (Myszka, 
1997).  Thermodynamic data can also be performed, by measuring binding kinetics at different 
temperatures (Rich and Myszka, 2004).  Although there are several types of optical biosensors 
currently available, BIAcore® continues to be the most widely used  (Natarajan et al., 2008).  
 
Surface plasmon resonance occurs when light is reflected under certain conditions from a 
conducting film at the border between two media that have different refractive indices.  The 
BIAcore SPR instrument for studying ligand-receptor interactions in real time was used to 
determine the binding affinity of the recombinant CD23 for its ligands IgE and CD21 SCR 1-2.  
This determination is important for the comparison of the recombinant protein to the naturally 
occurring protein in respect of the KD reported in literature, and serves as proof of biological 
activity of the refolded recombinant protein.  It was also important to gain insight into relative 
affinities for each of the three soluble CD23 fragments.   
 
In the Biacore systems, the surface of the sensor chip consists of four layers: glass, a thin gold 
film and an inert linker layer bonding a surface matrix.  Gold is chosen because of its chemical 
inertness and good SPR response.  The surface matrix, to which the receptor is immobilized, 
provides a hydrophilic environment for ligand interaction.  A solution of the analyte is passed 
through the flow cell where it interacts with the immobilized ligand on the sensor chip, the 
surface of which is exposed to the circulating analyte by means of a tight seal.  The established 
procedure for ligand immobilization links primary amine groups in the ligand to derivatised 
carboxyl groups on the sensor chip surface, although several alternative immobilization 
strategies are available (e.g. the streptavidin-biotin procedure used in this study).  As the 
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interaction proceeds, the concentration of the analyte on the surface layer increases, giving an 
SPR response that can be monitored by a fixed array of light-sensitive diodes covering the whole 
wedge of reflected light.  By using a wedge of incident light and a fixed array of detectors, the 
response angle can be monitored continuously.  When molecules in the sample bind to the 
surface of the sensor, the concentration and subsequently the refractive index at the surface 
changes and an SPR response is detected.  A quantitative measure of the progress of the 
interaction can be obtained by plotting the response against time during the course of an 
interaction.  This plot is called a sensorgram.  The response values of SPR are expressed in 
resonance units (RU).  One RU represents a change of 0.0001º in the angle of the intensity 
minimum.  This is approximately equivalent to a change in concentration of ~ 1 pg/mm
2
 on the 
sensor surface, for most proteins (Stenberg et al., 1991).    
5.2 Materials 
BiotinTag
TM
 Micro-Biotinylation Kit was obtained from Sigma-Aldrich (St Louis, USA), human 
myeloma IgE kappa chain was obtained from Biodesign
TM
 (Maine, USA).  CM5 sensor chip, 
streptavidin Sensor Chip, HBS, and ethanolamine were obtained from BIAcore AB (Uppsula, 
Sweden).  All other reagents were of analytical grade.  CD89 was a recombinant protein 
produced in E. coli donated by Katja Wenig (Max-Plank Institute for Biochemistry, Martinsried, 
Germany). 
5.3 Methods 
5.3.1 Biotinylation 
BiotinTag, a micro-biotinylation kit, is designed for the small scale (<1 mg) preparation of 
biotin-labelled polyclonal and monoclonal antibodies as well as conjugation of biotin to other 
proteins. 
Firstly, the sodium phosphate buffer was reconstituted with deionised water to obtain 0.1 M 
sodium phosphate buffer (pH 7.2).  BAC-SulfoNHS was reconstituted with 30 µL DMSO and 
brought to 1 mL with 0.1 M sodium phosphate buffer (pH 7.2) and vortexed to resuspend evenly 
and obtain a resulting concentration of 5 mg/mL.  Protein concentration was determined by BCA 
and biotinylation of proteins was obtained by mixing with 6-(biotinamidocaproylamido) caproic 
acid succinamide ester at a molar ratio of 1:13.  This mixture was incubated with gentle stirring 
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for 30 minutes at room temperature.  Initially, PBS was reconstituted with 800 µL of deionised 
water and mixed to dissolve; it was then brought to 1 litre to yield a final concentration of 0.01 
M (pH 7.4).  This buffer served as an equilibration buffer of the microspin G-50 column 
provided, and for elution of the labelled protein from the column.  The resin was resuspended by 
vortexing.  Once the bottom plug was removed, the column was placed into a microcentrifuge 
tube for support.  The column was pre-spun for 1 minute at 700 x g.  The column was then 
equilibrated in PBS by application of 200 µL to the column and spun for 1 minute at 700 x g.  
This step was repeated.  Labelled protein was isolated by loading the biotinylation reaction 
mixture to the top-centre of the resin.  The column was spun for 2 minutes at 700 x g.  The 
purified sample was collected at the bottom on the support tube.  The protein was eluted with 
PBS (pH 7.4) and the column was spun for 1 minute at 700 x g.  This last step was repeated 
twice and each fraction was collected in a separate vesicle.  Therefore, a total of four fractions 
were obtained.  The protein concentration was determined by protein micro-assay (BCA).  The 
fractions containing the protein (fractions 1-3) were pooled and stored at -80 °C (Wilcheck and 
Bayer, 1988). 
5.3.2 HPLC 
High performance liquid chromatography (HPLC) was performed using a Superdex 200, 
10/30GL column (Amersham Biosciences, Cat No. 17-5175-01) in HEPES buffered saline with 
calcium chloride (HBS-Ca, 10 mM HEPES, pH 7.4, 150 mM NaCl, 4 mM CaCl2, and 0.005% 
(v/v) Tween 20) at a flow rate of 0.75 ml/min, monitoring absorption at 280nm on an Agilent 
1100 Series HPLC (Agilent Technologies, USA).  The column was calibrated with Gel Filtration 
LMW Calibration Kit (GE-Healthcare: 28-4038 41) in KRIST buffer (2 mM MOPS, 150 mM 
NaCl, 0.02% (w/v) NaN3). 
5.3.3 Surface Plasmon Resonance Spectroscopy 
All experiments were performed at 25°C on a Biacore T100 instrument.  Proteins were coupled 
using a streptavidin capture system.   
A specific binding surface was prepared by coupling biotinylated CD23 fragments (derCD23, 
sCD23 and exCD23) as well as CD89 to a stable streptavidin capture system (SA chip).  
Coupling densities of 1000 resonance units (RUs) were used in order to collect steady state 
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binding data.  IgE and CD21 (SCR 1-2) were injected over the sensor chip at 30 µL/min with a 
5-min association phase followed by a 6-min dissociation phase using HBS-Ca as running buffer.  
When necessary, regeneration of the sensor surface was performed using two 30 second pulses 
of HBS containing 10 mM EDTA.  Interaction was also tested at higher flow rates and showed 
no change in interaction characteristics, thereby eliminating the probability of mass transport 
effects.  Injections included a zero concentration (i.e. buffer only) and a duplicate run of the 
highest concentration of protein.  IgE, CD23 and CD21 proteins behaved with no nonspecific 
binding to control flow cells, efficient regeneration of sensor surfaces, and excellent 
reproducibility.  Standard double reference data subtraction methods were used before analysis 
of kinetic and equilibrium binding.  Curve fit and other data analyses were performed using 
BiaEvaluation Version 1 software (Biacore, Sweden). 
5.3.4 CD23 ligand interactions 
The protein structures solved by NMR (Hibbert et al., 2005) and X-ray crystallography 
(Wurzburg et al., 2006) were used to build structures illustrating the exact positions of proposed 
interacting residues for the ligands of CD23.  Interactions of calcium, CD21, IgE and integrin 
were used with CD23 to form structures.   These structures were produced using the Molecular 
Biology Toolkit (MBT) (Moreland et al., 2005).  
5.4 Results and discussion 
5.4.1 HPLC analysis 
Native molecular weight determination and analysis of oligomer status within the CD23 protein 
samples were determined by gel filtration HPLC.  Chromatographs show derCD23 (Figure 32 a) 
to be homogenous with more than 96 % (Table 4) of the protein eluting at the expected 
molecular weight (16 kDa) of derCD23.  sCD23 (Figure 32 b) also proved to be homogenous 
with more than 97 % (Table 4) of the protein eluting at 25 kDa.  In contrast, exCD23 (Figure 32 
c) displayed heterogeneity within the protein.  Almost 65% of the protein consisted of oligomeric 
fragments (Table 4). Thirty percent of the protein had a Mr of ~ 124 kDa consistent with the 
formation of trimers.  Only 18% of exCD23 had a Mr of ~ 39 kDa, the size of a monomer, 14% 
of this protein the same size as sCD23 and 4% the same size as derCD23, suggesting partial 
degradation of the exCD23 fragment.  Moreover, based on molecular weight, 34% of exCD23 
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appeared to consist of a mixture of homodimeric and heterodimeric fragment formed by 
interactions between diverse CD23 fragments (Mr ~53 kDa).  
 
Figure 32: Analysis of CD23 by size exclusion HPLC.  Chromatographic profiles of (a) derCD23, (b) sCD23 (c) 
exCD23 were determined by HPLC using a Superdex 200, 10/30GL column as described in section 5.3.2. 
(a) 
(b) 
(c) 
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Table 4: Percentage purity of CD23 analyzed by size exclusion chromatography. 
Sample Peak Retention time  
(min) 
Area  
(%) 
Mr 
(kDa) 
Oligomer 
Status 
derCD23 14.638 2.78 38  
 16.492 96.33 22 Monomer  
 22.301 0.90 4  
sCD23 13.384 1.89 55  
 15.403 97.42 30 Monomer  
 22.25 0.69 4  
exCD23 10.59 30.66 124 Trimer  
 13.527 34.02 53  
 14.523 17.79 39 Monomer  
 15.461 13.83 30  
 16.478 3.71 22  
HPLC analysis revealed that derCD23 and sCD23 fragments were highly pure monomers but 
that exCD23 forms oligomers in solution, with only ~18% of the protein remaining monomeric.  
HPLC analysis indicated approximately equal proportions of trimeric exCD23 and an oligomer 
of ~ 53kDa that we speculate may arise from either homodimeric exCD23 or possibly 
heterodimers of exCD23 and partial cleavage fragments representing principally sCD23. 
The partial degradation was expected as exCD23 has previously been shown to be subject to 
auto-proteolysis (Delespesse et al., 1989), and it has been shown that it is not stable in solution 
(Sarfati et al., 1992).  It has also been shown, by RIA and Scatchard analysis, that CD23 
fragments that conserve a region of the stalk region, are able to form oligomers (Kelly et al., 
1998; Schulz et al., 1997), and that oligomerization of CD23 allows the lectin domains to come 
within close proximity of each other and to cooperate in binding one IgE molecule, resulting in 
high avidity binding.  
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5.4.2 SPR spectroscopy of the CD23-IgE and CD21 interactions 
Initially, a CM5 chip was used to facilitate amine coupling of proteins (FcIgA, CD21 and IgE) to 
the chip as ligands.  CD23 fragments were used as analytes and run over the stable chip at 
various concentrations, but it was found that no binding was observed (data not shown).  
Therefore, the orientation was reversed, using biotinylated CD23 as immobilized ligands, and 
CD21 SCR 1-2 and IgE as analytes.   
The streptavidin system was found to be the most efficient immobilisation method available, as 
the biotinylated CD23 was stable on the chip.  FcIgA receptor (CD89) was used as a control 
protein, as it was structurally similar to other ligands, also being an Fc receptor, but has not been 
shown to bind IgE or CD21.  derCD23 was immobilized on FC1 at 704.6 RU, sCD23 on FC2 at 
1008.2 RU, exCD23 on FC3 at 913.1 RU and FcIgA on FC4 at 959.1 RU . 
The ability of the BIACORE
®
 system to analyze interaction in real time means that data can be 
obtained not only on affinity of ligand for its receptor but also on the kinetics of the interaction 
(Malmqvist and Karlsson, 1997).  Yet, generating data suitable for detailed kinetic analysis 
ultimately depends on a number of experimental conditions.  These consist of high flow rates and 
low amounts of immobilized ligand, numerical integration of the differential rate equations and 
global fitting (using all the data from experiments with different concentrations in fitting of 
results to theoretical models), including mass transport parameters (Myszka et al., 1997).  
Generating data suitable for detailed kinetic analysis ultimately depends on starting with high-
quality samples and care must be taken to ensure that samples are homogeneous.  Myszka and 
colleagues (1997) reports that  assays must be arranged to avoid avidity effects which result 
when proteins contain multiple binding sites and tend to self associate in solution (MacKenzie et 
al., 1996).  One way to avoid problems of this kind is to assess the aggregation state of the 
reactants, as well as the stoichiometry of the complex, by the use of analytical ultracentrifugation 
(Myszka et al., 1997). 
Although kinetic data would give far more information with reference to binding of ligand to 
analyte, kinetic analysis proved unreliable (figure 33), since it was found that the fast on/off rates 
hindered the collection of accurate kinetic data.  Also the immobilization of ~1000 RU, and 
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possibly heterologous protein formation proved best suited to obtaining more accurate data from 
equilibrium experiments (figure 34).  Concentrations of up to 3000 nM of analyte were run over 
the ligand surfaces and an association time of 5 minutes and dissociation time of 6 minutes were 
allowed in order to obtain equilibrium data.  
  (A) (D)  
(B)                    (E)   
(C)            (F)  
Figure 33:  Kinetic SPR analysis of CD23 interaction with full length IgE and CD21 (SCR 1-2).  Immobilized (A) 
derCD23; (B) sCD23; and (C) exCD23 interaction with IgE; and immobilized (D) derCD23; (E) sCD23; and (F) 
exCD23 interaction with CD21 (SCR 1-2).  The binding of IgE and CD21 to immobilized CD23 was determined over 
a range of ligand concentrations: 62.5 (green), 125 (blue), 250 (pink), 500 (turquoise), 1000 (yellow), 2000 nM 
(grey) and 3000 nM (red) with a 100 s association phase and 450 s dissociation phase at 30 µL/min.    
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(A) (D)  
(B) (E)  
 
(C) (F)   
Figure 34: Steady State SPR analysis of CD23 interaction with full length IgE and CD21 (SCR 1-2).  Immobilized (A) 
derCD23; (B) sCD23; and (C) exCD23 interaction with IgE; and immobilized (D) derCD23; (E) sCD23; and (F) 
exCD23 interaction with CD21 (SCR 1-2).  The binding of IgE and CD21 to immobilized CD23 was determined over 
a range of ligand concentrations: 62.5 (green), 125 (blue), 250 (pink), 500 (turquoise), 1000 (yellow), 2000 nM 
(grey) and 3000 nM (red) as described in methods.     
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The dissociation constants for the interactions between CD23 fragments and IgE and CD21 
(Table 5) show a trend towards increasing binding affinity to IgE as the size of the CD23 
increases, although the differences are not significantly different.  Binding of CD23 to CD21 
demonstrates that whereas both sCD23 and exCD23 bind CD21, the maximal response units 
given by derCD23 indicate that there was virtually no binding between derCD23 and CD21.  The 
relative affinities obtained indicate that CD21 interactions with CD23 are apparently weaker than 
those with IgE.  Table 5 also illustrates statistical data in the form of standard error, and a chi 
squared value, which represents the curve fidelity.  Both these values represent accurate and 
reproducible data below the instrument noise (~2 RU). 
The equilibrium constants were determined from global fitting of association and dissociation 
phases of the sensorgrams, as well as fits of equilibrium RU (Rmax) against concentration of 
analyte using BIAevaluation software (figure 35).  In this instance, the measured binding is 
between exCD23 and IgE.  The vertical line represents the equilibrium dissociation constant.  As 
the value obtained is less than half the highest analyte concentration tested, the result can be 
deemed accurate. 
    
Figure 35: Steady state binding curve for exCD23 interaction with IgE.  The KD is represented by the vertical line 
showing the concentration of analyte at 50 % Rmax.    
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Table 5:  Dissociation constants for binding interactions of CD23 to IgE and CD21. Data display equilibrium 
experiments based upon steady-state levels. 
 KD (µM) SE(KD) (µM) χ
2
 Rmax (RU) Published KD
 
values (µM)
 
IgE binding to CD23  
derCD23 2.16 0.06 0.16 236 1.3 at high density to Cε2-4
$
 
1.0
 
to Cε2-4
#
 
sCD23 1.85 0.06 1.45 485  
exCD23 0.98 0.11 0.68 71 1.1
 
at low density to Cε2-4
$
 
     3.9 at high density to Cε 2-4
$
 
     0.1 as a trimeric protein
# 
2.0 as a monomeric protein
# 
CD21 binding to CD23    
derCD23 None    0.87 at low density to SCR 1-2
$
  
0.26 to SCR 1-4
& 
sCD23 4.00 0.26 0.70 238  
exCD23 6.50 0.89 0.15 90  
$,
 
Hibbert et al., 2005, #, McCloskey et al., 2007
 
&, Asokan et al., 2006 
Analysis of steady state data by SPR revealed a direct relationship between the length of the stalk 
region of CD23 and increasing affinity for IgE.  It must also be noted that previous binding 
experiments using derCD23 and exCD23 for binding to IgE used only the recombinant Fc 
portion of IgE, Cε2-4 (Hibbert et al., 2005; McCloskey et al., 2007), whereas these experiments 
used native IgE.  This could contribute to some discrepancy in binding affinity.  Consistent with 
a previous study by Chen et al. (2002) and Kelly et al., (1998),  who showed the stalk region of 
CD23 is necessary for binding IgE, our data further suggests that the longer the stalk, the higher 
the binding affinity.  The changes are, however, subtle, since derCD23 contains only a small 
region of the stalk, yet it‟s binding to IgE is not significantly diminished.  Contrary to previous 
work (Kilmon et al., 2004), it was found that the transmembrane and cytoplasmic domains were 
not necessary for high affinity binding to IgE.   
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It was found that the binding affinity of exCD23 for IgE was lower than expected, when 
compared with previous reports.  Using murine IgE and murine CD23 (Dierks et al., 1993) 
showed dual affinity binding of ~0.2 - 0.7 µM and ~2 - 7 µM for oligomeric CD23 forms and 
~5-10 µM for monomeric forms of CD23.  Using human CD23 with the addition of a leucine 
zipper motif (Chen et al., 2002) determined an affinity of 42 µM.  These binding studies were 
performed on native oligomeric and forced trimeric proteins (by addition of leucine zipper), 
respectively.  In addition to this, the discrepancy in binding, may be attributed to the 
heterogeneity of the recombinant exCD23, as HPLC analysis revealed both minor fragmentation 
of the protein into its shorter forms (sCD23 and derCD23), and formation of oligomers.  As it 
was therefore difficult to determine absolute KD values, relative values alone were analysed.  
DerCD23 and sCD23 which were monomeric at the concentration used for binding analysis, 
produced low micromolar range binding affinities (~ 1 – 2 µM) that were directly comparable to 
monomeric binding affinities previously published (McCloskey et al., 2007).   
Importantly equilibrium dissociation constants were also determined in order to characterize and 
compare the interactions between each of the soluble CD23 fragments and CD21 SCR 1-2.  This 
has not previously been comparatively analyzed with each of the soluble CD23 forms.  The 
equilibrium dissociation constants, determined by monitoring steady state levels, showed that the 
interaction between CD23 (sCD23 and exCD23) and CD21 occurs with similar affinities (4 and 
6.5 µM, respectively).  Although a higher maximal response was observed with sCD23 than with 
exCD23, it is speculated that the oligomerization of exCD23 may have partially altered the 
nature of the interaction with CD21.  While it was previously shown that derCD23 binds to 
CD21 with a KD value of 0.87 µM (Hibbert et al., 2005), this value was only obtained with a 
very high density (3000 RU) of immobilised CD23.  In contrast to these authors, our data shows 
virtually no binding between derCD23 and CD21 SCR 1-2.  According to Hibbert et al., (2005), 
6 amino acid residues (S293, E294, G295, S296, A297 and E298) of derCD23 include a section 
of the CD21 binding region, however no direct evidence was provided.  Our data demonstrates 
that when the entire length of the “tail” portion (residues 289-321) is present, the relevant CD23 
fragments indeed bind SCR 1-2 (sCD23 and exCD23), whereas the truncated fragment derCD23 
is unable to bind SCR 1-2.  The derCD23 used in all experiments is identical to that used in the 
study by Hibbert et al. (2005).  Thus, strong evidence is seen confirming that the SCR 1-2 
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binding site lies within this tail portion of CD23 and that the presence of the entire length of the 
“tail” in the CD23 molecule is necessary for binding to SCR 1-2.  Gilbert et al., (2006) have 
shown that differential binding effects are readily explained in terms of the flexibility of full 
length CD21.  Full length CD23 is said to bind both SCR 1-2 and SCR 5-8 of CD21 (Aubry et 
al., 1994), permitting CD23 to simultaneously form contacts with both SCR 1-2 and SCR 5-8. 
There is also no evidence disproving derCD23 binding to SCR 5-8 alone, which will only be 
evident on binding analysis between SCR 5-8 and perhaps structures of CD23 in complex with 
CD21. 
5.5 Conclusion 
The isolation of CD23 cDNA (Kikutani et al., 1986) led to the discovery by sequence homology 
studies that the extracellular region between amino acid residues 163 and 282 has similarity with 
C-type animal lectins (Drickamer, 1988).  Deletion mapping experiments then localized the IgE-
binding site of CD23 in the C-terminal ectodomain between amino acid residues 163 and 282 
(Bettler et al., 1989).  Surprisingly CD23 did not bind to the carbohydrate moieties of IgE, 
despite the striking similarity between IgE-binding and lectin homology domains (Vercelli et al., 
1989).  While CD23 binding to IgE is carbohydrate-independent, the binding is still calcium 
dependent (Richards and Katz, 1990).  Taking advantage of the structural similarity between 
CD23 and C-type lectins, allowed Bettler et al., (1992) to construct a set of homolog-scanning 
mutants.  The analysis of these mutants disclosed that the IgE-binding site is complex, with 
residues likely to contact the ligand at two distinct locations.  The C-type lectin domain sits atop 
the stalk domain, followed by ~30 tail amino acids, who‟s function is unknown (Wurzburg et al., 
2006). 
 
CD21 was first shown as a ligand for CD23 by Aubry et al., (1992).  Soon after CD21 was 
shown to bind the lectin domain, similar to IgE (Mossalayi et al., 1992).  Further, Aubry et al., 
(1994) also showed that CD23 binds SCR domains 1-2 and 5-8 with protein-protein and protein-
carbohydrate interactions, respectively.      
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Through the first half of the new millennium several important structures increased our 
knowledge of CD23 and its ligands.  Two IgE-Fc structures (Wan et al., 2002; Wurzburg et al., 
2000) and two of the N-terminal SCR 1-2 domains of CD21 were solved (Prota et al., 2002; 
Szakonyi et al., 2001) by  X-ray crystallography.  The first CD23 structure was solved by NMR 
using only the lectin domain (Hibbert et al., 2005), a study used to determine the IgE and CD21 
binding residues by chemical shift analysis (figure 36 and 37a).  Shortly afterwards, Wurzburg et 
al., (2006) solved the crystal structures of the soluble C-terminal fragment of CD23 in the 
presence and absence of Ca
2+
 (figure 37b).  Calcium binding is observed at the principal binding 
site, not at an auxiliary site as concluded from NMR by Hibbert et al., (2005).  In the apo-crystal 
structure, the Ca
2+
 site shows an arginine residue from a neighbouring loop is bound, but in the 
calcium bound form, there is disorder created and the differences in these structures shows an 
overlap with regions previously identified by homolog scanning (Bettler et al., 1992) as 
important for IgE-Fc interactions.  Therefore, although calcium is not shown to be necessary for 
binding, there are localized changes surrounding the principle calcium binding site that affect the 
affinity for IgE.   
The structure of the Ca
2+
 bound CD23 lectin domain differs significantly upon Ca
+2 
in three 
regions: the calcium binding site, the Loops 1 and 4 region, and the N and C termini.  Residues 
that act as calcium ion ligands become reordered upon calcium binding, and most of the changes 
are in the side chain orientations.  Upon calcium binding, the conformation and flexibility of 
Loops 1 and 4 change significantly.  Loop 4 is adjacent to the Ca
2+
 binding site on one side and 
packs next to Loop 1 on the other side.  In the apo form, Loop 4 (residues 253-257) is ordered, 
and the side chain of R253 points into the Ca
2+
 binding site.  When calcium binds, it replaces the 
R253 side chain in the binding site, and Loop 4 residues 253-257 become disordered.  Loop 1 
residues are affected by the increased flexibility of Loop 4.  The main chain path changes, 
moving Loop 1 towards Loop 4 and converting reverse turn 4 from a type I to a type III‟ turn.  
The change in conformation at this turn is most evident in the movement of residue L228, which 
points away from Loop 4 in the apo form but points towards Loop 4 and moves 5.4 Å closer to it 
in the Ca
2+
 bound form.  The observed N and C termini of the protein are truncated in the Ca
2+
 
bound form, with residues 158-159 and 289-291 missing from the Ca
2+
 bound structure 
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(Wurzburg et al., 2006).  The changing of Loops 1 and 4 on calcium binding, offer an 
explanation for the calcium-dependent, but carbohydrate-independent, binding of IgE to CD23.   
Residues from Loops 1, 2, and 4 surround a hydrophobic pocket on the back face of the lectin.  
The crystal structure of CD23 shows that residues in segment 224-233 (Loop 1 region) contact 
adjacent residues from the other three segments (185-190, 238-243, and 251-256), suggesting 
that Loop 1 residues form the core of the IgE binding surface.  Given that some CD23 isoforms 
are involved in transporting IgE complexes (Ewart et al., 2002; Montagnac et al., 2005; Yokota 
et al., 1992), it seems possible that calcium-dependent IgE binding could also provide a means of 
regulating IgE binding and release in a physiological setting (Wurzburg et al., 2006). 
 
Figure 36:  Ligand interaction sites on CD23. The αVβ5 integrin (open circles) (Borland et al., 2007), IgE (open 
triangles), and CD21 (filled circles) sites were determined by (Hermann et al., 1999) (Bettler et al., 1989; Hibbert 
et al., 2005) and (Aubry et al., 1992), respectively. 
It is known that the stalk of CD23 mediates oligomerization of the protein and facilitates a high 
affinity interaction with IgE (Kelly et al., 1998), but the lectin head is the site of interaction with 
the Cε3 domain of IgE (Kilmon et al., 2001).  Hibbert et al., (2005) showed by NMR analysis 
that self-association is accompanied by a change in chemical shifts of some of the peaks in the 
HSQC spectrum.  These residues (L189, K212, H213, N225, E231, V240 and Y242) map to two 
distinct regions, separate from the IgE and CD21 binding residues, suggesting a possible self 
association interaction surface.  Therefore, not only are the binding sites on CD23 for IgE and 
CD21 distinct from each other and from the trimerization interface, but CD23 can bind both 
ligands simultaneously to form a trimolecular complex.  
 
1   MEEGQYSEIEELPRRRCCRRGTQIVLLGLVTAALWAGLLTLLLLWHWDTTQSLKQLEERA 
 
61  ARNVSQVSKNLESHHGDQMAQKSQSTQISQELEELRAEQQRLKSQDLELSWNLNGLQADL 
 
121 SSFKSQELNERNEASDLLERLREEVTKLRMELQVSSGFVCNTCPEKWINFQRKCYYFGKG 
 
181 TKQWVHARYACDDMEGQLVSIHSPEEQDFLTKHASHTGSWIGLRNLDLKGEFIWVDGSHV 
 
241 DYSNWAPGEPTSRSQGEDCVMMRGSGRWNDAFCDRKLGAWVCDRLATCTPPASEGSAESM 
 
301 GPDSRPDPDGRLPTPSAPLHS 
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Figure 37: Structure of sCD23 showing ligand interaction sites.  (a) Ribbon representation of CD23 NMR structure 
18TD (Hibbert et al., 2005) showing the proposed interaction sites for IgE (residues shown as ball-and-stick 
representation in green), αVβ5 integrin (red), and CD21 SCR 1-2 (blue). The structure was drawn with MBT (b) 
Crystal structure of the human apo-CD23.  The primary (Ca1) and secondary (Ca2) calcium binding sites of a 
classical C-type lectin are labelled as yellow diamonds. The hatched region indicates the putative carbohydrate 
binding site of a classical C-type lectin.  L1 and L4 indicate loops 1 and 4 respectively.  The figure was obtained 
from Wurzburg et al., (2006). 
The oligomeric state of CD23 significantly affects IgE binding affinity.  Each IgE-Fc dimer 
contains two potential CD23 binding sites, and it has been demonstrated that two CD23 lectin 
domains bind to one IgE-Fc (Shi et al., 1997).  Native CD23 is thought to be trimeric with a 
binding affinity of 0.1 µM (Chen et al., 2002; Dierks et al., 1993; Kelly et al., 1998).  
Oligomeric CD23 binds IgE with a dual affinity, with the lower affinity being attributed to 
binding of a single lectin domain of CD23 (2 µM) and the higher affinity component attributed 
to binding of an additional lectin domain (Chen et al., 2002).  It has been found that while the 
stalk region enhances CD23 oligomerization, a region further down (termed the neck region) 
appears to be necessary for high affinity binding, by being tightly associated and potentially 
allowing for some flexibility in orienting the lectin domains to bind IgE (Kilmon et al., 2004).   
This is the first study to comparatively show the binding affinities of derC23, sCD23 and 
exCD23 to native human IgE and to CD21 SCR 1-2.  In this study, it was found that exCD23, as 
expected; formed trimers in solution, as well as being naturally susceptible to endogenous 
proteases.  Analysis showed a mixture of mainly trimeric exCD23, monomeric exCD23, and 
oligomers thought to be homodimeric and heterodimeric fragments of exCD23 and diverse CD23 
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fragments.  In contrast derCD23 and sCD23 were found to be highly pure monomers.  exCD23 
was found to have the highest binding affinity for IgE (despite this mixture of fragments in 
solution), followed by sCD23 and derCD23 (decreasing in size of stalk and neck region).  
Although the recorded binding affinity of exCD23 did not enter the range of previously recorded 
trimeric exCD23, and was found to be closer to monomeric CD23, the decreased binding affinity 
was more than likely attributable to the mixture of fragments in solution.  It is therefore likely 
that a dual binding affinity would have been found on kinetic analysis of binding.  Remembering 
also, that previous binding analysis was only between the Cε3 fragment of IgE and CD23 where 
this study used native IgE, which could also attribute to differences in binding affinities.  Taking 
all this into account, it is likely that oligomeric CD23 increases binding affinity for IgE, and that 
a certain part of the stalk/neck region of CD23 is responsible for enhancing oligomerization and 
high affinity binding to IgE.    
Binding affinity of exCD23 and sCD23 to CD21 SCR 1-2 showed similar affinities, whereas 
derCD23 showed no binding to CD21.  It is suspected that the CD21 SCR 1-2 binding site on 
CD23 falls on the „tail section‟ of CD23, which follows the lectin head domain, and includes the 
last 29 residues at the C-terminal end of CD23.  derCD23 has very few residues of this tail 
section (probably only 4-6 residues).  Nevertheless, while suspected to be at a lower affinity for 
CD21 than other soluble CD23 fragments, derCD23 has previously been shown to bind to CD21 
SCR 1-2, but only at a very high immobilization of derCD23 on the chip surface (3000 RU) by 
Hibbert et al. (2005).  Hibbert et al., (2005) has also suggested that binding affinity between 
CD23 and CD21 would possibly increase on binding to full length CD21 (SCR 1-15),  justified 
by the relative comparative binding affinity for SCR 1-2, SCR 1-4 and SCR 1-15 shown by 
Asokan et al., (2006) to CD23.  Bringing to attention that the interaction of CD23 with CD21 
involves not only domains 1 and 2 of CD21, but also domains 5-8, which interact with CD23 in a 
carbohydrate-dependent manner (Aubry et al., 1994) it is likely due to the presence of this 
additional binding site, that there would be an increase in binding affinity.   
It is also evident, on examination of the solution structure of CD21 shown by Gilbert, et al., 
(2006), that there exists a flexible proximal SCR domain, a situation that is conducive to the 
dispersed binding sites of CD21 to come together and also making it probable for possible multi-
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point attachments to be made to the CD23 trimer, perhaps to the head as well as the tail regions.  
Light could be shed on the interactions of CD21 and derC23 by studying SCR 5-8 interactions 
and through structural complexes. 
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6 The effect of CD23 and CD23-CD21 interactions on IgE secretion 
6.1 Introduction 
CD23 is implicated in IgE regulation as well as inflammatory or lymphoproliferative diseases.  
As discussed in Chapter 1, the cleavage of cell surface CD23 by endogenous proteases releases 
soluble fragments of various sizes (37, 33, 29, 25 and 16 kDa), all of which have been shown to 
contain the lectin domain.  We have shown in Chapter 5, together with other studies (McCloskey 
et al., 2007) that fragments that also contain stalk sequences form trimers in a concentration-
dependent manner or upon IgE binding, whereas those lacking any stalk region are monomeric 
(Table 4).  These sCD23 fragments also differ in their trimerization tendencies depending on the 
length of the residual stalk (Schulz et al., 1997).  All these fragments are found in the circulation 
of normal human subjects.  Elevated concentrations of circulating sCD23 fragments are 
commonly associated with pathogenesis of allergic, inflammatory diseases, and leukaemias.  All 
fragments retain binding to IgE, and several have been shown to have cytokine activities, 
stimulating the secretion of IL-1β, TNF-α, and IL-6 (Armant et al., 1994; Beavil et al., 1995; 
Daniels et al., 2005; Mossalayi et al., 1997).  CD23 can also act as an adhesion molecule, 
interacting with CD21, CD18/CD11b and CD18/CD11c, and the vitronectin receptor (Hibbert et 
al., 2005).  These interactions control important aspects of immune regulation.  Perturbation of 
such molecular interactions may promote allergy and other inflammatory disorders (Bonnefoy et 
al., 1997).  
It has been shown that triggering of CD21 by CD23 increased the IL-4-induced germline ε 
transcription levels (Basaki et al., 2002) and had a synergistic effect on the expression of the ε 
transcript induced by T-cells.  Therefore, in allergic individuals, T-cell-associated CD23 could 
interact with B-cell-associated CD21 leading to an increase in IgE production. Adhesion pairing 
between CD23 and CD21 may (A) alter IgE production, and (B) exacerbate allergy by several 
mechanisms (section 1.2.3).  The ability of CD23 to bind both IgE and CD21 may allow cross-
talk between the B-cell receptor and the complement system, enhancing overall IgE production 
(Gould and Sutton, 2008).  However, the exact CD21 binding site is unknown, although our 
current studies implicate the C-terminal tail residues of CD23 (chapter 5).  Yet flexibility of the 
CD21 structure lends itself to possible multi-point attachments to the CD23 trimer.     
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In this study we have engineered recombinant human CD23 fragments resembling those yielded 
by the dust mite protease Der pI (derCD23), and by ADAM10-mediated proteolysis of an 
intermediate soluble form of CD23 (sCD23) as well as the entire CD23 ectodomain (exCD23).   
We have investigated the effect that interactions between the three recombinant soluble CD23 
fragments and CD21 have on IgE regulation.  Various approaches were taken to accomplish this; 
using PBMCs as a model.  In order to monitor potential regulation of IgE secretion from B-cells 
by the recombinant proteins produced in this study, it is necessary to initially stimulate the cells 
to undergo IgE isotype switching.  In order to verify switching of the cells to IgE production 
after stimulation of the cells with various switch-factors, phospho-STAT 6 was detected by flow 
cytometry.  After isotype switching was verified, quantification of secreted IgE levels with and 
without the addition of CD23 and CD21 SCR 1-2 was measured by ELISA.  Lastly, cells 
(initially the Raji B lymphocyte cell line and later PBMCs) were also subjected to siRNA 
interference to down regulate CD21 production.   
6.1 Materials 
The Raji cell line was obtained from the American Type Culture Collection (ATCC) (Virginia, 
USA), Roswell Park Memorial Institute (RPMI) 1640 and Iscoves modification of Dulbecco‟s 
medium (IMDM) and Penicillin-Streptomycin were obtained from LONZA (Basel, Switzerland), 
foetal calf serum (FCS) from Gibco (California, USA), BD Vacutainer CPT tubes with sodium 
heparin from Beckton-Dickinson (Texas, USA), IL-4 from Immunotech (Quebec, Canada), 
Accutase from Sigma (Virginia, USA), CD21 SCR 1-2 was donated by Joyce Fingeroth 
(Harvard Medical School, Division of Infectious Diseases, Beth Israel Deaconess Medical 
Center, Harvard Institutes of Medicine, Boston, USA), monoclonal anti-human CD40, rabbit 
anti-human CD21, rabbit anti-human CD19, rabbit anti-human CD16, rabbit anti-human CD45, 
rabbit anti-human CD3, rabbit IgG-FITC isotype control, rabbit IgG1-EDC isotype control, goat 
anti-rabbit-FITC secondary antibody and Intraprep Permeabilization reagent were from Beckman 
Coulter (Brea, USA), rabbit anti-phospho-STAT6 was from Cell Signalling (Boston, USA).  
BSA was obtained from Roche (Basel, Switzerland), trypan blue and CellTitre Blue 
TM
 from 
Promega (Madison, USA), CD21 siRNA, transfection reagent and transfection medium were 
from Santa Cruz Biotechnology (California, USA).  The IgE Enzyme Immunoassay kit was from 
Immunospec (California, USA).  Low binding round bottomed 96-well plates, 25 cm
2
 and 75 
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cm
2
 flasks were from Corning (Quebec, Canada).  All other reagents used were of the highest 
analytical grade.   
6.2 Human cell lines used in this study 
The Raji cell line is a B-lymphoblastoid cell line established from a Burkitt‟s lymphoma of the 
left maxilla in an 11-year-old Black male.  The cells routinely express CD21 on the cell surface, 
but it is said to have an impaired IL-4 response associated with a defective STAT-6 function 
despite the presence of a high number of IL-4 receptors (Shubinsky et al., 1997).  Although, 
these cells were useful for investigating CD21 expression in siRNA experiments, these cells do 
not express IgE (Savelyeva and Mamaeva, 1988), and therefore it was important to use PBMCs 
for experiments investigating IgE regulation. 
6.3 Methods 
6.3.1 Routine maintenance of cells 
All cell lines were routinely maintained in 25 or 75 cm
2
 cell culture flasks in growth medium 
consisting of RPMI 1640 cell culture medium, supplemented with 10% foetal calf serum (FCS) 
with addition of 0.01% (w/v) each of penicillin and streptomycin.  The cells were grown at 37°C 
in a humidified atmosphere with 5% CO2 and 95% air.  Raji cells were maintained between 1 x 
10
5
 and 1 x 10
7
 cells/mL.  Raji cells were diluted by addition of fresh medium, or medium was 
replaced every three days, either by centrifugation (160 x g for 5 minutes) then aspirating spent 
medium and resuspending the cells in fresh medium, followed by transferring into new 75 cm
2 
flasks, or by simple subculturing of the cells.  Raji cells were subcultured using a 1:5 split ratio.  
PBMCs were freshly isolated and seeded directly for experimentation and therefore no routine 
maintenance was necessary.  PBMCs were left for 24 hours after seeding before treatment began.  
Seeding density was normally 1 x 10
6
 cells/mL and it was found that in order to stimulate B-
cells, the most effective growth medium was IMDM supplemented with 10% FCS with the 
addition of 0.01% (w/v) each of penicillin and streptomycin.   It is also important to note that the 
most effective culture plates for culture of PBMCs are low binding round bottomed 96-well 
plates.    
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6.3.2 Cell counting by Trypan Blue 
An equal volume of cell suspension and trypan blue [0.4% (w/v) in phosphate buffered saline 
(calcium and magnesium free) containing 0.5 M EDTA (PBSA)] was mixed and left at room 
temperature for 2 minutes.  The cells were then counted in an improved Neubauer 
haemocytometer.  Viable cells excluded the dye, whereas non-viable cells appeared blue due to 
leaky membranes allowing trypan blue into the cells. 
6.3.3 Cell Viability using CellTitre BlueTM 
Due to the variability of cell numbers in suspension cultures, as well as the possibility of the 
treatment affecting cell proliferation, the viability of the cells in each well in each experiment 
was determined so that the results could be normalized using viable cell numbers.   
 
The CellTitre Blue
TM
 viability assay kit provides a homogenous, fluorometric method for 
estimating the number of viable cells present in multiwell plates.  It uses the indicator dye 
resazurin to measure the metabolic capacity of cells, which is an indicator of viability.  Viable 
cells retain the ability to reduce resazurin into resorufin, which is highly fluorescent.  Nonviable 
cells rapidly lose metabolic capacity, do not reduce the indicator dye, and thus do not generate a 
fluorescent signal (O'Brien et al., 2000).  CellTitre Blue
TM
 was used to test cell viability by 
adding 20 µL to the cells in 96-well plates and incubating for 2 hours at 37ºC.  The fluorescent 
signal was measured at 544EX/590EM using a Fluoroskan Ascent FL Thermo Labsystems 
fluorescent microtitre plate reader, and the corresponding cell number obtained from a standard 
curve (Addendum C). 
6.3.4 Isolation of peripheral blood mononuclear cells 
Most cell separation techniques are based on differences in the physical or biological properties 
of cells.  Isolation of mononuclear cells from whole blood is a first step for many in vitro assays. 
One currently accepted technique for mononuclear cell separation, referred to as the FICOLL™ 
Hypaque™ method, employs a liquid density gradient medium of FICOLL™ 400 and sodium 
metrizoate or sodium diatrizoate solution (Boyum, 1984).  The procedure uses uncoagulated 
blood, collected by routine phlebotomy, which is diluted with a buffered solution, and then 
carefully layered onto the medium.  This preparation is then centrifuged to isolate the 
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mononuclear cells above the medium.  The cells are harvested by carefully pipetting them from 
the liquid interface.  The BD Vacutainer® CPT™ Cell Preparation Tube with Sodium Heparin 
combines a blood collection tube containing a sodium heparin anticoagulant with a FICOLL™ 
Hypaque™ density fluid and a polyester gel barrier which separates the two liquids.  The result 
is a convenient, single tube system for the collection of whole blood and the separation of 
mononuclear cells.  By using these Vacutainer tubes for mononuclear cell isolation, the 
following percentages of cells were expected (Needham, 1987):  
 Total Mononuclear cells          ~ 92 % 
 Lymphocytes                           ~ 80 % 
 Monocytes                               ~ 12 % 
 RBC Contamination within total mononuclear cells               ~ 17 % 
 Granulocyte contamination within total mononuclear cells     ~ 8 % 
PBMCs were isolated from 13 donor individuals that formed the study group (refer to Results 
and Discussion, section 6.5.3).  A single donor with hyper-IgE syndrome participated in the 
study but had to take several immunosuppressant medications on a daily basis to prevent illness 
and improve his quality of life (including Dapsone, Azapress, Erythromycin and Fannagin).  Any 
donors taking any nature of allergic medication (such as those mentioned above, or 
antihistamine) discontinued medication for 24 hours prior to blood collection.   
  
The cells were isolated from donors by Ficoll density gradient centrifugation by collecting blood 
from a large arm vein, directly into VacuTainer cell preparation tubes.  Two to four tubes were 
filled with blood from each donor.  The tubes were immediately inverted eight times.  Within 
half an hour, the tubes were centrifuged at 1800 x g for 30 minutes (Eppendorf 5804R 
centrifuge).  The top layer above the plug was poured off into two labelled 15 mL tubes.  These 
tubes were centrifuged (300 x g, 15 min at room temperature).  With a plugged glass pipette, the 
plasma layer was removed and dispensed into a labelled 15 mL tube (this was stored at -20°C 
and later used to determine total serum IgE levels - see section 6.4.7.2).  About 50 µL of plasma 
was left with the PBMC pellet.  The tube was grated against the bottom of a U-shaped 96-well 
microtitre plate until the cells were completely resuspended in the solution.  Growth medium was 
poured into the 15 mL tubes containing the resuspended PBMCs (to a final volume of ~ 13 mL).  
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The tube was capped and inverted to mix, followed by centrifugation for 15 minutes at 300 x g at 
room temperature.  The supernatant was removed using a glass pipette, leaving about 50 µL of 
supernatant.  The tube was, once again, grated to resuspend the PBMCs and this suspension was 
further suspended in ±1 mL of growth medium.  Twenty microlitres of the PBMC mixture was 
used for counting, before seeding the remaining cells in 96-well culture plates.     
6.3.5 Measurement of cell surface markers 
Initially, PBMCs were analysed for specific leukocytes (T-cells, B-cells and monocytes) 
amongst the cell population using flow cytometry.  Initially rabbit anti-human CD45-PC7, was 
used as a general leukocyte stain.  This enabled total leukocyte quantification.  In a separate 
experiment on the same cell population, subsequent analysis of individual cells was performed.  
T-cells were detected using rabbit anti-human CD3-PC7, B-cells were detected with rabbit anti-
human CD19-FITC, and monocytes were detected with rabbit anti-human CD16-PC5.   
Next, the presence of CD21 on the surface of B-cells within a PBMC population was quantified 
using an anti-CD21-FITC antibody.  PBMCs were stained with CD19-FITC for the presence of 
B-cells.  Once located, the population was gated.  Within the gated population, in a separate tube, 
the presence of CD21 was detected using rabbit anti-human CD21-FITC antibody.   
In all of these experiments, PBMCs were isolated, counted and seeded.  After 24 hour 
incubation, cells were treated for 15 minutes at 37°C with Accutase to release any adherent cells 
within the PBMC population.  Cells were transferred to a flow cytometry analysis tube at 1 x 10
5
 
cells/mL and centrifuged for 5 minutes at 300 x g to pellet the cells.  The supernatant was 
discarded.  The cells were washed with 1 mL incubation buffer [0.5% (w/v) BSA in PBS] and 
blocked in 100 µL incubation buffer for 10 minutes.  Cells were then gently agitated manually 
for 1-2 seconds.  Primary antibody (described above) was added and incubated for 60 minutes at 
room temperature in the dark, if more than one primary antibody was used, they were added 
simultaneously.  After incubation, the cells were rinsed in incubation buffer (1 mL) twice, 
centrifuged as before and the supernatant was discarded.  After incubation the cells were rinsed 
twice with incubation buffer as before.  Finally, cells were resuspended in 0.5 mL PBS and 
analysed by flow cytometry, recording 10 000 gated events, using a Cytomics FC 500 Flow 
cytometer (Beckman Coulter, USA).   
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6.3.6 Analysis of STAT 6 signalling 
IgE isotype switching is initiated by IL-4 or IL-13 induction of germline Cε  transcription and is 
subsequently brought about by CD40 ligation by CD154 or agonistic anti-CD40 antibodies 
(Basaki et al., 2002).  A B-cell requires a minimum of two signals to initiate CSR to IgE.  One 
signal is delivered by CD40 and one by the IL-4 receptor, both of which are provided to the B-
cell by a CD40 ligand on, and an IL-4 cytokine secreted from an activated Th2 cell during the 
germinal centre reaction (Pongratz et al., 2006).   
In contrast to CSR, which initiates the IgE response, the amount of IgE produced by a B-cell is 
controlled by a regulatory mechanism that is activated within the B-cell itself.  This mechanism 
involves changes in the activity of the 3‟ IgH enhancer, located downstream to the IgH region 
where CSR occurs (Stevens et al., 2000) and is induced by transcription factors activated 
subsequent to B-cell activation.  Another mechanism endogenous to the B cell (i.e the 
stimulation or release of CD23), also significantly regulates the level of IgE production. 
(Pongratz et al., 2006). 
In addition to these well-characterized mechanisms of endogenous B-cell regulatory activity, a 
homeostatic mechanism exists externally to the B-cell itself by which the level of IgE produced 
is regulated.  This homeostatic mechanism involves activation of the sympathetic nervous system 
and subsequent release of norepinephrine (NE) from nerve endings that penetrate the 
parenchyma of all lymphoid tissues (Pongratz et al., 2006).   
CSR to IgE in B-cells stimulated with anti-CD40 and IL-4 involves a number of molecular 
events that include expression of Cε germline transcripts (GLTs), expression of the gene for 
activation-induced cytidine deaminase (AID), S-regions (Sµ to Sε) deletion switch 
recombination, and expression of mature Iµ-Cε transcripts (Manis et al., 2002).  The importance 
of CD40L-CD40 interactions in isotype switching is illustrated by several observations.  The 
mAb‟s directed against CD40 can replace T-cells in IL-4–driven isotype switching to IgE in vitro 
(Jabara et al., 1990).  Soluble human CD40 (sCD40) inhibits in vitro T cell–driven IL-4–
dependent IgE synthesis (Fanslow et al., 1992), and donors with the X-linked hyper-IgM (X-
HIM) syndrome are deficient in CD40L and lack serum IgG, IgA, and IgE due to defective 
isotype switching in vivo (Fuleihan et al., 1995).  In addition, mice with targeted disruption of 
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the CD40L or CD40 genes lack serum IgE and fail to undergo isotype switching after 
immunization with T cell–dependent antigens (Jabara et al., 1990). 
In order to monitor potential regulation of IgE secretion from B-cells by the recombinant 
proteins produced in this study, it is necessary to initially stimulate the cells to undergo IgE 
isotype switching.  Mechanisms used in vitro to stimulate B-cell activation and CSR are 
described below: 
Medically, phytohaemagglutinin (PHA) is used as a mitogen to trigger cell division in T-
lymphocytes (Carlson, 2007).  Staphylococcal toxins, such as toxic shock syndrome toxin-1 
(TSST-1), are prototypic superantigens leading to a polyclonal expansion of T lymphocytes 
expressing a specific T-cell receptor variable region gene and the production of high cytokine 
levels (Marrack and Kappler, 1990).  Superantigens are also able to activate B lymphocytes by 
bridging the T-cell receptor on the T lymphocyte with the class II major histocompatibility 
molecule on the B lymphocyte (Mourad et al., 1989).         
Upon activation by Janus kinases, STAT-6 translocates to the nucleus where it regulates 
cytokine-induced gene expression.  STAT-6 is activated via phosphorylation at Tyr641 and is 
required for responsiveness to IL-4 and IL-13 (Nelms et al., 1999).  In addition, STAT-6 is 
activated by IFN-α in B-cell lines, where it forms transcriptionally active complexes with STAT-
2 and p48 (Takeda et al., 1996).  Protein phosphatase 2A is also involved in regulation of IL-4-
mediated STAT-6 signalling.  Phospho-STAT-6 was therefore monitored to determine 
phosphorylation of STAT-6 and therefore positive IL-4 responsiveness, which would have a 
direct correlation to IgE isotype switching.  Phospho-STAT-6 (Tyr 641) antibody was supplied 
in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA and 50% glycerol.  For 
flow cytometry, a 1:100 times dilution was used.  A rabbit anti-human phospho-STAT-6 IgG1 
antibody was used, together with an FITC labelled goat anti-rabbit IgG (H + L) secondary 
antibody and an isotype control antibody (rabbit IgG1-FITC).  Cells were treated with two 
concentrations of IL-4 (20 and 100 ng/mL) for two different time intervals (30 minutes and 1 
hour) with anti-CD40 (5 µg/mL).  Because phospho-STAT-6 is an intracellular cytokine, the 
cells were fixed and permeabilized prior to staining.  The procedure for flow cytometry was 
followed as outlined in section 6.4.5. 
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PBMCs were always isolated (section 6.4.4), counted and seeded 24 hours in advance of flow 
cytometry analysis to make sure any stress from isolation did not interfere with experimentation.  
After incubation, cells were treated for 15 minutes at 37°C with Accutase to release any adherent 
cells within the PBMC population (monocytes tend to become adherent after seeding).  Raji cells 
were seeded directly from a maintained culture and did not require treatment with Accutase. 
Cells were transferred to a flow cytometry analysis tube at 1 x 10
6
 cells/mL and centrifuged for 5 
minutes at 300 x g to pellet the cells.  The supernatant was discarded.  In order to fix the cells, 50 
µL of Intraprep reagent 1 [Fixation reagent, containing 5% (v/v) formaldehyde] was added.  For 
permeabilization, the tubes were vortexed and incubated at room temperature for 15 minutes.  
After incubation, 1 mL of PBS was added to wash the cells, the cells were centrifuged and the 
supernatant was discarded, as before.  Fifty microlitres of Intraprep reagent 2 (PBS-buffered 
saponin-based permeabilizing and lysing medium, containing 0.1% sodium azide) was added to 
permeabilise the cells, and incubated with the cells for 5 minutes at room temperature.  The cells 
were washed with 1 mL incubation buffer [0.5% (w/v) BSA in PBS] and blocked in 100 µL 
incubation buffer for 10 minutes.   
Cells were then gently agitated manually for 1-2 seconds.  Rabbit anti-human phospho-STAT-6 
IgG1 primary antibody was added and incubated for 60 minutes at room temperature in the dark.  
After incubation, the cells were rinsed in incubation buffer (1 mL) twice, centrifuged as before 
and the supernatant was discarded.  Secondary goat anti-rabbit-FITC was incubated with the 
cells for 30 minutes at room temperature in the dark.  After incubation the cells were rinsed twice 
with incubation buffer as before.  Finally, cells were resuspended in 0.5 mL PBS and analysed 
by flow cytometry, recording 10 000 gated events, using a Cytomics FC 500 Flow cytometer 
(Beckman Coulter, USA).   
6.3.7 Analysis of IgE secretion 
6.3.7.1 Culture of PBMCs with recombinant proteins 
For analysis, PBMCs were routinely isolated (section 6.4.4) and seeded at a density of 1 x 10
6
 
cells/mL in a volume of 200 µL, into a round bottomed, low protein binding 96-well plate, and 
incubated in the presence of IL-4 (20 ng/mL) and anti-CD40 (5 µg/mL) to enable B-cell 
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switching to IgE synthesis.  A negative control was also created without the addition of switch 
factors.    
Initially, titration of CD23 at various concentrations (0-100 ng/mL) with PBMCs was performed 
in order to determine which concentration of recombinant soluble CD23 was best suited to 
stimulate production of IgE.   
Cells were incubated as above, with addition of recombinant CD23 (derCD23, sCD23 or 
exCD23) at 25 ng/mL (defined by titration experiment), either in the presence or absence of 
recombinant CD21 SCR 1-2 at 1 µg/mL.  After 14 day incubation at 37°C, the cells were 
subjected to IgE enzyme immunoassay (section 6.4.7.2).  It must be noted that as cells were 
normally incubated with treatment for 14 days, a small amount of evaporation was expected and 
therefore, test wells were seeded within the 96-well plate and surrounded by wells seeded with 
buffer to avoid uneven evaporation and subsequent „edge-effect‟ by perpetual concentration of 
test molecules.   
Previous studies have shown that B-cell proliferation and differentiation can be induced by 
cross-linking CD21 with either polymeric C3d or certain anti-CD21 mAbs in the presence of T- 
cell cytokines (Nemerow et al., 1985).  Further, sCD23 is also involved in proliferation of these 
cells, as well as the rescue of germinal centre B-cell centrocytes from apoptosis (Mossalayi et al., 
1992).  It was therefore expected that addition of both switch-factors (IL-4 and anti-CD40) and 
recombinant proteins (soluble CD23 and CD21) may cause proliferation of cells.  Consequently 
cell numbers were monitored in conjunction with IgE secretion after the 14 day incubation of 
PBMCs.  This was performed after centrifugation at 200 x g for 5 minutes, removal of cell 
supernatant (retained for IgE quantification) and addition of 100 µL of growth medium (IMEM 
+10% FCS) and 20 µL CellTitre Blue assay reagent as previously described (section 6.4.3).  IgE 
secretion was thus corrected for cell number and expressed as IU/mL/million cells. 
A standard curve was determined on the same day as isolation of PBMCs and cell numbers were 
determined by cell titre blue (CTB) assay (section 6.4.3).   
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6.3.7.2 Quantification of IgE 
The most direct approach to detect the effect recombinant soluble CD23 proteins, as well as 
CD21 SCR 1-2, have on IgE regulation is the quantitative determination of IgE secreted by B-
cells.  The IgE Quantitative Enzyme Immunoassay provided an assay for IgE, with a minimal 
sensitivity of 5 IU/mL. 
The total IgE assay is a two-step “sandwich” type assay in which two mouse monoclonal 
antibodies, directed against two different epitopes on IgE, are employed.  Samples or calibrators 
are incubated in wells coated with the first monoclonal antibody, the contents of the wells are 
then aspirated and the presence of IgE in the sample is revealed by incubation with a second 
monoclonal antibody conjugated with acetylcholinesterase (AChE).  After incubation, the wells 
are rinsed in order to remove non-bound components.  The bound enzymatic activity is then 
measured after the addition of a chromogenic substrate for AChE.     
In order to quantify IgE, after the 14 day incubation with recombinant proteins or controls, cells 
were centrifuged (200 x g) for 5 minutes and the resulting standards (20 µL) and supernatants 
were dispensed into appropriate wells (pre-coated and provided in the assay kit).  In the case of 
allergic and slightly allergic individuals 120 µL supernatant and in the case of hyper-allergic 
individuals only 20 µL were used for the assay.  Plasma saved from original PBMC isolations 
and stored at -20°C was thawed and assayed simultaneously to record donor total blood IgE 
levels.  Quantification of serum IgE levels enabled allocating donors into groups according to 
potential atopic risk.   
Zero buffer provided in the kit was dispensed to make the volume 120 µL in all wells.  The plate 
was thoroughly, but gently mixed for 10 seconds.  Following mixing, the plate was incubated at 
room temperature for 30 minutes.  Thereafter, the incubation mixture was removed and the wells 
rinsed 5 times with wash buffer.  Enzyme conjugate reagent (150 µL) was dispensed into each 
well, gently mixed for 5 seconds, and the plate incubated at room temperature for 30 minutes.  
The incubation mixture was removed and rinsed 5 times as before.  Tetramethylbenzidine (TMB) 
solution (100 µL) was dispensed into each well, gently mixed for 5 seconds, and the plate 
incubated at room temperature in the dark for 20 minutes.  The reaction was stopped by addition 
of Stop solution (100 µL) to each well.  The plate was gently mixed for 30 seconds, to ensure the 
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entire blue colour changed to yellow.  The absorbance was measured at a wavelength of 450 nm 
with a PowerWave XS microtitre plate reader (BioTek, USA).   
A standard curve was constructed by plotting the mean absorbance obtained from each IgE 
reference standard against its concentration in IU/mL (Addendum C).  The mean absorbance 
values for specimens were used to determine the corresponding concentrations of IgE in IU/mL 
from the standard curve.  The highest reliable concentration obtainable was 800 IU/mL.  It was 
therefore necessary to dilute supernatant obtained from individuals with concentrations of IgE 
higher than 800 IU/mL in their plasma samples.          
6.3.8 Down-regulation of CD21 on human cells and cell lines using siRNA 
6.3.8.1 Upregulation of CD21 on Raji cells 
It was thought that CD21 levels may not be high enough to properly quantify down regulation of 
CD21 with siRNA.  Various stimulants [PMA (Sengstake et al., 2006), LPS (Qin et al., 1998), 
vitamin D3 (Chen et al., 2007) and retinoic acid (Porat and Zan-Bar, 1995)], all with the addition 
of IL-4, are known to be involved in the enhanced activity of the CD21 promoter in B-cells.  
These were tested for induction of CD21 and expression on the surface of Raji cells.  Cells (1 
mL) were seeded at 500 000 cells/mL in a 24 well plate and allowed to incubate at 37°C for 24 
hours to reach exponential phase.  The treatments [PMA at 10 ng/mL, LPS at 1 µg/mL (Tolnay 
et al., 2002), vitamin D3 at 0.1 µM, or retinoic acid at 1 µM, all with IL-4 at 200 U/mL (Pongratz 
et al., 2006)] were added to the cells.  Medium (RPMI 1640 with 10% FCS) was used as 
negative control and as diluent for treatments.  After incubation for 24 and 48 hours, cells were 
stained (see section 6.4.5 for protocol) with 20 µL anti-CD21-FITC, as well as an IgG1 isotype 
control and subjected to analysis by flow cytometry (section 6.4.5) 
6.3.8.2 siRNA Transfection 
RNA interference (RNAi) was first identified in Caenorhabditis elegans by 2006 Nobel laureates 
Andrew Z. Fire and Craig C. Mello (Fire et al., 1998), and now represents one of the most 
promising discoveries in molecular biology.  Endogenous RNAi activity has been linked to the 
regulation of transposon mobility (Das et al., 2008), the determination of gene expression 
profiles (Kawasaki et al., 2005b) and cell fate (Georgantas III et al., 2007), and is a crucial 
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component of the innate cellular defence against viral infection.  Three unique RNAi 
mechanisms controlling target gene expression have been demonstrated.  RNAi regulates gene 
transcription by modifying heterochromatin formation (Kawasaki et al., 2005a) and RNAi 
exercises two forms of post-transcriptional control. First RNAi can inhibit the translation of 
target mRNA (Tamura et al., 2008) and second, RNAi can direct target mRNA destruction 
through the RNA induced silencing (RISC) complex (Hammond et al., 2001).  
The discovery of RNAi introduced an extraordinarily powerful laboratory tool for researchers 
and became a promising potential therapeutic tool.  In the laboratory, RNAi molecules are being 
used to down-regulate individual target gene expression in a variety of organisms and cell types, 
exploiting each of the three mechanisms of inhibiting gene expression described above.  These 
techniques are useful for manipulating an experimental system to explore individual gene and 
protein functions as well as their relationships to other genes and proteins.  RNAi also has 
exciting clinical potential (Zhanga et al., 2008).  An intense effort is now centred on the 
identification of therapeutic microRNA (miRNA) candidates, capable of regulating expression of 
multiple target genes by inducing mRNA cleavage and/or translational inhibition.  The target-
specific nature of action offers reduced toxicity but the clinical worth of these, as with other 
bioactive molecules, is determined by the ability to disseminate in the body and reach target sites 
at therapeutically relevant levels (He and Hannon, 2004).    
In the following experiments, the down-regulated gene was CD21, targeted by siRNA, which 
was first transfected into Raji cells to test the system, and later performed on isolated PBMCs 
with a view to establishing them as model for the regulation of IgE secretion by CD21 ligation.  
The control gene used was CD19, which is a 95 kDa transmembrane glycoprotein that is 
continuously expressed on the surface of B lymphocytes, where it activates intracellular 
signalling cascades involving both Ras and phosphatidylinositol 3-kinase pathways.  Expression 
of CD19 is continuous throughout B-cell development and through terminal differentiation of B-
cells into plasma cells (Zhou et al., 1992).   
Cells were seeded into a 24 well culture dish at a density of 1 x 10
5
cells/mL in 1 mL of antibiotic 
free normal growth medium, supplemented with 10% FCS.  The plate was incubated for 24 
hours.  Solution A provided with the siRNA kit was prepared by diluting 0.5 µg siRNA into 100 
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µL siRNA transfection medium for each sample.  Solution B was prepared by diluting 5 µL 
siRNA transfection reagent with 100 µL siRNA transfection medium.  Solution A was added to 
solution B and mixed by pipetting up and down.  The mixture was incubated at room 
temperature for 45 minutes.  The cells were washed once with 1 mL of siRNA transfection 
medium, and the medium was aspirated after washing.  For each transfection 0.4 mL siRNA 
transfection medium was added to each tube containing the siRNA.  The mixture was mixed 
gently and overlaid onto the washed cells.  The cells were incubated for 24 hours at 37°C in a 
CO2 incubator.  After incubation, 1 mL of normal growth medium containing twice the normal 
serum and antibiotic concentration was added, without removing the transfection mixture.  The 
cells were incubated for a further 24 hours.  After incubation the medium was aspirated and 
replaced with normal growth medium.  The cells were further incubated for 24-72 hours and 
assayed for verification of gene silencing by detection of the gene product by flow cytometry 
after addition of fresh medium (section 6.4.5). 
6.3.9 Data analysis 
All data points are a result of quadruplicate tests, unless stated otherwise.  Error bars on each 
data point represent standard error of the mean (SEM).  Data was analysed statistically by 
calculating the significance using a student two-tail t-test assuming equal variances.  Where 
applicable, a Tukey test, also known as an honestly significant difference (HSD) test, was 
performed.  This test compares the means of every treatment to the means of every other 
treatment; that is, it applies simultaneously to the set of all pair wise comparisons and identifies 
where the difference between two means is greater than the standard error would be expected to 
allow. 
6.4 Results and discussion 
6.4.1 Quantification of mononuclear cells 
Subsequent to PBMC isolation, cells were stained for CD45 [a general leukocyte marker (Hunt 
et al., 1995)] in order to determine the total number of leukocytes.  CD45 is a protein tyrosine 
phosphatase located in haematopoietic cells except erythrocytes and platelets.  CD45 is also 
called the common leukocyte antigen.  The protein tyrosine phosphatases constitute a family of 
receptor-like and cytoplasmic inducing enzymes that catalyze the dephosphorylation of 
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phosphotyrosine residues and are characterized by homologous catalytic domains (Braford et al., 
1994).  The same population of cells was also stained for CD16, a low-affinity IgG Fc receptor 
that is expressed on NK cells, granulocytes, activated macrophages, monocytes, and some T 
lymphocytes (Lanier et al., 1989), CD3, a T-cell surface marker (Zdolsek et al., 1999), and 
CD19, expressed on FDCs and B-cells (Braford et al., 1994), to quantify specific leukocytes 
within the population.  This quantification would shed light on the purity of B-cells being 
detected by CD19 and the type of response expected from PBMCs isolated from blood, 
especially after activation of CSR within the B-cell population. 
PBMCs were initially stained for CD45
+
 cells to detect leukocytes.  Ninety-one percent of 
PBMCs were found to stain CD45
+
.  A region was drawn around the leukocyte population.  It 
was found that the population yielded ~59% CD3
+ 
 cells, which represented T-cells, while ~19% 
were CD16
+
, which represented a mixture of monocytes, NK-cells, contaminating granulocytes 
and some CD16
+
 T-cells (Janeway et al., 2005. ).  Only ~5% of the population were CD19
+
 
which are B-cells.  If NK cells are not CD16
+
, they will fall into the unstained quadrant, as CD3 
stains for cytotoxic and helper T-cells, but not NK cells (Berrington, 2005).  The quantification 
of monocytes at 19% is quite high, as normally, monocytes constitute about 8-9% of the 
leukocyte population (de Almeida et al., 2000) but this is expected, as CD16 will also be found 
on the surface of other mononuclear cells (mentioned above), which would explain the elevated 
levels of CD16 expression amongst the population.   
What could be deduced is that B-cells constitute only ~5% of a freshly isolated PBMC 
population.  This means that of the 1 million cells/mL seeded, only 50 000 cells/mL are B–cells.  
Further, only 10 000 B-cells are seeded per well, if 200 µL (normal) is seeded.  It would 
therefore be expected that the relative level of IgE secretion and detection would be low.  Yet 
this low cell number may not necessarily impact negatively on future experiments as Rabah and 
Conrad (2002) have indicated that IgE production may respond negatively to increasing cell 
numbers in culture wells.  They showed that, while class switching to IgE is intact, as suggested 
by surface IgE staining, ELISPOT analysis provided evidence that the differentiation of IgE 
committed B-cells to the plasma cell stage was arrested at high cell doses.  These cells were also 
found to be more prone to apoptosis as assessed by Annexin staining (Rabah and Conrad, 2002).   
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A second experiment was performed in order to ensure the presence of CD21 on B-cells within a 
PBMC population.  CD19 was measured first to identify B-cells.  A region was drawn around 
this CD19
+
 population and then the presence of CD21 on these B-cells was detected (figure 38).  
The measured presence of CD21 (~82 %) is based on binding of an anti-CD21 mAb and the 
increased fluorescence intensity (blue squares) in comparison to an isotype control (solid grey 
line) presented in the overlay histograms (figure 38 b).  It is therefore evident that amongst the 
B-cells within a population of PBMCs, CD21 is indeed expressed on the surface of the vast 
majority of B lymphocytes.  The gated region (region B in figure 38 a) represented a very dense 
population of cells (possibly both B and T-cells) both similar in size and granularity according to 
measured side and forward scatter.  B-cells were not detected outside of this region. 
(a) (b)           
Figure 38:  Expression of CD21 on the surface of B-cells within a typical PBMC isolation.  (a) Dot plot of the 
population of PBMCs, showing demarcation of B-region, which represents the B-cell population amongst these 
cells.  (b) Overlay histogram showing expression of CD21 (blue squares) in comparison with isotype control (solid 
grey line) stained B-cells.       
The validation of the expression of CD21 on the surface of B-cells was important to prove.  This 
CD21 is able to respond to endogenous CD23 on the cell surface, or secreted by cells within the 
PBMC population, or to recombinant CD23 added to the cells.  The response, monitored in the 
form of IgE synthesis after the addition of recombinant CD23 and CD21 SCR 1-2, will also take 
into account the presence of naturally occurring CD21 on the B-cell surface. 
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6.4.2 Analysis of Stat6 signalling  
CSR was activated by incubation of the PBMCs with IL-4 and anti-CD40.  To verify the 
potential for CSR, phospho-STAT6 was measured since this transcription factor is known to be 
involved in C  transcript expression (Haque et al., 1997).  A positive indication of CSR would 
show phosphorylation of STAT6 in B-cells, and consequent translocation to the nucleus where it 
regulates cytokine induced gene expression and isotype switching of B-cells to express IgE. 
IL-4 was tested at a concentration of 20 and 100 ng/mL and incubation times were tested at both 
30 minutes and 1 hour.  Subsequent to incubation, cells were fixed, permeabilized and stained 
simultaneously for CD19 and phospho-STAT6 (figure 39).  From the results it was concluded 
that 20 ng/mL for 30 minutes was the optimum concentration and incubation time, respectively.  
Figure 39 shows (a) untreated control cells, with only the addition of growth medium, and (b) 
cells treated with IL-4 and anti-CD40.    G1 in figure 39 contains phospho-STAT-6
+
 cells, G2 
contains both phospho-STAT-6
+
 and CD19
+
 cells (and therefore B-cells in which STAT6 
signalling was activated), G3 contains unstained cells, and G4 contains only CD19
+
 cells.  
What is evident on comparison of these two populations of cells (treated and untreated with 
switch factors) is that on stimulation of the cells with IL-4 and anti-CD40, a large majority of 
cells (~81 %) in the PBMC population showed increased levels of phospho-STAT6.  These 
phospho-STAT6 levels increase by 14.2% within half an hour of addition of the switch-factors.  
What can also be seen is that in B-cells the activation of STAT-6 increases by 5.6%, which 
therefore represents the potential for CSR induction and will later lead to these switched B-cells 
starting IgE production.             
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(a) (b)  
Figure 39:  Analysis of STAT6 phosphorylation in isolated PBMCs treated with IL-4 and anti-CD40. (a) Negative 
control (IMDM + 10% FCS) (b) IL-4 (20 ng/mL) and anti-CD40 (MAB 89; 5 µg/mL) treatment for 30 minutes. Cells 
were stained with EDC labelled anti-CD19 and anti-phospho-STAT-6 detected using a FITC labelled secondary 
antibody. 
6.4.3 Total plasma IgE levels of donors 
The study group of donors for this investigation was made up of 13 donors, 60% of whom were 
female, and 40% were male.  The ages of the donors ranged from 20 to 72 years, with an average 
age of 32 years (Table 6).    
A summary of the plasma IgE levels obtained from 13 potential donors of blood for PBMC 
isolations is shown in Table 6.  In order to select candidates for the study, age, sex, but most 
importantly total plasma IgE levels were compared.   
For donors over the age of 14, values greater than 100 IU/mL indicate that atopic disease is 
highly probable (Grimbacher et al., 2002).  Therefore, donors with IgE levels equal to or lower 
than 100 IU/mL were classed as a low probability of atopic risk.  Donors with total IgE levels in 
the range of 101-500 IU/mL were classed as a moderate probability of atopic risk.  Donors with 
total IgE levels in the range of 500-2500 IU/mL were classed as having a very high probability 
of atopic risk, and donors with total IgE levels greater than 2500 IU/mL were classed as hyper-
IgE (as suggested by Swart-Maré Pathologists).  There was only one donor with hyper-IgE 
syndrome in the study group, because the condition is so rare.  The rest of the study group was 
divided so that three donors were tested for each atopic risk classification.  Table 6 indicates the 
CD19 (FL2 Log) CD19 (FL2 Log) 
P
h
o
sp
h
o
-S
TA
T
-6
 (
FL
1
 L
o
g)
 
P
h
o
sp
h
o
-S
TA
T
-6
 (
FL
1
 L
o
g)
 
P a g e  | 145 
 
identification of donors (A-M) classed by the probability of atopic risk.  Candidates B, C and H 
were used in preliminary optimization experiments, and were not used in final tests for IgE 
responses to recombinant proteins.   
Candidates showed a broad range of serum IgE levels.  This often hindered direct correlation of 
resulting IgE response to addition of recombinant proteins.  Where possible, results from 
different donors in each atopic risk category have been combined and an average has been 
shown.  However,  as there was little difference in the response by donors of the same group to 
treatment in comparison to the negative control (medium only), only one member per group has 
been represented as an example to illustrate the IgE response to recombinant proteins (figure 41).  
Table 6:  Total plasma IgE levels of donors and classification by probability of atopic disease. 
Identification Donor age Donor sex Total IgE level 
(IU/mL) 
Probability of 
atopic disease  
A 20 Male 52 Low 
B 42 Male 32 Low 
C 26 Male 60 Low 
D 28 Female 100 Low 
E 49 Female 100 Low 
F 20 Female 229 Moderate 
G 30 Female 416 Moderate 
H 46 Female 188 Moderate 
I 72 Female 130 Moderate 
J 20 Female 2186 Very high 
K 20 Female 1208 Very high 
L 25 Male 1220 Very high 
M 29 Male 9206 Hyper-IgE 
 
It has been shown (Kerkhof et al., 2003), that the variation of total blood IgE levels was less in 
the age group 20-44 than 45-70 years but comparable in males and females.  Therefore, when 
appropriate, it was decided to choose donors of similar ages to represent each group.  Donors D, 
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G, L and M were chosen to represent „low‟, „moderate‟, „very high‟ and „hyper allergic‟ atopic 
risk categories, respectively.   
6.4.4 Titration of CD23 
CD23 at various concentrations (12.5 – 100 ng/mL) was used to stimulate IgE secretion from 
PBMCs, isolated from donor „B‟, an individual with low atopic risk, which enabled selection of 
the best concentration of recombinant CD23 for further experiments (figure 40).  It is evident 
that the addition of 25 and 50 ng/mL CD23 had the greatest effect on IgE secretion.  More or less 
than this concentration does not increase IgE secretion, showing lack of concentration 
dependence.  These concentrations were ubiquitous with all variants of CD23 added.  For further 
experiments 25 ng/mL was used as there was no significant difference between 25 and 50 ng/mL 
(p > 0.5; t-test) in terms of the effect on IgE secretion, regardless of which recombinant CD23 
was added.   
(a)  
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(c)  
Figure 40:  IgE production from PBMCs isolated from donor ‘B’ stimulated with switch factors (IL-4 and anti-
CD40) and CD23 at various concentrations. (a) derCD23, (b) sCD23, (c) exCD23.  Bar graphs represent IgE 
production (IU/mL/million cells) in comparison to a negative (no switch factors or CD23 added) and positive 
(switch factors added but no CD23) control.  Error bars represent SEM of triplicate values.  *, p < 0.05, **, p < 
0.005, representing significance compared to negative control; t-test. 
6.4.5 Effect of recombinant CD23 and CD21 on IgE secretion by PBMCs 
CD23 is implicated in the pathogenesis of autoimmunity and allergic disease, and levels of 
expression of CD23 are enhanced both as membrane and soluble forms in allergic individuals.  
CD23 expression is enhanced by IL-4 in a wide range of human cells, including B-cells 
(McCloskey et al., 2007).  While membrane CD23 performs a variety of functions, including IgE 
antibody-dependent presentation of antigens in human B-cells, soluble fragments of CD23 both 
negatively and positively regulated IgE synthesis in human B-cells (Delespesse, 1992; Gould et 
al., 2003).  To our knowledge, this is the first time that a combination of soluble CD23 fragments 
as well as CD21 SCR 1-2 have been incubated with PBMCs to investigate the effect on IgE 
synthesis. 
The addition of recombinant CD23 to PBMCs, with and without the presence of CD21 SCR 1-2, 
showed both positive and negative effects on IgE secretion, dependent on the combination and 
identity of recombinant protein added.  It has previously been shown that both size of CD23 
fragment (Aubry et al., 1992; Sarfati et al., 1992) and oligomeric structure (McCloskey et al., 
2007) of CD23 is important in controlling IgE secretion by B-cells.  CD21 has not only been 
implicated in inducing activation and differentiation of human monocytes through binding to 
membrane CD23 (Fremeaux-Bacchi et al., 1998a), but also to form a complex with trimeric 
CD23 and inhibit CD23-induced IgE synthesis by B-cells (Fremeaux-Bacchi et al., 1998b). 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
100 50 25 12.5 pos neg
[I
g
E
] 
IU
/m
L
/m
ill
io
n
 c
e
lls
* 
* 
[exCD23] 
ng/mL 
P a g e  | 148 
 
One member per donor group is illustrated as an example of group behaviour towards 
recombinant proteins, in respect of the IgE concentration in cell supernatant (figure 41).  Donors 
D, G, L and M were chosen to represent „low‟, „moderate‟, „very high‟ and „hyper allergic‟ 
atopic risk categories, respectively.  Figure 41 (a) shows donor D, classed as having a low atopic 
risk (b) shows donor G, classed as having a high atopic risk (c) shows donor L, classed as having 
a very high atopic risk and (d) shows donor M, diagnosed medically with Hyper-IgE syndrome.   
Figure 41 (a) shows the low atopic risk representative as having no significant response (p > 
0.05; t-test) toward recombinant derCD23 or sCD23 in comparison to the negative control, with 
or without the addition of SCR 1-2.  exCD23, however, shows a significant increase (p < 0.05; t-
test) in IgE levels in comparison to the negative control, and the response is further increased (p 
< 0.05; t-test) on addition of SCR 1-2.   
Figure 41 (b and c) show the moderate atopic risk representative (b) and the high atopic risk 
representative (c) as having no significant response (p > 0.05; t-test) toward recombinant 
derCD23, sCD23 or exCD23 in comparison to the negative control, nor is there a significant 
response (p > 0.05; t-test) with derCD23 or sCD23 with the addition of SCR 1-2.  The 
combination of treatment with exCD23 and SCR 1-2, however, shows a significant increase (p < 
0.05; t-test) in IgE levels in comparison to the negative control.  
Figure 41 (d) shows the hyper-IgE donor to have no response to any of the combinations of 
recombinant proteins added, in comparison to the negative control (p > 0.05; t-test).  Hyper-IgE 
patients are known to have a defective IgE catabolism (Grimbacher et al., 2002).  Therefore, the 
serum of the patient is shown to have extremely elevated levels of IgE.  Figure 41 (d) shows that 
even the negative control (no addition of switch factors or recombinant protein) has a very high 
level of IgE secretion, and therefore, the continued presence of IgE and the inability of the cell to 
catabolise it, would probably mar any response seen from the addition of recombinant proteins.   
In summary, the results indicate that there is not a large change in the amount of IgE secreted by 
the cells in response to the presence or absence of recombinant proteins (either CD23 or CD21 
SCR 1-2), although a trend can be seen between individuals towards the various combinations of 
treatments. This trend shows monomeric derCD23 and sCD23 decreasing IgE synthesis, while 
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exCD23 increases IgE synthesis, in comparison to the negative control.  CD21 SCR 1-2 is shown 
to further increase the effect of exCD23 on IgE synthesis and reverse the inhibitory effect of 
sCD23 to a stimulatory one.  CD21 SCR 1-2 shows no visible effect on cells treated with 
derCD23.   
Previously, soluble CD23 fragments (derCD23 and exCD23) were incubated with B-cells 
isolated from human tonsils (McCloskey et al., 2007).  These authors showed that 100 ng/mL of 
monomeric CD23 inhibited, while oligomeric CD23 stimulated IgE synthesis.  It is notable that 
25 ng/mL (1.5 nM for derCD23, 1 nM for sCD23 and 0.75 nM for exCD23) used in our study is 
3 orders of magnitude below the observed KD for binding to CD21, which perhaps explains the 
low response in respect of IgE synthesis.  Taking this into account, in contrast to McCloskey et 
al. (2007) no significant effect with far higher levels (100 ng/mL) of CD23 in comparison to the 
negative control was found in respect of influence on IgE synthesis. 
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(b)  
(c)   
 (d)  
Figure 41:  IgE secretion by PBMCs treated with recombinant CD23 in the presence or absence of CD21 SCR 1-2.  
(a) individual ‘D’ with a low probability of atopic risk, (b) individual ‘G’ with a moderate probability of atopic 
risk, (c)  individual ‘L’ with a very high atopic risk and (d) donor ‘M’ with hyper IgE syndrome.  Values are 
averages of triplicate experiments, with error bars representing SEM.  Stars indicate p<0.05 compared to 
negative control; t-test.  PBMCs were cultured for 14 days with switch factors (IL-4 at 20 ng/mL and anti-CD40 at 
5 µg/mL) in the presence of soluble CD23 fragments (at 25 ng/mL) in both the presence and absence of CD21 
SCR 1-2 (at 1 µg/mL).  IgE was measured in the cell supernatants by specific ELISA and corrected for viable cell 
number. 
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Attention must be drawn to the y-axis in figure 41, measuring IgE concentration, which 
illustrates; the concentration of IgE (IU/mL/million cells) secreted by the cells increases with 
atopic risk, regardless of added treatment of recombinant proteins.  The higher the risk of atopy, 
the higher the amount of IgE secreted by the cells.  This was expected, as it has been shown that 
even resting B-cells can produce high levels of IgE in allergic individuals, which will obviously 
increase in conjunction with the severity of allergy (Gould et al., 2003). 
The influence of recombinant proteins on cell proliferation (figure 42) illustrates a very small 
difference in terms of cell number between cells incubated with recombinant proteins and the 
negative control.  In the individual representing the low atopic risk group, there is only a 
significant difference between negative control (p < 0.05; t-test) and exCD23 in the presence of 
SCR 1-2.  In the individual representing the moderate atopic risk group, there is only a 
significant difference between negative control (p < 0.05; t-test) and exCD23.  All other 
treatments show no significant difference (p > 0.05; t-test) between the recombinant protein 
treatment and the negative control.  All treatments, in all groups show some proliferation during 
the 14 day incubation; this change is represented by the black horizontal line (figure 42), 
illustrating seeding density (1 million cells/mL).   
Incubation of B-cells with IL-4 and anti-CD40 have previously caused cell proliferation 
(Frotscher et al., 2002), and it has also been shown that B cell proliferation and differentiation 
can be induced by cross-linking CD21 with either polymeric C3d or certain anti-CD21 mAbs in 
the presence of T-cell cytokines (Nemerow et al., 1985).  Further, sCD23 has also been shown to 
be involved in proliferation of these B-cells, as well as the rescue of germinal centre B-cell 
centrocytes from apoptosis (Mossalayi et al., 1992).  Our experiments showed a very small, if 
any, difference in total PBMC proliferation in comparison to the negative control.   
It can be seen that the negative control group also shows proliferation of PBMCs, although no 
cytokines or recombinant proteins were added to this group.  The results are difficult to interpret 
as they represent a mixed population of cells, showing that only 5% are B-cells.  An increased 
proliferation of the negative control could be caused by endogenous elevated levels of 
stimulatory cytokines or an increased presence of CD23 on the surface of or in solution with the 
negative control cells.   
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It is also possible that there is a decrease in the proliferation of the test group, in comparison to 
the control cells (without the addition of switch factors), which would also give rise to a small 
difference between test cells and control cells.  If this is the case, it could be attributed to a B-cell 
density that is too high.  It has been shown (Rabah and Conrad, 2002) that cells plated to contain 
a B-cell concentration that is too high (>2500 cells/well) are more prone to apoptosis.  As 
mentioned previously, in our experiments, ~10 000 cells/well were seeded.  Nevertheless, all 
experiments were corrected for total cell number, in order to normalize the IgE secretion.  
 
Figure 42:  The influence of recombinant proteins on proliferation of PBMCs.  One member per group illustrated 
as an example of group behaviour towards recombinant proteins, in respect of the cell proliferation.  Cell 
number was measured after 14 days incubation using Celltitre Blue and fluorescence quantified by a standard 
curve.  Error bars represent SEM (n=4).  Stars identify significance p< 0.05 compared to negative control (t-test).  
Horizontal line represents seeding density (1 million cells/mL). 
On reflection of the results represented thus far, in terms of individuals representing atopic risk 
groups, the only recombinant protein to show a significant effect on the production of IgE in 
comparison to the negative control is exCD23 (figure 41), and the influence of exCD23 was 
further increased by CD21 SCR 1-2.  This mirrors data collected by McCloskey et al., (2007) 
who showed that the oligomeric state of CD23 dictates whether IgE synthesis will increase or 
decrease.  Oligomers increase, while monomers decrease IgE synthesis, which correlates with 
my data showing  exCD23 to be 65% oligomeric by GFC HPLC (chapter 5).   
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To further explore these effects in respect of all individuals tested, despite the vast differences in 
basal IgE secretion amongst atopic risk groups (shown in figure 41), it was necessary to 
standardise the response across atopic groupings.  
To do so, average percentage change in IgE in comparison to the negative control was calculated 
for each atopic risk group using all donors (figure 43).  A Tukey test was performed in order to 
quantify significant difference between each atopic risk group, with respect to influence of 
recombinant proteins on IgE secretion.  It was found that there is only significant difference with 
a 50% confidence level (p = 0.5; Tukey test) between the low and high atopic risk group.  It is 
therefore shown that although the level of IgE secreted from the cells in response to recombinant 
CD23 increases with atopic risk, the relative amount in comparison to the negative control is not 
significantly different from one group to another.  
 
Figure 43:  IgE secretion by PBMCs treated with recombinant CD23 in the presence or absence of CD21 SCR 1-2 
expressed as a percentage change in IgE from the negative control.  Data is shown for atopic risk groups 
classified according to table 6.  Error bars represent SEM (n=3).  *, p<0.05 in comparison to negative control 
(Tukey-test) 
The effect of CD21 SCR 1-2 addition to CD23-treated PBMCs was also statistically compared 
across atopic risk groups (table 7; also shown in figure 43 and 44).  The treatment with derCD23, 
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with and without CD21 SCR 1-2 shows that production of IgE in comparison to the negative 
control decreased in both cases across all atopic risk groups.  No significant difference between 
cells that are treated with derCD23 and those treated with the combination of derCD23 and 
CD21 SRC 1-2 was shown (p > 0.5; t-test).  This was not surprising, as derCD23 in this study 
was not shown to bind CD21 SCR 1-2.  In addition to this, no significant difference in IgE levels 
in comparison to the control cells was seen after incubation with derCD23.     
In all groups sCD23 is shown to decrease the production of IgE in comparison to the negative 
control, while, upon addition of CD21 SCR 1-2, all categories show an increase in IgE 
concentration in comparison to the negative control.  In the „high‟ group, this increase is 
significantly different (p < 0.05; t-test).  The group with low and moderate atopic risk shows a 
significant difference with a confidence level of 74% (p = 0.375; Tukey test). 
In all categories, exCD23 increases the production of IgE in comparison to the negative control.  
Upon addition of CD21 SCR 1-2, the production of IgE in comparison to the negative control is 
further increased.  The comparison of treatment between PBMCs treated with exCD23 alone and 
exCD23 and CD21 SCR 1-2 shows a significant difference for the low atopic risk group (p < 
0.05; t-test), the moderate atopic risk group (p < 0.05; t-test) and the high atopic risk group (p < 
0.05; t-test).  As mentioned previously exCD23 was shown to be 65% oligomeric, with 34% of 
the protein trimeric and the rest a mixture of homodimeric and heterodimeric fragments (figure 
32 and table 4).  The increase in IgE synthesis may therefore have been even more significant 
had the exCD23 been fully oligomeric. 
Interaction between membrane CD21 and CD23 has been shown to increase IgE production 
(Bonnefoy et al., 1997).  It has also been shown that soluble CD21 forms biologically active 
complexes with CD23 and that CD21 is present in normal plasma as a complex with trimeric 
CD23.  This complex inhibits soluble CD23-induced IgE synthesis from B-cells (Fremeaux-
Bacchi et al., 1998b).  Taking this information into account, our results are contradictory to this, 
and to our hypothesised theory that CD21 would down-regulate IgE synthesis by cells stimulated 
with soluble CD23 fragments.  It was found that CD21 SCR 1-2 significantly increased 
production of IgE, regardless of the effect evoked by recombinant sCD23 and exCD23 alone.  
The study by Fremeaux-Bacchi et al., (1998b) used a soluble form of CD21 from human serum 
P a g e  | 155 
 
and found in culture supernatants of human lymphoblastoid cell lines.  This soluble CD21 is 
released by human B and T lymphocytes as a 135 kDa protein corresponding to the entire 
extracytoplasmic portion of the molecule that is cleaved and shed from the cell membrane 
(Fremeaux-Bacchi et al., 1996).  This is in contrast to our form of CD21 which only consists of 
the first two SCR domains.  Our form of CD21, therefore does not contain the other site of 
interaction for CD23, i.e SCR 5-8.   
Thus far, we have showed the effect of each CD23 fragment on IgE production alone and upon 
addition of CD21 SCR 1-2.  It is now important to compare the soluble recombinant CD23 
fragments to each other in respect to the influence they have on IgE synthesis (1) without the 
addition of CD21 SCR 1-2 and (2) with the addition of CD21 SCR 1-2 (shown in table 7).  Table 
7 represents an average change in IgE concentration across each atopic risk group (actual values 
shown in Addendum D).  Table 7 shows this comparison in respect to statistical evidence for 
significant difference between treatments.   
Table 7:  Statistical evidence of significant difference between recombinant protein treatments on IgE synthesis 
by donor PBMCs. 
 Atopic 
risk Recombinant protein treatment t-test Confidence level Tukey-test 
Low derCD23 and sCD23 p = 0.370 N/A N/A 
  derCD23 and exCD23 p = 0.042 confidence = 94% p = 0.094 
  sCD23 and exCD23 p = 0.012 confidence = 94% p = 0.094 
  derCD23 and sCD23 with CD21 SCR 1-2 p = 0.050 confidence = 84% p = 0.250 
  derCD23 and exCD23 with CD21 SCR 1-2 p = 0.013 confidence = 94% p = 0.094 
  sCD23 and exCD23 with CD21 SCR 1-2 p = 0.041 confidence = 94% p = 0.094 
Moderate derCD23 and sCD23 p = 0.920 N/A N/A 
  derCD23 and exCD23 p = 0.520 N/A N/A 
  sCD23 and exCD23 p = 0.250 confidence = 74% p = 0.375 
  derCD23 and sCD23 with CD21 SCR 1-2 p = 0.167 confidence = 83% p = 0.250 
  derCD23 and exCD23 with CD21 SCR 1-2 p = 0.133 confidence = 90% p = 0.156 
  sCD23 and exCD23 with CD21 SCR 1-2 p = 0.760 N/A N/A 
High derCD23 and sCD23 p = 0.560 N/A N/A 
  derCD23 and exCD23 p = 0.290 confidence = 74% p = 0.375 
  sCD23 and exCD23 p = 0.012 confidence = 94% p = 0.094 
  derCD23 and sCD23 with CD21 SCR 1-2 p = 0.030 confidence = 94% p = 0.094 
  derCD23 and exCD23 with CD21 SCR 1-2 p = 0.007 confidence = 94% p = 0.094 
  sCD23 and exCD23 with CD21 SCR 1-2 p = 0.770 N/A N/A 
N/A = Not applicable (Tukey test was not performed if significance calculated from student T-test showed p > 0.5) 
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In summary, the findings compare recombinant protein treatment and the effect on IgE synthesis 
in respect to change from the negative control.  This is measured as a percentage.  It was found 
that there was no significant difference between derCD23 and sCD23 across all atopic risk 
groups (both decrease in IgE synthesis), whereas both derCD23 and sCD23 showed a significant 
difference in comparison to exCD23 (showing an increase in IgE synthesis).   
Further, only a small change in IgE synthesis was seen upon addition of CD21 when comparing 
sCD23 and exCD23, while the addition of CD21 to sCD23 and exCD23 caused a significant 
increase in IgE in comparison to derCD23 (table 7).   
This effect is further illustrated in figure 44.  As previously mentioned, CD21 SCR 1-2 has no 
effect on cells treated with derCD23, while it was shown to increase levels of IgE secreted by 
cells treated with sCD23 and exCD23, regardless of the effect caused by CD23 alone.  Figure 44 
compares the effect of CD21 SCR 1-2 added to sCD23 and exCD23, respectively, in terms of the 
degree of change in percent IgE secreted.  It was found that there is no significant difference (p > 
0.05) between the effect of CD21 SCR 1-2 with sCD23 in comparison to exCD23 treated 
PBMCs (figure 44).  This is expected as we (chapter 5) have found that the binding affinity for 
CD21 is not dependent on the length of CD23 molecule.   
    
Figure 44:  The effect of CD21 SCR 1-2 on cells treated with CD23.  The difference in percentage change in IgE 
concentration (%) between sCD23 and exCD23 on addition of CD21 SCR 1-2 expressed as an average of all 
donors in atopic risk groups.  Error bars represent SEM.   
It is speculated that upon increasing length of the CD21 molecule (either to include the second 
CD23 binding site, or full length CD21), the binding affinity between CD21 and all forms of 
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soluble CD23 will also increase accordingly, as shown previously with derCD23 (Asokan et al., 
2006).  Further investigation of binding analysis between SCR 5-8 of CD21 and CD23, and the 
effect this would have on IgE synthesis would be interesting.  It is perhaps due to this binding 
that the soluble form of CD21 circulating in human serum (Fremeaux-Bacchi et al., 1998a) can 
cause an inhibitory effect on IgE synthesis.  It would also be interesting to investigate the 
influence CD21 SCR 1-2 has on trimer formation in soluble fragments of CD23, provided there 
is a sufficient amount of stalk/neck region.  CD21 SCR 1-2 may, in some way also promote 
binding of sCD23 to CD21 on the cell surface, whereby an increase in IgE concentration would 
result.   
Finally, IgE secretion data from all ten donors (A, D, E, F, G, I, J, K, L, M) were converted to 
percentage change in IgE concentration compared to the negative control (figure 45), while the 
absolute concentrations of IgE can be seen in addendum D.  From figure 43 and 45 it is evident 
that although changes in IgE concentration may be small, there is a trend in all individuals, 
despite substantially different plasma IgE levels and probability of allergic disease.   
 
Figure 45:  IgE secretion as a percentage in comparison to the negative control for all donors. 
It has been shown that soluble CD23 is implicated in the up-regulation of IgE synthesis;  its 
attachment to CD21 on peripheral blood B-cells before differentiation into IgE-secreting plasma 
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cells enhances IgE synthesis (Aubry et al., 1992).  It is suggested (Hibbert et al., 2005), that 
soluble CD23 may up-regulate IgE synthesis by co-ligation of membrane IgE and CD21, 
resulting in selective proliferation of B-cells and ultimately higher levels of IgE synthesis.  
Aubry et al., (1992) expressed and purified full-length recombinant CD23, incorporated it into 
fluorescent liposomes and showed interaction with cell-surface CD21 on B-cells, some T-cells 
and follicular dendritic cells.  They also showed that triggering of CD21 either with an anti-
CD21 antibody or with recombinant soluble CD23 was shown to increase specifically IL-4-
induced IgE production from PBMCs.   
It has also been shown that tunicamycin-treated cells release small CD23 fragments (the same 
size as derCD23), caused by the deletion of the C-terminal end of CD23 (Sarfati et al., 1992).  
These small CD23 fragments were found to bind to IgE and down-regulate the ongoing and IL-
4-stimulated synthesis of IgE.  More recently, McCloskey et al., (2007) has shown that soluble 
CD23 fragments that are monomeric will inhibit IgE synthesis, while trimeric fragments will 
stimulate it.  All this data confirms data shown in figure 43 and 45, i.e that monomeric CD23 (in 
the form of derCD23 and sCD23) will inhibit, and oligomeric CD23 (in the form of exCD23) 
will stimulate IgE synthesis.  The derCD23 and exCD23 used in this study are identical to those 
used by McCloskey et al., (2007), and Hibbert et al., (2005) although in contrast to these studies, 
our derCD23 was not shown to bind CD21, despite being monomeric.   
It is suggested that exCD23 oligomerises upon binding to IgE-Fc (Hibbert et al., 2005; 
McCloskey et al., 2007).  A mechanism for the up-regulation of IgE synthesis was originally 
suggested by analogy to the process of up-regulation of antibody synthesis in the immune 
response by C3d fragments of complement component C3.  Here C3d fragments, covalently 
linked to the antigen, co-ligate antigen receptor (IgM) and CD21 on naïve B-cells (Carter and 
Ormerod, 2000; Dempsey et al., 1996), leading to cell proliferation and antibody synthesis.  It is 
also suggested that exCD23 binding to IgE and CD21 in IgE-switched B-cells might be 
analogous to antigen-C3dg complexes binding to IgM and CD21 in unswitched naïve B-cells, 
thus promoting IgE synthesis in the allergic response (Carter and Ormerod, 2000; McCloskey et 
al., 2007).   
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It was observed, in this study, that the negative control (where no switch factors were added to 
the cells) showed both an increase in proliferation and IgE synthesis, which could be due to the 
upregulation in expression of membrane CD23 and release of endogenous soluble fragments.  
McCloskey et al., (2007) has quantified endogenous soluble fragments of CD23 in tonsil B-cells 
to be 30-50 ng/mL.  This is, at times, double the amount of recombinant CD23 added to the cells 
in our experiments.   
Surface or soluble CD23 expression is repeatedly observed during various allergic reactions or in 
atopic patients.  In humans, the expression of CD23 is strikingly increased in allergic disorders, 
in terms of membrane expression on B-cells and monocytes, but also in terms of sCD23 
production.  Soluble CD23 from epithelial cells has been shown to potentiate histamine release 
and basophilic cell differentiation (Sarfati et al., 1992).  Membrane-bound CD23 ligation induces 
the release of various inflammatory mediators from human macrophages, eosinophils and 
epithelial keratinocytes (Munoz et al 1998).  The endogenous levels of CD23, both membrane 
and soluble forms, increase in correlation to atopic status.  
In contrast to exCD23, monomeric derCD23 and sCD23 were found to inhibit IgE synthesis.  
The mechanism by which this occurs may also be understood by taking endogenous CD23 into 
account.  Clearly, endogenous CD23 is involved in IgE synthesis induced by CD40-ligation and 
IL-4, since Lumiliximab, an anti-CD23 mAb, has been shown to block IgE synthesis in human 
B-cells (Poole et al., 2005). Monomeric CD23 may therefore act by blocking the binding of 
endogenous trimeric soluble CD23 to CD21 and IgE, thereby limiting the effect induced by 
trimeric soluble CD23.  It is therefore thought that modification of the oligomeric state of CD23 
could possibly be a mechanism of down-regulating IgE synthesis. 
The exact CD21 binding site on the CD23 molecule is unknown, and incompletely represented in 
the NMR (Hibbert et al., 2005) and crystal (Wurzburg et al., 2006) structures, although it is 
thought that CD21 binds to the C-terminal tail section of CD23.  The full C-terminal tail region 
was not present in derCD23, making it similar to mouse CD23.  It is therefore likely, that 
similarly to mice, only a negative-feedback mechanism operates with derCD23 (one possible 
reason why humans but not mice suffer from allergy).  This could lead to investigation of 
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another reason to modulate the oligomeric state and thus the activity of soluble CD23 fragments 
as a potential therapeutic role for derCD23 in the treatment of allergic disease.  
6.4.6 Down-regulation of CD21 on human cells and cell lines using siRNA 
6.4.6.1 Upregulation of CD21 on Raji cells 
Three stimulants (PMA, retinoic acid, and vitamin D3) were tested for the upregulation of CD21 
on the surface of Raji cells (figure 46).  PMA was chosen for  its ability to activate NF-κB, 
which has been shown to enhance the activity of the CD21 promoter in primary B-cells (Tolnay 
et al., 2002).  Retinoic acid and vitamin  D3 were chosen for their ability to increase the presence 
of precursors (CD38) for CD21 activation (Chen et al., 1987).  Figure 46 illustrates the positive 
expression of CD21 on the surface of Raji cells, even in the absence of stimulants.  It was found 
that a shift from the negative control (indicated in green), was not shown in the case of retinoic 
acid and vitamin D3.  PMA conversely caused a slight down-regulation of CD21 in comparison 
to the negative control.  It is also evident that the addition of PMA decreases cell number, 
therefore the decrease in fluorescence may also involve cell viability, and thus decreased CD19 
and CD21 expression.   
  (a)          (b )  
 
Figure 46:  Upregulation of CD21 on the surface of Raji cells.  Cells were incubated with PMA (pink), retinoic acid 
(blue), vitamin D3 (red) or medium as negative control (dark green) for (a) 24 and (b) 48 hours.  The isotype 
control is shown in grey. 
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This experiment proved that, although treatment would normally enhance the presence of CD21 
on the surface of B-cells, Raji cells constitutively express a large amount of CD21 on their cell 
surface, and it is not necessary to treat the cells for CD21 expression.  Therefore, for siRNA 
experiments with Raji cells, untreated cells were used to avoid potential negative effects on cell 
viability or signal transduction pathways. 
6.4.6.2 siRNA interference of CD21 in Raji cells and PBMCs 
siRNA was used to mediate inhibition of CD21 and CD19 gene expression in Raji cells and later 
in PBMCs.  CD19 was used as a positive control; being a general B-cell marker.  A negative 
control was also included, which used a scrambled sequence that would not lead to the specific 
degradation of any known cellular mRNA.  The basic principle of the assay is the addition of 
gene silencers to the cell by lipid-based transfection.  siRNA then binds RNA-induced silencing 
complex (RISC) which causes siRNA to unwind and the siRNA/RISC complex associates with 
the target mRNA and cleaves it causing inhibition of gene expression (Fire et al., 1998)         
Although Raji cells have not been shown to produce IgE (Capron et al., 1977), and therefore 
cannot be used as a model for IgE analysis, they have been shown to express a large amount of 
CD21 on their surface (figure 46 and dot blot verification, figure 27).   Therefore, in order to test 
the CD21 siRNA interference system, Raji cells were initially used to show down-regulation of 
CD21 on the cell surface.   
Flow cytometry analysis (figure 47) shows an increase in fluorescence intensity (shift towards 
the right) in comparison to the isotype control (mouse-IgG1), which confirms expression of 
CD19 (figure 47 a) and CD21 (figure 47 b) on these cells.  A decrease in fluorescence intensity 
was achieved when Raji cells were transfected with siRNA against CD19 (figure 47 a) and CD21 
(figure 47 b).  CD19
+
 cells decreased from 92.7% to 76.8% (15.9% knockdown).  Knockdown is 
shown in figure 47 (a) and is illustrated by the shift towards the left from the negative control.  
CD21
+
 cells decreased from 77.9% to 56.8% (21.1% knockdown).  Knockdown of CD21 is 
shown in figure 47 (b) and is once again illustrated by the shift towards the left from the negative 
control.          
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(a)                                                                                    (b) 
Figure 47:  Down-regulation of CD19 and CD21 by siRNA interference in transfected Raji cells. (a) CD19 and (b) 
CD21.  Grey line represents the IgG1 isotype control, red line represents the negative control cells treated with 
siRNAs (sc-37007), which contains a scrambled sequence that will not lead to the specific degradation of any 
known cellular mRNA, and blue line represents the cells treated with CD19 siRNA (sc-29968) in (a) and CD21 
siRNA  (sc-29974) in (b).   
The percentage of CD21 knocked down by siRNA interference was disappointing, as 
knockdown with other CD21 siRNA has shown to be up to 93% in B16 melanoma cells, detected 
as a shift from the negative control using flow cytometry (Alshamsan et al., 2008).      
Raji cells are found to routinely express CD21 on the cell surface, but are said to have an 
impaired IL-4 response associated with a defective STAT-6 function despite the presence of a 
high number of IL-4 receptors (Shubinsky et al., 1997).  Interestingly, IL-4 is found to down 
regulate CD21 expression (Shubinsky et al., 1997), and its impairment in Raji cells could 
contribute to the large amount of CD21 on the cell surface.  Although, these cells were useful for 
investigating CD21 expression in siRNA experiments, they do not express IgE (Capron et al., 
1977), and therefore it was important to use PBMCs for experiments investigating IgE 
regulation.    
In the same way as siRNA had targeted CD19 and CD21 for decreased gene expression in Raji 
cells, PBMCs transfected with CD21 siRNA were stained for CD19 and CD21.  This detects B-
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cells expressing CD21 on their surface.  A decrease in fluorescence intensity was achieved when 
PBMCs were transfected with siRNA against CD21, resulting in knockdown of CD21 by 99.3%  
(figure 48).   
 
 
Figure 48:  siRNA induced inhibition of CD21 gene expression in PBMCs.  Grey line represents the IgG1 isotype 
control, red line represents the negative control cells treated with siRNAs (sc-37007), and blue line represents 
the CD21 siRNA (sc-29974 treated cells). 
The level of CD21 expression is developmentally regulated.  It is highest on mature B 
lymphocytes and on a subpopulation of immature blastic thymocytes.  The CD21 promoter 
region contains potential binding sites for transcription factors SP-1, AP-2, AP-1 and shares four 
homology regions with the human CD23 promoter.  Cell and stage-specific CD21 expression 
could be related to an intronic silencer that binds the CBF1 repressor protein (Makar et al., 
1998).  Expression of CD21 on B and T lymphocytes is upregulated by infection of these cells 
with the lymphocytotropic virus EBV and HTLV-1 (Calender et al., 1987).  Interestingly, 
lymphoma cells transfected with the EBNA-2 gene of EBV also upregulate expression of CD23 
(Cordier et al., 1990). 
A major function of CD21 is to contribute to human B cell activation and proliferation.  On the 
surface of B lymphocytes, CD21 was found to form a complex with the membrane proteins 
CD19, TAPA-1 and Leu-13 (Bradbury et al., 1992).  CD21 serves as a ligand fixing sub-unit 
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where CD19 behaves as the signal transducing molecule.  Co-ligation of the CD21/CD19 
complex with the antigen-receptor enhances activation of PLC and PI3-kinase, thus decreasing 
the requirement for the number of membrane IgM molecules that need to be ligated to trigger B 
cell activation (Caroll and Fischer, 1997). 
It has been shown that IgE upregulation to some extent is caused through CD21-CD23 
interactions, (Aubry et al., 1992; Basaki et al., 2002) and therefore, downregulation of the CD21 
gene may have some therapeutic potential for individuals with atopic risk.  Studies have shown 
(Fremeaux-Bacchi et al., 1999), however, that CD21 knock-out mice had demonstrated an 
impaired immune response to T-cell-dependent antigens, including a defect in the switched IgG 
response and a decrease in the number and size of germinal centres.  This confirms that 
expression of CD21 on B-cells was critical in generation of immune response (Caroll and 
Fischer, 1997). 
Despite this, an excellent way to test the effect recombinant CD23 has on B-cells, as well as the 
effect of interaction between CD23 and recombinant CD21 SCR 1-2 would be to first silence the 
CD21 gene, thereby eliminating endogenous effects of CD21 on the cell surface.  Preliminary 
investigation shows the CD21 knockdown will be achieved in PBMCs, allowing this aspect to be 
investigated in future experiments.  
6.4.7 Conclusion 
In order to monitor potential regulation of IgE secretion from B-cells by the recombinant 
proteins produced in this study, PBMCs were used as a model to investige the effect that 
interactions between the three recombinant soluble CD23 fragments and CD21 have on IgE 
regulation.  It was initially necessary to stimulate the cells to undergo IgE isotype switching, 
using switch factors and to verify switching of the cells to IgE production by detecting phospho-
STAT 6.  After isotype switching was verified, quantification of secreted IgE levels with and 
without the addition of CD23 and CD21 SCR 1-2 was measured by ELISA.  Lastly, cells 
(initially the Raji B lymphocyte cell line and later PBMCs) were also subjected to siRNA 
interference to down regulate CD21 production.   
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It was found that B-cells only make up ~5% of the PBMC population, and that these cells were 
able to be activated, via STAT-6 phosphorylation, to enter class switch recombination (CSR) by 
the addition of switch factors (IL-4 and anti-CD40).  It was also proven evident that amongst the 
B-cells within a population of PBMCs, CD21 is indeed expressed on the surface of the vast 
majority of B lymphocytes.  This CD21 is able to respond to endogenous CD23 on the cell 
surface, or secreted by cells within the PBMC population, or to recombinant CD23 added to the 
cells.       
Titration experiments dictated that 25 ng/mL of CD23 was the most efficient concentration to 
up-regulate IgE synthesis in PBMCs; furthermore, soluble CD23 proteins were incubated with 
PBMCs in the presence and absence of CD21 SCR 1-2 to investigate the effect that these 
recombinant proteins have on IgE synthesis.    
Results showed that the influence of recombinant proteins (both CD23 and CD21) on IgE 
synthesis was slight.  It was shown that while derCD23 had no significant effect, monomeric 
sCD23 down-regulated, and the mixture of monomeric and oligomeric exCD23 up-regulated IgE 
synthesis.  On addition of CD21 SCR 1-2 to the cells switched and treated with soluble CD23, it 
was found that in both cases for sCD23 and exCD23, IgE synthesis was increased, while for 
derCD23, there was no noticeable difference in IgE synthesis.  This confirmed previous data 
(chapter 5) showing the lack of binding between derCD23 and CD21 SCR 1-2. 
It has been shown that IgE upregulation to some extent is caused through CD21-CD23 
interactions, (Aubry et al., 1992; Basaki et al., 2002) and therefore, downregulation of the CD21 
gene may have some therapeutic potential for individuals with atopic risk, but it has also been 
shown that expression of CD21 on B-cells was critical in generation of immune response (Caroll 
and Fischer, 1997), showing that the benefit of downregulation of the CD21 gene may be 
outweighed by the cost. 
A means of testing the effect of interaction between CD23 and recombinant CD21 SCR 1-2 
would be to eliminate endogenous effects of CD21 on the cell surface, by gene silencing.  
Preliminary investigation shows the CD21 knockdown will be achieved at a far better percentage 
in PBMCs than in Raji cells, allowing this aspect to be investigated in future experiments.  
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7 Conclusion and recommendations for future studies 
Soluble CD23 occurs naturally by proteolytic cleavage within the stalk region (Letellier et al., 
1989) resulting in a 37 kDa fragment (exCD23), which further degrades into smaller soluble 
CD23 fragments, two of these being identical to sCD23 and derCD23 (Beavil et al., 1995).  It 
has been found that these soluble molecules have various cytokine activities (Armant et al., 
1994; Hermann et al., 1999; Lecoanet-Henchoz et al., 1997) and it is possible that CD23 
provides a link between allergic atopy and primary immune deficiencies.  These conditions share 
some clinical symptoms, such as an increase in serum IgE and soluble CD23 levels, and are 
characterised by an imbalance in Th1/Th2 cells (Grimbacher et al., 2002).  It is also important to 
remember that CD23 has pleiotropic effects and may be involved in both positive and negative 
IgE regulation, depending onto which ligand it has bound (Delespesse et al., 1991) and also on 
which oligomeric state it adopts (McCloskey et al., 2007).  Taking this into account, it is clear 
there is still much to learn about this protein.   
Current therapy for atopic disease is leaning towards addressing causes, rather than symptomatic 
treatment that was historically favoured.  The much discussed anti-IgE antibody has been 
brought about in Omalizumab, which is found to effectively neutralize IgE, and may even cause 
apoptosis of committed B-cells by crosslinking membrane IgE (Chang and Shiung, 2006).  This 
antibody is proving to be useful to a wide range of allergic disorders, but the expense of 
producing it makes it far beyond reach for most applications.  Use of Omalizumab is still in early 
stages, and recently a possible link has been made between the use of Omalizumab and adverse 
cardiovascular events (Osterweil, 2009).  
It is said that an ounce of prevention is worth a pound of cure.  CD23 also appears to be a 
promising target for understanding the sensitization phase of allergic disease.  CD23 has been 
targeted using Lumiliximab.  This antibody has been shown to block IgE release from B-cells in 
vitro and in addition to reducing IgE synthesis, this antibody may play a role in modulating 
APCs, as well as allergen focusing and presentation to T-cells, thereby decreasing Th2 cell 
responses.  This therapy also suffers from the same cost implications as Omalizumab.  The 
inhibition of CD23 proteolysis could also be a promising therapeutic approach.   
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The need to design a small molecule that inhibits the IgE-FcεRI interaction by „locking‟ IgE or 
FcεRI in an inactive conformation, based on what is known about the structural changes 
accompanying complex formation is also evident as another therapeutic approach.     
From this study it can be concluded that three biologically active recombinant forms of human 
soluble CD23 were engineered, expressed and purified.  These constructs were most efficiently 
expressed using the pET vector system and cloning was successfully confirmed by DNA 
sequencing.  The proteins engineered represent those formed in vivo by proteolytic cleavage.  
derCD23 (with an apparent molecular mass of 16.5 kDa) is a recombinant protein representing 
the protein resulting from cleavage of CD23 with the dust mite protease Der pI.  Soluble CD23 
(sCD23 with an apparent molecular mass of 25 kDa) is an intermediate form of shed CD23 
resulting from ADAM 10-mediated proteolysis, with a longer length of stalk region than 
derCD23.  exCD23 (with an apparent molecular mass of 37 kDa) is the largest of the 
recombinant CD23 proteins generated and contains the entire extracellular domain sequence.  
The derCD23 and exCD23 produced in our study are the same proteins produced in the same 
way by Hibbert et al., (2005) and McCloskey et al., (2007).  sCD23 has also previously been 
expressed in insect cells (Wurzburg et al., 2006) and in our laboratory in bacterial cells (Daniels 
et al., 2005).   
Molecular weight determination and analysis of oligomer content within the CD23 protein 
samples were determined by gel filtration HPLC, performed using a Superdex 200, 10/30GL 
column.  Chromatographs showed derCD23 to be homogeneous and monomeric, as was sCD23.  
In contrast, exCD23 displayed heterogeneity within the protein.  Almost 65% of the protein 
consisted of oligomeric fragments with only ~18% of the protein remaining monomeric.  HPLC 
analysis indicated approximately equal proportions of trimeric exCD23 and an oligomer of ~53 
kDa that is speculated to arise from either homodimeric exCD23 or possibly heterodimers of 
exCD23 and partial cleavage fragments representing principally sCD23.  It has been found that 
recombinant exCD23 is not stable during storage (Letellier et al., 1989) and thus, entirely pure 
preparations of exCD23 are difficult to yield, as was the case in our study. 
Ultimately we have engineered proteins with differences in their characteristics that have shown 
to be important for binding to both IgE and CD21 ligands.  exCD23 contains enough of the 
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stalk/neck region to become oligomeric and allows investigation of oligomeric state and high 
affinity binding.  sCD23 contains a large portion of the stalk region, on which trimerization is 
dependent, but perhaps not enough of the stalk region necessary for high affinity binding at the 
concentrations tested in my experiments.  derCD23 has a full neck region, but a stalk region that 
is even shorter than sCD23, but more importantly is missing the tail region, said to contain the 
binding site for CD21.  These fragments were certainly found to shed light on the diverse roles of 
CD23.   
We have also shown successful cloning of CD21 SCR 1-2, SCR 5-8, and full length CD21 SCR 
1-15, into insect cell expression vectors.  Sequencing results confirm positive alignment with 
human sequences of CD21 (GenBank accession code NM_001877).  Ultimately no expression 
was seen by insect cells though, but confirmation of transfection is supported by a very high 
expression of a positive control monitoring β-galactosidase expression using X-gal as a substrate.  
Further, upon monitoring of gene expression by RT-PCR, CD21 SCR 1-2 showed clear evidence 
of transcription, but no transcriptional evidence was found for SCR 5-8 and SCR 1-15.  Due to 
these low expression levels, the CD21 SCR 1-2 used in further experiments was donated as 
purified protein from a yeast expression host.    
The equilibrium dissociation constants for the interactions between the recombinant CD23 
fragments and two of the ligands involved in IgE regulation, CD21 and IgE, were determined by 
SPR spectroscopy.  It has been shown that each IgE-Fc dimer contains two potential CD23 
binding sites, and it has also been shown that two CD23 lectin domains bind to one IgE-Fc (Shi 
et al., 1997).  Oligomeric CD23 has been found to bind IgE with a dual affinity, the lower 
affinity attributed to single lectin domain binding and the higher affinity due to avidity effects 
caused by oligomers.  Although kinetic experiments were performed, the immobilization of 1000 
RU ligand proved best suited to obtain more accurate data from equilibrium experiments.  
Dissociation constants were determined for derCD23 (2.16 µM), sCD23 (1.85 µM) and exCD23 
(0.98 µM).  Analysis of steady state data by SPR spectroscopy revealed a direct relationship 
between the length of the stalk region of CD23 and increasing affinity of IgE.  It must also be 
noted that previous binding experiments used only the recombinant Fc portion of IgE (Cε2-4), 
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whereas our experiments used native IgE.  This could contribute to some discrepancy in binding 
affinity in comparison to previously published data.   
Native CD23 is thought to be trimeric with a binding affinity of 0.1 µM for IgE (Chen et al., 
2002; Dierks et al., 1993; Kelly et al., 1998).  It was also found that binding affinity of exCD23 
for IgE was 10-fold lower than expected in our experiments when compared with previous 
reports (Chen et al., 2002).  This may be attributed to the heterogeneity of the exCD23 shown by 
GFC-HPLC analysis.  Kinetic binding analysis, using homogenous exCD23, done in future 
experiments may shed light on a definite explanation for this.   
Generating data suitable for detailed kinetic analysis ultimately depends on starting with high-
quality samples and care must be taken to ensure that samples are homogeneous.  Myszka (1997) 
reports that  assays must be arranged to avoid avidity effects which result when proteins contain 
multiple binding sites and tend to self associate in solution (MacKenzie et al., 1996).  It is 
suggested that to avoid problems of this kind the aggregation state of the reactants, as well as the 
stoichiometry of the complex, be assessed using analytical ultracentrifugation. 
As it was difficult to determine absolute KD values, relative values alone were analysed.  It has 
been found that the oligomeric state of CD23 significantly affects IgE binding affinity. 
Consistent with a previous study by Chen et al. (2002) who showed the stalk region of CD23 is 
necessary for binding IgE, our data further suggest that the longer the stalk, the higher the 
binding affinity, although changes are subtle.  These subtle changes are illustrated by derCD23, 
which contains only a small region of the stalk, yet its binding to IgE is not significantly 
diminished.  This further confirms that the stalk region is necessary for binding IgE, but it is 
oligomerization of CD23 which holds the key to high affinity binding.  While the stalk region 
enhances CD23 oligomerization, the neck region appears to be less tightly associated, potentially 
allowing for some flexibility in orientating the lectin domains to bind IgE, enabling the high-
affinity interaction (Kilmon et al., 2004).   
derCD23 and sCD23 which were monomeric at the concentration used for binding analysis, 
produced low micromolar range binding affinities (~1-2 µM) that were directly comparable to 
monomeric binding affinities previously published (McCloskey et al., 2007).  It has also been 
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shown, by way of domain deletion mutants, that the oligomerised complex on cell surfaces 
increases in stability as the length of the stalk region of CD23 increases (Chen et al., 2003).  This 
stabilization of oligomerised cell surface CD23 protects the molecule from cleavage from 
endogenous protease ADAM 10.   
We have importantly determined equilibrium dissociation constants in order to characterize and 
compare the interactions between each of the soluble CD23 fragments and CD21 SCR 1-2.  This 
has previously not been analyzed with each of the soluble CD23 forms.  The equilibrium 
dissociation constants, determined by monitoring steady state levels, showed that the interaction 
between CD23 (sCD23 and exCD23) and CD21 occurs with similar affinities (4 and 6.5 µM, 
respectively).  Although a higher maximal response was observed with sCD23 than with 
exCD23, it is speculated that the oligomerization of exCD23 may have partially altered the 
nature of the interaction with CD21.  While it was previously shown that derCD23 binds to 
CD21 with a KD of 0.87 µM (Hibbert et al., 2005), this value was only obtained with a very high 
density of immobilised CD23.  In contrast, our data shows no binding between derCD23 and 
CD21 SCR 1-2.   
The exact CD21 binding site is unknown.  According to Hibbert et al. (2005), 6 amino acid 
residues (S293, E294, G295, S296, A297 and E298) of derCD23 include a section of the CD21 
binding region, however no direct evidence was provided.  The data in this study demonstrates 
that when the entire length of the “tail” portion (residues 289-321) is present, the relevant CD23 
fragments indeed bind SCR 1-2.  Thus, this is seen as strong evidence confirming that the SCR 
1-2 binding site lies within this tail portion and that the presence of the entire length of the “tail” 
in the CD23 molecule is necessary for binding to SCR 1-2.  It cannot be ruled out, however that 
the region between Met
150
 and Ser
156
 on the N-terminal side of the lectin domain (present on 
sCD23, but not on derCD23) may also be responsible for CD21 binding.  Also, possible multi-
point attachment of CD21 to CD23 cannot be ruled out.  Mutagenesis experiments directed to the 
N-terminal region (Met
150
 and Ser
156
) may prove interesting in checking that it is indeed the tail 
region of CD23 that is responsible for CD21 binding.   
Hibbert et al., (2005) suspected that on increasing the length of CD21, binding to CD23 may also 
be increased.  This is in agreement with work performed by Asokan et al., (2006) who in fact 
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showed this to be the case by performing SPR interaction between increasing lengths of CD21.   
Analysis of binding data for all three CR2 proteins (SCR 1-2, SCR 1-4 and SCR 1-15) to 
immobilized derCD23 did not fit into simple 1:1 Langmuir binding models but rather fit better to 
a two-site model.  Asokan et al., (2006) found that KD for this proposed binding model fit well, 
with a range of 0.33– 4.0 µM, 0.15–10.0 µM, and 0.25–3.5 µM for SCR 1-2, SCR 1-4, and SCR 
1-15, respectively.  Gilbert et al. (2006) have shown that differential binding effects are readily 
explained in terms of the flexibility of full length CD21. 
The novelty of my study was to show (1) how the different soluble CD23 fragments in 
circulation influence IgE synthesis and (2) the role of soluble CD21 SCR 1-2. 
We hypothesised that soluble forms of CD23 will bind CD21 and IgE with varying affinities 
depending on their size.  We have shown that as the stalk region of CD23 increases, so does the 
affinity for IgE.  We have also shown that the presence of the neck region facilitates oligomer 
formation, the stalk region stabilizes these oligomers, and that oligomeric CD23 also has a higher 
binding affinity for IgE.   
We have found that binding affinity for CD21 is not dependent on the length of the stalk region 
of CD23, but that it is most likely the tail region that is responsible for CD21 binding.  Future 
studies with full length CD21 will be able to clarify whether there is increased binding affinity of 
all CD23 fragments for CD21 on increasing the length of CD21.   
PBMCs were isolated from individuals with varying levels of serum IgE, quantified by ELISA.  
This enabled classing of patients into groups represented by risk for atopic disease.  Using flow 
cytometry analysis of the PBMC population quantified the B-cells at ~5%, with 82% of these 
being CD21
+
 B-cells.  This proved that CD21 was being expressed on the B-cell surface, an 
important finding to ensure possible interaction of membrane CD21 with both membrane and 
soluble CD23.   
Initiation of CSR to IgE was confirmed after stimulation with switch factors IL-4 and anti-CD40 
by measuring STAT-6 activation.  In future, it may also be useful to measure the CTs by RT-
PCR, revealing class switching to IgE, instead of IgE levels by ELISA.  This has been previously 
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tested by Basaki et al., (2002) and Takhar et al., (2007) and found to be a more sensitive method 
than ELISA (Alinovi et al., 2008). 
Although slight, derCD23 and sCD23 decrease IgE synthesis while exCD23 is shown to 
stimulate it.  The influence of derCD23 on IgE synthesis is unchanged upon addition of CD21 
SCR 1-2, which confirms SPR experiments showing no interaction between derCD23 and CD21 
SCR 1-2.  
As mentioned previously, the response from PBMCs in respect to IgE synthesis was low.  
Previous experiments by McCloskey et al. (2007) found that endogenous levels of soluble CD23 
were ~30 ng/mL in the supernatant of cells stimulated only with switch factors (IL-4 and anti-
CD40).  It is therefore possible that this concentration could negate effects by added recombinant 
proteins, or at the very least, decrease observed effects.  Future work should monitor endogenous 
levels of both CD23 and CD21, as we have shown that switch factors caused phosphorylation of 
STAT-6, and it is known that STAT-6 regulates CD23 expression (Haque et al., 1997).  It might 
be interesting to monitor various oligomeric states of CD23.  As we have shown, monomeric 
soluble CD23 fragments caused an opposite effect to oligomeric ones.  It is possible that the 
oligomeric state of endogenous CD23 levels may also vary with atopic risk of individual donors. 
Future work should also investigate the effect of seeding density on IgE synthesis, and perhaps 
even measure apoptosis.  Rabah and Conrad (2002) have indicated that IgE production may 
respond negatively to increasing cell density (>2500 cells/well) in culture wells.  They showed 
that, while class switching to IgE is intact, as suggested by surface IgE staining, ELISPOT 
analysis provided evidence that the differentiation of IgE committed B-cells to the plasma cell 
stage was arrested at high cell densities, and B-cells were more prone to apoptosis.  Another 
option is to use isolated populations of B-cells and T-cells and compare responses to 
recombinant proteins against those with PBMCs. 
My study confirms that CD23 and its interaction with CD21 play a central role in the regulation 
of IgE synthesis.  The mechanism by which this regulation occurs remains intensely debated.  To 
briefly recap from chapter one, two current theories exist.  The first proposes that CD23 both 
enhances IgE synthesis at low concentrations of IgE and suppresses it at high concentrations, 
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engaging in both positive and negative feedback.  This theory suggests soluble CD23 cleaved 
from the membrane of immune cells, stimulates up-regulation of IgE synthesis by the co-ligation 
of membrane IgE and CD21.  On the other hand, interaction of membrane CD23 with circulating 
IgE or IgE-allergen complexes stabilizes membrane CD23, which prevents signalling of IgE 
synthesis by unknown pathways (Hibbert et al., 2005).  A second model also proposes that IgE 
binding to membrane CD23 results in negative signalling, but does not support the positive 
signalling mediated by soluble CD23 through CD21.  Arguing that the lack of a phenotype of 
sCD23 in mice, importantly the absence of data demonstrating an interaction between murine 
sCD23 and CD21 may negate such opposition (Conrad, 2007).  This theory may too be 
supported by our derCD23 protein, which is also not shown to bind CD21 (SCR 1-2).  We have 
found evidence to support trimolecular complex formation between soluble CD23 and membrane 
CD21 and IgE, causing IgE upregulation, although this seems only to be the case with 
oligomeric CD23.  Monomeric CD23 was shown to decrease IgE synthesis.   
We have found that different soluble fragments and their oligomeric state fine tune the immune 
response.  We propose a model (figure 49) of how modulation of IgE synthesis by soluble CD23 
fragments is possible.  Here we show how soluble CD23 oligomers stimulate up-regulation of 
IgE synthesis by the co-ligation of membrane IgE and CD21.  Signalling to the nucleus will be 
delivered by both the Igα and Igβ chains of the BCR complex, and CD19 of the CD21/CD19 
complex, although these signal transduction pathways must still be elucidated.  IL-4 and CD40L 
act through STAT6 (Nelms et al., 1999) and NFκB (Annamalai et al., 1997), respectively, to 
stimulate Cε germline gene transcription and class switching to IgE, although the negative 
signalling pathway of CD23 is unknown.  On the other hand, soluble CD23 monomers, and 
specifically monomers lacking the tail portion that fail to bind CD21, bind membrane IgE and 
down-regulate IgE synthesis.  This results from a breakdown of the co-ligation of membrane IgE 
and CD21 through soluble CD23.  
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  (a)                                                                                    (b) 
Figure 49:  Proposed regulation of IgE modulation by soluble fragments of CD23: (a) soluble CD23 oligomers, 
cleaved from membrane CD23, stimulate up-regulation of IgE synthesis by the co-ligation of membrane IgE and 
CD21.  (b) soluble CD23 monomers lacking the tail portion that fail to bind CD21, bind membrane IgE and down-
regulate IgE synthesis.   
The second main hypothesis for my study was to investigate how CD21 soluble fragments could 
down-regulate IgE synthesis stimulated by soluble CD23.   
It has been suggested that soluble CD23 will stimulate IgE synthesis by binding membrane 
CD21 (Hibbert et al., 2005) and that T-cell derived CD23 can cross link B-cell derived CD21 
and increase IgE synthesis (Bonnefoy et al., 1997).  However, it has also been shown that certain 
soluble forms of CD21 can have a suppressive effect on IgE synthesis (Fremeaux-Bacchi et al., 
1998b) 
CD21 SCR 1-2 in this case was hypothesized to down-regulate IL-4 stimulated CD23 
upregulation of IgE, in the same way as the naturally occurring 135 kDa soluble CD21 form 
found to be circulating in serum (Fremeaux-Bacchi et al., 1998b).  Contrary to this, CD21 SCR 
IgE CD23 
CD21 
IgE 
CD23 
CD21 
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1-2 significantly increased the stimulatory effect mediated by exCD23 and reversed the 
inhibitory effect of sCD23 on IgE synthesis, to a stimulatory one.   
Full length CD23 is said to bind both SCR 1-2 and SCR 5-8 of CD21 (Kijimoto-Ochiai, 2002), 
permitting CD23 to simultaneously form contacts with both SCR 1-2 and SCR 5-8.  There is 
currently no evidence that derCD23 binds to SCR 5-8 alone, which opens further investigations.  
Prota et al., (2002) have stated that „flexibility between domains and the requirement of more 
than one domain for many interactions are hallmarks of many SCR-containing proteins‟, but it is 
unclear what the importance of these properties are ligand binding.  Future studies can endeavour 
to block CD21 SCR 1-2 with specific inhibitors or specific mAb‟s, on full-length CD21, or to 
construct SCR 5-8 alone.  This CD21 can subsequently be used to investigate binding activity to 
CD23 without SCR 1-2 involvement.  It would also be valuable to test the consequent effect of 
this CD21 on IgE synthesis.   
With reference to increasing IgE synthesis, future studies could investigate whether CD21 SCR 
1-2 is able to increase trimer formation in soluble CD23 fragments.  These trimeric fragments, 
possibly detected by HPLC or analytical ultracentrifugation, will cause the stimulatory effect on 
IgE synthesis by co-ligating membrane IgE and CD21 (refer to fig 14a in chapter 1).  
Investigation of interactions between CD21 SCR 5-8 and CD23 should enlighten IgE regulation 
by CD21 and CD23 interactions.   
It has been shown that several soluble receptors interact with counterpart membrane receptors to 
trigger specific biologic responses.  For example, Lecoanet-Henchoz, et al., (1995) showed that 
soluble CD23 and soluble CD16 promote the release of proinflammatory cytokines through 
binding to CD11b/CD11c on human monocytes.  The purified soluble 135 kDa form of CD21 
was not shown to induce secondary cellular events on CD23-expressing cells causing 
proinflammatory cytokine release, but this may not be the case for CD21 SCR 1-2.  It is possible 
that upon stimulation of Th2 cytokines, subsequent stimulation of IgE synthesis may occur, 
explaining the increase in IgE synthesis found in my studies.  It would therefore be valuable, in 
future studies, to monitor possible Th2 cytokine release on addition of CD21 SCR 1-2 as well as 
the release of proinflammatory cytokines.  This can be performed using multiplex kits available 
for flow cytometry.       
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It has been shown (Asokan et al., 2006) that CD21 SCR 1-2 binds IFNα in the same region as 
other ligands for CD21 (such as CD23).  It is therefore possible that recombinant CD21 SCR 1-2 
added to the cells was also able to bind IFNα.  It is possible that some genes are induced in B- 
cells by IFNα solely or preferentially through CD21 SCR 1-2.  IFNα binding may impart a BCR-
independent signal through CD21 SCR 1-2 in a similar fashion as previously described for other 
ligands.  IFNγ specifically inhibits the IgE-enhancing activity of TH-cell-line supernatants and 
inhibits the effect of IL-4 on cell proliferation and induction of DNA synthesis.    It is possible 
that IFNα behaves in a similar fashion to IFNγ, for instance, and if this is the case, binding of 
IFNα by recombinant CD21 SCR 1-2 in solution would compromise IFNα binding to its receptor 
and therefore negate the inhibitory effect of IFNα on IgE synthesis.  Each of these possibilities is 
a testable hypothesis for future experiments. 
It has been shown that IgE upregulation to some extent is caused through CD21-CD23 
interactions, (Aubry et al., 1992; Basaki et al., 2002) and therefore, down-regulation of the CD21 
gene may have some therapeutic potential for individuals with atopic risk.  We have also shown 
that CD21 is present on 82.3% of B-cells in a PBMC population stained for CD21 surface 
markers.  Preliminary investigation shows a very high response of PBMCs to siRNA directed 
against silencing CD21.  Although it has been confirmed that expression of CD21 on B-cells was 
critical in generation of immune response (Caroll and Fischer, 1997), in vitro CD21 knockdown 
may eliminate effects of endogenous CD21, and therefore allow exclusive investigation of CD23 
and recombinant CD21 SCR 1-2. 
This study also showed that derCD23 does not bind to CD21 SCR 1-2, and also marginally 
decreased IgE synthesis.  A logical hypothesis is that other, yet unidentified, signalling 
molecules associate with CD23 to carry out the negative regulation of IgE.  IgE binding to 
mouse membrane CD23 trimers (which lack the C-terminal tails that in human CD23 trimers 
bind CD21) interferes with the upregulation of IgE class switching induced by IL-4 and CD40L 
(Mossalayi et al., 1992).  This could lead to investigation of another mechanism to modulate the 
oligomeric state of CD23 and thus the activity of soluble CD23 fragments.  
Taking all the information gained in this study into account, it is evident that therapies 
recommended should involve stabilising membrane CD23, or preventing shedding of soluble 
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CD23 (eg using ADAM-10 inhibitors).  Although, proteolysis and subsequent shedding of 
membrane CD23 from the cell surface is not necessarily exclusively responsible for increased 
IgE synthesis.  Smaller fragments of soluble CD23 have been shown by me, and others 
(McCloskey et al., 2007; Sarfati et al., 1992) to suppress IgE synthesis.  Although IgE synthesis 
decreased when PBMCs were treated with metalloprotease inhibitor BB94 (inhibiting ADAM 10 
activities), it was also found that ADAM 10 was necessary for several physiological and 
pathological processes in some species.  For example, in flies, mice and worms, ADAM10 is 
required for Notch signalling (Rooke et al., 1996; Wen et al., 1997).  Therefore blocking ADAM 
10 may depend on its necessity in human homeostasis (Weskamp et al., 2006), and it is 
important to test this prior to inhibiting this protease.  Another alternative is to form antibodies 
blocking the cleavage sites on CD23.   
It will also be interesting to monitor ADAM protease activity in PBMCs from individuals with a 
high level of IgE synthesis and correlate these levels to soluble circulating CD23 fragments. and 
monitor whether there could be increased competition between these fragments and membrane 
CD23 for binding to IgE.  
Probably the most important finding in this study with relation to potential therapy for allergic 
disease is the stabilization of cell-surface CD23, which would benefit the control of allergic 
disease, and certainly warrants further investigation of CD23 as a therapeutic agent.  In support 
of this, clinical trials performed with IDEC-152 (anti-lectin-CD23) have demonstrated its 
efficacy in lowering IgE levels in atopic patients (Rosenwasser and Meng, 2005). 
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ADDENDUM A - DNA and translated protein sequence for human CD23. 
DNA: TCGGGAGAATCCAAGCAGGACCGCCATGGAGGAAGGTCAATATTCAGAGAT 204 
 +2: Start codon for CD23     M  E  E  G  Q  Y  S  E  I      9 
DNA: CGAGGAGCTTCCCAGGAGGCGGTGTTGCAGGCGTGGGACTCAGATCGTGCT 255 
 +2:  E  E  L  P  R  R  R  C  C  R  R  G  T  Q  I  V  L  26 
DNA: GCTGGGGCTGGTGACCGCCGCTCTGTGGGCTGGGCTGCTGACTCTGCTTCT 306 
 +2:  L  G  L  V  T  A  A  L  W  A  G  L  L  T  L  L  L  43 
       5’GCTACAATTGACACCACACAG-3’   exCD23 
DNA: CCTGTGGCACTGGGACACCACACAGAGTCTAAAACAGCTGGAAGAGAGGGC 357 
 +2:  L  W  H  M  D  T  T  Q  S  L  K  Q  L  E  E  R  A  60                                                  
DNA: TGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCCACCACGGTGA 408 
 +2:  A  R  N  V  S  Q  V  S  K  N  L  E  S  H  H  G  D  77 
DNA: CCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGGA 459 
 +2:  Q  M  A  Q  K  S  Q  S  T  Q  I  S  Q  E  L  E  E  94 
DNA: ACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTG 510 
 +2:  L  R  A  E  Q  Q  R  L  K  S  Q  D  L  E  L  S  W  111 
DNA: GAACCTGAACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATT 561 
 +2:  N  L  N  G  L  Q  A  D  L  S  S  F  K  S  Q  E  L  128 
DNA: GAACGAGAGGAACGAAGCTTCAGATTTGCTGGAAAGACTCCGGGAGGAGGT 612 
 +2:  N  E  R  N  E  A  S  D  L  L  E  R  L  R  E  E  V  145 
         5’(A)7CATATGGAGTTGCAGG-3’     sCD23(pET)                        
                  5’AGAGTTGCATATGTCCAGCGGC-3’    derCD23 
DNA: GACAAAGCTAAGGATGGAGTTGCAGGTGTCCAGCGGCTTTGTGTGCAACAC 663 
 +2:  T  K  L  R  M  E  L  Q  V  S  S  G  F  V  C  N  T  162 
DNA: GTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTACTACTTCGGCAA 714 
 +2:  C  P  E  K  W  I  N  F  Q  R  K  C  Y  Y  F  G  K  179 
DNA: GGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGG 765 
 +2:  G  T  K  Q  W  V  H  A  R  Y  A  C  D  D  M  E  G  196 
DNA: GCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCA 816 
 +2:  Q  L  V  S  I  H  S  P  E  E  Q  D  F  L  T  K  H  213 
DNA: TGCCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGG 867 
 +2:  A  S  H  T  G  S  W  I  G  L  R  N  L  D  L  K  G  230 
DNA: GGAGTTTATCTGGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCC 918 
 +2:  E  F  I  W  V  D  G  S  H  V  D  Y  S  N  W  A  P  247 
DNA: AGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGACTGCGTGATGATGCGGGG 969  
 +2:  G  E  P  T  S  R  S  Q  G  E  D  C  V  M  M  R  G  264 
DNA: CTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGGCGCCTGGGT 1020 
 +2:  S  G  R  W  N  D  A  F  C  D  R  K  L  G  A  W  V  281 
DNA: GTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCCGCGGA 1071 
                                             GGTTCTGCGGA  
 +2:  C  D  R  L  A  T  C  T  P  P  A  S  E  G  S  A  E  298 
DNA: GTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCC 1122 
 +2:  S  M  G  P  D  S  R  P  D  P  D  G  R  L  P  T  P  315    
          GTAAGCTTGACA (pET derCD23)                   
DNA: CTCTGCCCCTCTCCACTCTTGAGCATGGATACAGCCA    1159 
                      CTTGAGCATGGATCCAGCCA SCD23 
     CTCTGCCCCTCTCGAGTCTTGA ExCD23                                           
      S  A  P  L  H  S  *         321 
Figure A1: DNA and translated protein sequence for human CD23.  Annotated are the annealing positions of 
forward and reverse primers for derCD23 (blue), sCD23 (green) and exCD23 (red).  The reverse primer has been 
inverted.  The underlined region in the primers indicates the positions of restriction endonuclease sites.  The 
start (ATG) and stop (TGA) codons are shown in bold text within the CD23 sequence.  Adjacent numbering 
annotates the position of both cDNA (top) and protein (bottom).   
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derCD23     ATCACAGCAGCGGCCTGGTGCCGCGCGGC---------AGCCATA--TGTCCAGCGGCTT 118 
human                 GGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCCAGCGGCTT 660 
                         *   *  ***   *  *   *   **         **    *  ************* 
derCD23          CAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGGGCAGCT 238 
human CD23          CAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGGGCAGCT 780 
                    ************************************************************ 
derCD23             GGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGCCACACCGG 298 
human CD23            GGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGCCACACCGG 840 
                    ************************************************************ 
derCD23             CTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTGGATGGGAG 358 
human CD23            CTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTGGATGGGAG 900 
                   ************************************************************ 
derCD23             CCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGA 418 
human CD23            CCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGA 960 
                    ************************************************************ 
derCD23            CTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGG 478 
human CD23            CTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGG 1020 
                   ************************************************************ 
derCD23             CGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCTGCGGA 538 
human CD23            CGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCCGCGGA 1080 
                    ****************************************************** ***** 
derCD23             GTA----------AGCTTGCGGCCGCACTCGAGCA-CCACCA--CCACCACCACTGAGAT 585 
human CD23            GTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCCCTCTGCCCC 1140 
                    **              *   * **  ** *   *  ** **   ***** ** ***     
 
Figure A2:  DNA sequencing results for derCD23 in p28bderCD23His pET vector aligned with the human CD23 
sequence (accession number BC064417); human CD23 indicates the published sequence, the numbers on the 
right show the position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons 
shown in red. 
sCD23                 ACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT--ATGGAGTTGCAGGTGTCCAGCGGCTT 141 
humanCD23             GGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCCAGCGGCTT 660 
                        *    *  *  *  *  * *    *** *   ************************** 
sCD23                 TGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTACTACTTCGG 201 
humanCD23             TGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGTGCTACTACTTCGG 720 
                      ************************************************************ 
sCD23                 CAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGGGCAGCT 261 
humanCD23             CAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACATGGAAGGGCAGCT 780 
                      ************************************************************ 
sCD23                 GGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGCCACACCGG 321 
humanCD23             GGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATGCCAGCCACACCGG 840 
                      ************************************************************ 
sCD23                 CTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTGGATGGGAG 381 
humanCD23             CTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCTGGGTGGATGGGAG 900 
                      ************************************************************ 
sCD23                 CCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGA 441 
humanCD23             CCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGAGCCAGGGCGAGGA 960 
                      ************************************************************ 
sCD23                 CTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGG 501 
humanCD23             CTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCGACCGTAAGCTGGG1020 
                      ************************************************************ 
sCD23                 CGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCCGCGGA 561 
humanCD23             CGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCGAAGGTTCCGCGGA1080 
                      ************************************************************ 
sCD23                 GTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCCCTCTGCCCC 621 
humanCD23             GTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCACCCCCTCTGCCCC1140 
                      ************************************************************ 
sCD23                 TCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGC 681 
humanCD23             TCTC---------------  
 
Figure A3:  DNA sequencing results for sCD23 in p28sCD23His pET vector aligned with the human CD23 sequence 
(accession number BC064417); human CD23 indicates the published sequence, the numbers on the right show 
the position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons shown in red.                                                                  
P a g e  | 193 
 
ExCD23   --------------------------------------ATGGGCAGCAGCCATCATCATC 266 
CD23   CCCAAGACC-TCCATCCCCAGCTGGGAGGTGGGGTGCAGGCAGGTGGGGGCACTGACAAT 595 
                                        *  *  * **    **                   
ExCD23   ATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGACACCACACAGAGTCTAA 326 
CD23   CCCCCCTCTCCACTCCTCTTCTCTCCCCCTCCCCAGACTGGGACACCACACAGAGTCTAA 655 
                * * * ** ** * * * * * * ******************** 
ExCD23   AACAGCTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCC 386 
CD23   AACAGCTGGAAGAGAGGGCTGCCCGGAACGTCTCTCAAGTTTCCAAGAACTTGGAAAGCC 715 
************************************************************ 
ExCD23   ACCACGGTGACCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGG 446 
CD23   ACCACGGTGACCAGATGGCGCAGAAATCCCAGTCCACGCAGATTTCACAGGAACTGGAGG 775 
************************************************************ 
ExCD23   AACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGA 506 
CD23   AACTTCGAGCTGAACAGCAGAGATTGAAATCTCAGGACTTGGAGCTGTCCTGGAACCTGA 835 
************************************************************ 
ExCD23  ACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAG 566 
CD23   ACGGGCTTCAAGCAGATCTGAGCAGCTTCAAGTCCCAGGAATTGAACGAGAGGAACGAAG 895 
************************************************************ 
ExCD23   CTTCAGATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGG 626 
CD23   CTTCAGATTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGG 955 
************************************************************ 
ExCD23  TGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGT 686 
CD23   TGTCCAGCGGCTTTGTGTGCAACACGTGCCCTGAAAAGTGGATCAATTTCCAACGGAAGT 1015 
************************************************************ 
ExCD23  GCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACA 746 
CD23   GCTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACA 1075 
************************************************************ 
ExCD23   TGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 806 
CD23   TGGAAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 1135 
************************************************************ 
ExCD23  CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 866 
CD23   CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 1195 
************************************************************ 
ExCD23   GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 926 
CD23   GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 1255 
************************************************************ 
ExCD23  GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 986 
CD23   GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 1315 
************************************************************ 
ExCD23   ACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCG 1046 
CD23   ACCGTAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGCG 1375 
************************************************************ 
ExCD23   AAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCA 1106 
CD23   AAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCCA 1435 
************************************************************ 
ExCD23   CCCCCTCTGCCCCTCTCGAGCACCACCACCACCACCACTGA*------------------ 1147 
CD23   CCCCCTCTGCCCCTCTCCACTCTTGAGCATGGATACAGCCAGGCCCAGAGCAAGACCCTG 1495 
               ***************** *                                                                             
Figure A4: DNA sequencing results for exCD23 in p28exCD23 pET vector aligned with the human CD23 sequence 
(accession number BC064417); human CD23 indicates the published sequence, the numbers on the right show 
the position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons shown in red. 
SCR1-2                GCTGGAGCCACCCGCAGTTCGAAAAGGGTGCAGATGACGACGACAAGATTTCTTGTGGCT 162 
SCR1-2Piex_IEterm     GCTGGAGCCACCCGCAGTTCGAAAAGGGTGCAGATGACGACGACAAGATTTCTTGTGGCT 660 
HUMAN                 GCTCGGGGTTTTCTTGGCTCT----CGTCGCACCGGGGGTCCTCGGGATTTCTTGTGGCT 167 
                      *** * *     *   * **      *  ***   *  * *  *  ************** 
SCR 1-2         CTCCTCCGCCTATCCTAAATGGCCGGATTAGTTATTATTCTACCCCCATTGCTGTTGGTA 222 
SCR 1-2Piex_IEterm    CTCCTCCGCCTATCCTAAATGGCCGGATTAGTTATTATTCTACCCCCATTGCTGTTGGTA 720 
human                 CTCCTCCGCCTATCCTAAATGGCCGGATTAGTTATTATTCTACCCCCATTGCTGTTGGTA 227 
                      ************************************************************ 
SCR 1-2               CCGTGATAAGGTACAGTTGTTCAGGTACCTTCCGCCTCATTGGAGAAAAAAGTCTATTAT 282 
SCR 1-2Piex_IEterm    CCGTGATAAGGTACAGTTGTTCAGGTACCTTCCGCCTCATTGGAGAAAAAAGTCTATTAT 780 
human                 CCGTGATAAGGTACAGTTGTTCAGGTACCTTCCGCCTCATTGGAGAAAAAAGTCTATTAT 287 
                      ************************************************************ 
SCR 1-2               GCATAACTAAAGACAAAGTGGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATT 342 
SCR 1-2Piex_IEterm    GCATAACTAAAGACAAAGTGGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATT 840 
human                 GCATAACTAAAGACAAAGTGGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATT 347 
                      ************************************************************ 
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SCR 1-2               TCAATAAATATTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCT 402 
SCR 1-2Piex_IEterm    TCAATAAATATTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCT 900 
human                 TCAATAAATATTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCT 407 
                      ************************************************************ 
SCR 1-2               CTACACCCTACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTTCTCCATGA 462 
SCR 1-2Piex_IEterm    CTACACCCTACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTTCTCCATGA 960 
human                 CTACACCCTACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTTCTCCATGA 467 
                      ************************************************************ 
SCR 1-2               ACGGAAACAAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGGGCCGACACGACTACCAA 522 
SCR 1-2Piex_IEterm    ACGGAAACAAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGGGCCGACACGACTACCAA 1020 
human                 ACGGAAACAAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGGGCCGACACGACTACCAA 527 
                      ************************************************************ 
SCR 1-2               CCTGTGTAAGTGTTTTCCCTCTCGAGTGTCCAGCACTTCCTATGATCCAC--CGCTCATC 580 
SCR 1-2Piex_IEterm    CCTGTGTAAGTGTTTTCCCTCTCGAGTGTCCAGCACTTCCTATGATCCAC--CGCTCATC 1078 
human                 CCTGTGTAAGTGTTTTCCCTCTCGAGTGTCCAGCACTTCCTATGATCCACAATGGACATC 587 
                      **************************************************  ******** 
SCR 1-2               ACC--AGTGAGAACACCATCACCACCACTAAGTGATTAACCTCAGGTTATACATAT-ATT 637 
SCR 1-2Piex_IEterm    ACC--AGTGAGAACACCAYCMCCTCCACTAAGTGATTAACCTCAGGTTATACATAT-ATT 1135 
human                 ACACAAGTGAGAATGTTGGCTCCATTGCTCCAGGATTGTCTGTGACTTACAGCTGTGAAT 647 
 
 
Figure A5:  DNA sequencing results for SCR 1-2 in pIEx10-SCR 1-2 vector aligned with the human CD21 sequence 
(accession number NM001877); ‘human’ indicates the published sequence, the numbers on the right show the 
position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons shown in red.  
Deletions, insections or mutations are shown in green. 
Human CD21       CAGTAT--GTGAAGAAATTTTTTGCCCATCACCTCCCCCTATTCTCAATGGAAGACATAT 957 
SCR 5-8Prom      AGATGACGACGACAAGATTTTTTGCCCATCACCTCCCCCTATTCTCAATGGAAGACATAT 190 
                    *      **  * ******************************************** 
Human CD21       AGGCAACTCACTAGCAAATGTCTCATATGGAAGCATAGTCACTTACACTTGTGACCCGGA 1017 
SCR 5-8Prom      AGGCAACTCACTAGCAAATGTCTCATATGGAAGCATAGTCACTTACACTTGTGACCCGGA 250 
                 ************************************************************ 
human CD21       CCCAGAGGAAGGAGTGAACTTCATCCTTATTGGAGAGAGCACTCTCCGTTGTACAGTTGA 1077 
SCR 5-8Prom      CCCAGAGGAAGGAGTGGAGTTCAGCCTTATTGGAGAGAGCACTCTCCGTTGTACAGTTGA 310 
                 **************** * **** ************************************ 
human CD21       TAGTCAGAAGACTGGGACCTGGAGTGGCCCTGCCCCACGCTGTGAACTTTCTACTTCTGC 1137 
SCR 5-8Prom      TAGTCAGAAGACTGGGACCTGGAGTGGCCCTGCCCCACGCTGTGAACTTTCTACTTCTGC 370 
                 ************************************************************ 
human CD21       GGTTCAGTGTCCACATCCCCAGATCCTAAGAGGCCGAATGGTATCTGGGCAGAAAGATCG 1197 
SCR 5-8Prom      GGTTCAGTGTCCACATCCCCAGATCCTAAGAGGCCGAATGGTATCTGGGCAGAAAGATCG 430 
                 ************************************************************ 
human CD21       ATATACCTATAACGACACTGTGATATTTGCTTGCATGTTTGGCTTCACCTTGAAGGGCAG 1257 
SCR 5-8Prom      ATATACCTATAACGACACTGTGATATTTGCTTGCATGTTTGGCTTCACCTTGAAGGGCAG 490 
                 ************************************************************ 
human CD21       CAAGCAAATCCGATGCAATGCCCAAGGCACATGGGAGCCATCTGCACCAGTCTGTGAAAA 1317 
SCR 5-8Prom      CAAGCAAATCCGATGCAATGCCCAAGGCACATGGGAGCCATCTGCACCAGTCTGTGAAAA 550 
                 ************************************************************ 
human CD21       GGAATGCCAGGCCCCTCCTAACATCCTCAATGGGCAAAAGGAAGATAGACACATGGTCCG 1377 
SCR 5-8Prom      GGAATGCCAGGCCCCTCCTAACATCCTCAATGGGCAAAAGGAAGATAGACACATGGTCCG 610 
                 ************************************************************ 
human CD21       CTTTGACCCTGGAACATCTATAAAATATAGCTGTAACCCTGGCTATGTGCTGGTGGGAGA 1437 
SCR 5-8Prom      CTTTGACCCTGGAACATCTATAAAATATAGCTGTAACCCTGGCTATGTGCTGGTGGGAGA 670 
                 ************************************************************ 
human CD21       AGAATCCATACAGTGTACCTCTGAGGGGGTGTGGACACCCCCTGTACCCCAATGCAAAGT 1497 
SCR 5-8Prom      AGAATCCATACAGTGTACCTCTGAGGGGGTGTGGACACCCCCTGTACCCCAATGCAAAGT 730 
                 ************************************************************ 
human CD21       GGCAGCGTGTGAAGCTACAGGAAGGCAACTCTTGACAAAACCCCAGCACCAATTTGTTAG 1557 
SCR 5-8Prom      GGCAGCGTGTGAAGCTACAGGAAGGCAACTCTTGACAAAACCCCAGCACCAATTTGTTAG 790 
                 ************************************************************ 
human CD21       ACCAGATGTCAACTCTTCTTGTGGTGAAGGGTACAAGTTAAGTGGGAGTGTTTATCAGGA 1617 
SCR 5-8Prom      ACCAGATGTCAACTCTTCTTGTGGTGAAGGGTACAAGTTAAGTGGGAGTGTTTATCAGGA 850 
                 ************************************************************ 
human CD21       GTGTCAAGGCACAATTCCTTGGTTTATGGAGATTCGTCTTTGTAAAGAAATCACCTGCCC 1677 
SCR 5-8Prom      GTGTCAAGGCACAATTCCTTGGTTTATGGAGATTCGTCTTTGTAAAGAAATCACCTGCCC 910 
                 ************************************************************ 
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human CD21       ACCACCCCCTGTTATCTACAATGGGGCACACACCGGGAGTTCCTTAGAAGATTTTCCATA 1737 
SCR 5-8Prom      CGGGCTTCTCCTCAATTTCCGCTCATCAC-CACCATCATCACCATCACCACCACTAAGTG 969 
                     *  *   * *  * *       *** ****   *   ** *         *   *  
human CD21       TGGAACCAC-GGTCACTTACACATGTAACCCTGGGCCAG------AAAGAGGAGTGGAAT 1790 
SCR 5-8Prom      ATTAACCTCAGGTTATACATATATTTTGAATTTAATTAATTATACATATATTTATATATT 1029 
                                                     
Figure A6:  DNA sequencing results for SCR 5-8 in pIEx10-SCR 5-8 vector aligned with the human CD21 sequence 
(accession number NM001877); ‘human’ indicates the published sequence, the numbers on the right show the 
position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons shown in red.  
Deletions, insections or mutations are shown in green. 
human             TTTCTTGGCTCTC----GTCGCACCGGGGGTCCTCGGGATTTCTTGTGGCTC-TCCTCCG 175 
SCR 1-15Prom      ACCCGCAGTTCGAAAAGGGTGCAGATGACGACGACAAGATTTCATGTGGCTCCTCCTCCG 171 
                     *   * **      *  ***   *  * *  *  ****** ******** ******* 
human             CCTATCCTAAATGGCCGGATTAGTTATTATTCTACCCCCATTGCTGTTGGTACCGTGATA 235 
SCR 1-15Prom      CCTATCCTAAATGGCCGGATTAGTTATTATTCTACCCCCATTGCTGTTGGTACCGTGATA 231 
                  ************************************************************ 
human             AGGTACAGTTGTTCAGGTACCTTCCGCCTCATTGGAGAAAAAAGTCTATTATGCATAACT 295 
SCR 1-15Prom      AGGTACAGTTGTTCAGGTACCTTCCGCCTCATTGGAGAAAAAAGTCTATTATGCATAACT 291 
                  ************************************************************ 
human             AAAGACAAAGTGGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATTTCAATAAA 355 
SCR 1-15Prom      AAAGACAAAGTGGATGGAACCTGGGATAAACCTGCTCCTAAATGTGAATATTTCAATAAA 351 
                  ************************************************************ 
human             TATTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCTCTACACCC 415 
SCR 1-15Prom      TATTCTTCTTGCCCTGAGCCCATAGTACCAGGAGGATACAAAATTAGAGGCTCTACACCC 411 
                  ************************************************************ 
human             TACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTTCTCCATGAACGGAAAC 475 
SCR 1-15Prom      TACAGACATGGTGATTCTGTGACATTTGCCTGTAAAACCAACTTCTCCATGAACGGAAAC 471 
                  ************************************************************ 
human             AAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGGGCCGACACGACTACCAACCTGTGTA 535 
SCR 1-15Prom      AAGTCTGTTTGGTGTCAAGCAAATAATATGTGGGGGCCGACACGACTACCAACCTGTGTA 531 
                  ************************************************************ 
human             AGTGTTTTCCCTCTCGAGTGTCCAGCACTTCCTATGATCCACAATGGACATCACACAAGT 595 
SCR 1-15Prom      AGTGTTTTCCCTCTCGAGTGTCCAGCACTTCCTATGATCCACAATGGACATCACACAAGT 591 
                  ************************************************************ 
human             GAGAATGTTGGCTCCATTGCTCCAGGATTGTCTGTGACTTACAGCTGTGAATCTGGTTAC 655 
SCR 1-15Prom      GAGAATGTTGGCTCCATTGCTCCAGGATTGTCTGTGACTTACAGCTGTGAATCTGGTTAC 651 
                  ************************************************************ 
human             TTGCTTGTTGGAGAAAAGATCATTAACTGTTTGTCTTCGGGAAAATGGAGTGCTGTCCCC 715 
SCR 1-15Prom      TTGCTTGTTGGAGAAAAGATCATTAACTGTTTGTCTTCGGGAAAATGGAGTGCTGTCCCC 711 
                  ************************************************************ 
human             CCCACATGTGAAGAGGCACGCTGTAAATCTCTAGGACGATTTCCCAATGGGAAGGTAAAG 775 
SCR 1-15Prom      CCCACATGTGAAGAGGCACGCTGTAAATCTCTAGGACGATTTCCCAATGGGAAGGTAAAG 771 
                  ************************************************************ 
human             GAGCCTCCAATTCTCCGGGTTGGTGTAACTGCAAACTTTTTCTGTGATGAAGGGTATCGA 835 
SCR 1-15Prom      GAGCCTCCAATTCTCCGGGTTGGTGTAACTGCAAACTTTTTCTGTGATGAAGGGTATCGA 830 
                  ************************************************************ 
human             CTGCAAGGCCCACCTTCTAGTCGGTGTGTAATTGCTGGACAGGGAGTTGCTTGGACCAAA 895 
SCR 1-15Prom      CTGCAAGGCCCACCTTCTAGTCGGTGTGTAATTGCTGGACAGGGAGTTGCTTGGACCAAA 888 
                  ************************************************************ 
human             ATGCCAGTATGTGAAGAAATTTTTTGCCCATCACCTCCCCCTATTCTCAATGGAAGACAT 955 
SCR 1-15Prom      ATGCCAGTATGTGAAGAAATTTTTTGCCCATCACCTCCCCCTATTCTCAATGGGAGACAT 941 
                  ************************************************************ 
human             ATAGGCAACTCACTAGCAAATGTCTCATATGGAAGCATAGTCACTTACACTTGTGACCCG 1015 
SCR 1-15Prom      ATAGGCAACTCACTAGCAAATGTCTCATATGGAAGCATAGTCACTTACACTTGTGACCCG 998 
                  ************************************************************ 
human             GACCCAGAGGAAGGAGTGAACTTCATCCTTATTGGAGAGAGCACTCTCCGTTGTACAGTT 1075 
SCR 1-15Prom      GACCCAGAGGAAGGRKGGAACTTCATCCTT------------------------------ 1024 
                  ******************************                              
human             GGAAGCACACAGGCATGATGGCAGAAAACTTTCTATATGGAAATGAAGTCTCTTATGAAT 2336 
SCR 1-15term      GGAAGCACACAGGCATGATGGCAGAAAACTTTCTATATGGAAATGAAGTCTCTTATGAAT 203 
                  ************************************************************ 
human             GTGACCAAGGATTCTATCTCCTGGGAGAGAAAAAATTGCAGTGCAGAAGTGATTCTAAAG 2396 
SCR 1-15term      GTGACCAAGGATTCTATCTCCTGGGAGAGAAAAAATTGCAGTGCAGAAGTGATTCTAAAG 263 
                  ************************************************************ 
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human             GACATGGATCTTGGAGCGGGCCTTCCCCACAGTGCTTACGATCTCCTCCTGTGACTCGCT 2456 
SCR 1-15term      GACATGGATCTTGGAGCGGGCCTTCCCCACAGTGCTTACGATCTCCTCCTGTGACTCGCT 323 
                  ************************************************************ 
human             GCCCTAATCCAGAAGTCAAACATGGGTACAAGCTCAATAAAACACATTCTGCATATTCCC 2516 
SCR 1-15term      GCCCTAATCCAGAAGTCAAACATGGGTACAAGCTCAATAAAACACATTCTGCATATTCCC 383 
                  ************************************************************ 
human             ACAATGACATAGTGTATGTTGACTGCAATCCTGGCTTCATCATGAATGGTAGTCGCGTGA 2576 
SCR 1-15term      ACAATGACATAGTGTATGTTGACTGCAATCCTGGCTTCATCATGAATGGTAGTCGCGTGA 443 
                  ************************************************************ 
human             TTAGGTGTCATACTGATAACACATGGGTGCCAGGTGTGCCAACTTGTATCAAAAAAGCCT 2636 
SCR 1-15term      TTAGGTGTCATACTGATAACACATGGGTGCCAGGTGTGCCAACTTGTATCAAAAAAGCCT 503 
                  ************************************************************ 
human             TCATAGGGTGTCCACCTCCGCCTAAGACCCCTAACGGGAACCATACTGGTGGAAACATAG 2696 
SCR 1-15term      TCATAGGGTGTCCACCTCCGCCTAAGACCCCTAACGGGAACCATACTGGTGGAAACATAG 563 
                  ************************************************************ 
human             CTCGATTTTCTCCTGGAATGTCAATCCTGTACAGCTGTGACCAAGGCTACCTGCTGGTGG 2756 
SCR 1-15term      CTCGATTTTCTCCTGGAATGTCAATCCTGTACAGCTGTGACCAAGGCTACCTGCTGGTGG 623 
                  ************************************************************ 
human             GAGAGGCACTCCTTCTTTGCACACATGAGGGAACCTGGAGCCAACCTGCCCCTCATTGTA 2816 
SCR 1-15term      GAGAGGCACTCCTTCTTTGCACACATGAGGGAACCTGGAGCCAACCTGCCCCTCATTGTA 683 
                  ************************************************************ 
human             AAGAGGTAAACTGTAGCTCACCAGCAGATATGGATGGAATCCAGAAAGGGCTGGAACCAA 2876 
SCR 1-15term      AAGAGGTAAACTGTAGCTCACCAGCAGATATGGATGGAATCCAGAAAGGGCTGGAACCAA 743 
                  ************************************************************ 
human             GGAAAATGTATCAGTATGGAGCTGTTGTAACTCTGGAGTGTGAAGATGGGTATATGCTGG 2936 
SCR 1-15term      GGAAAATGTATCAGTATGGAGCTGTTGTAACTCTGGAGTGTGAAGATGGGTATATGCTGG 803 
                  ************************************************************ 
human             AAGGCAGTCCCCAGAGCCAGTGCCAATCGGATCACCAATGGAACCCTCCCCTGGCGGTTT 2996 
SCR 1-15term      AAGGCAGTCCCCAGAGCCAGTGCCAATCGGATCACCAATGGAACCCTCCCCTGGCGGTTT 863 
                  ************************************************************ 
human             GCAGATCCCGTTCACTTGCTCCTGTCCTTTGTGGTATTGCTGCAGGTTTGATACTTCTTA 3056 
SCR 1-15term      GCAGATCCCGTTCACTTGCTCCTGTCCTTTGTGGTATTGCTGCAGGTTTGATACTTCTTA 923 
                  ************************************************************ 
human             CCTTCTTGATTGTCATTACCTTATACGTGATATCAAAACACAGAGCACGCAATTATTATA 3116 
SCR 1-15term      CCTTCTTGATTGTCATTACCTTATACGTGATATCAAAACACAGAGCACGCAATTATTATA 983 
                  ************************************************************ 
human             CAGATACAAGCCAGAAAGAAGCTTTTCATTTAGAAGCACGAGAAGTATATTCTGTTGATC 3176 
SCR 1-15term      CAGATACAAGCCAGAAAGAAGCTTTTCATTTAGAAGCACGAGAAGTATATTCTGTTGATC 1043 
                  ************************************************************ 
human             CATACAACCCAGCCAGCTGATCAGAAGACAAACTGGTGTGTGCCTCATTGCTTGGAATTC 3236 
SCR 1-15term      CATACAACCCAGCCAGCTAAACCGGGCTTCTCCTCAATTTCCGCTCATCACCACCA--TC 1101 
                  ****************** * * *        **    *    *****  *    *  ** 
human             AGCGGAATATTGATTAGAAAGAAACTGCTCTAATATCAGCAAGTCTCTTTATATGGCCTC 3296 
SCR 1-15term      ATCACCATCACCACCACTAAGTGA 
Figure A7:  :  DNA sequencing results for SCR 1-15 in pIEx10-CD21 vector aligned with the human CD21 sequence 
(accession number NM001877); ‘human’ indicates the published sequence, the numbers on the right show the 
position in the sequence, and the asterisks indicate proper alignment.  Start and stop codons shown in red.  
Deletions, insections or mutations are shown in green. 
derCD23TriEx       CAAGCTGGACTGCCACCCGCATGTT-CGAAAAGGGTGCAGATGACGACG-ACAAGATGAG 342 
human              TTTGCTGGAAAGACTCCGGGAGGAGGTGACAAAGCTAAGGATGGAGTTGCAGGTGTCCAG 654 
                      ******  * * ** * * *    ** ** * *   ****  *  * *   *   ** 
derCD23TriEx       CGGCTTTGTGTGCAACACGTGCCCTGAACCGGAGAAGTGGATCAATTTCCAACGGAAGTG 402 
human              CGGCTTTGTGTGCAACACGTGCCCTGAACCGGAGAAGTGGATCAATTTCCAACGGAAGTG 708 
                   ************************************************************ 
derCD23TriEx       CTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACAT 462 
human              CTACTACTTCGGCAAGGGCACCAAGCAGTGGGTCCACGCCCGGTATGCCTGTGACGACAT 768 
                   ************************************************************ 
derCD23TriEx       GGATAGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 522 
human              GGA-AGGGCAGCTGGTCAGCATCCACAGCCCGGAGGAGCAGGACTTCCTGACCAAGCATG 827 
                   *** ******************************************************** 
derCD23TriEx       CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 582 
human              CCAGCCACACCGGCTCCTGGATTGGCCTTCGGAACTTGGACCTGAAGGGGGAGTTTATCT 887 
                   ************************************************************ 
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derCD23TriEx       GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 642 
human              GGGTGGATGGGAGCCACGTGGACTACAGCAACTGGGCTCCAGGGGAGCCCACCAGCCGGA 947 
                   ************************************************************ 
derCD23TriEx       GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 702 
human              GCCAGGGCGAGGACTGCGTGATGATGCGGGGCTCCGGTCGCTGGAACGACGCCTTCTGCG 1007 
                   ************************************************************ 
derCD23TriEx       ACCGTAAAGCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGC 762 
human              ACCGTAA-GCTGGGCGCCTGGGTGTGCGACCGGCTGGCCACATGCACGCCGCCAGCCAGC 1066 
                   ******* **************************************************** 
derCD23TriEx       GAAGGTTCAGCAGAACC---GGGCTTCTCCTCAATTTCCGCTCATCACCACCATCA--TC 817 
human              GAAGGTTCCGCGGAGTCCATGGGACCTGATTCAAGACCAGACCCTGACGGCCGCCTGCCC 1126 
                   ******** ** **  *   ***       ****   * *  * * **  **  *    * 
Figure A8:  DNA sequencing results for derCD23 in TriEx vector aligned with a published CD21 sequence, 
accession number NM002_002, Human CD23 indicates the published sequence, the numbers on the right show 
the position in the sequence, and the asterisks indicate proper alignment.  Start codon shown in red.  Deletions, 
insections or mutations are shown in green. 
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ADDENDUM B – Vector maps for derCD23 and sCD23  
(a)   
(b)  
Figure B1: Vector maps of the constructs used for expression of soluble CD23 from the pTriEx vector. (a) derCD23 
and (b) sCD23.   
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ADDENDUM C – Standard Curves  
 
 
Figure C1: An example of IgE standard curve used for the quantification of IgE concentrations in human plasma 
and cell SNF.  The equation obtained from a log regression curve is shown on the graph, along with the 
correlation coefficient.   
 
 
 
 
 
 
Figure C2: An example of PBMC cell viability standard curve used for the quantification of cell number.  The 
equation obtained from a linear regression curve is shown on the graph, along with the correlation coefficient. 
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ADDENDUM D   
 
 
Table D1:  IgE production from PBMCs stimulated with IL-4 (20 ng/mL) and anti-CD40 (5 µg/mL) in the presence 
of CD23 and/or CD21 for 14 days shown as a concentration (IU/mL/million cells)  
Atopic 
risk 
Donor derCD23 sCD23 exCD23 derCD23 
+ CD21 
sCD23 + 
CD21 
exCD23 + 
CD21 
 
Low A 5.32 4.66 6.53 5.08 6.71 10.25  
Low D 4.49 2.85 4.92 3.85 5.24 6.07 
 Low E 2.93 1.81 3.60 2.84 3.12 5.31 
Moderate F 3.19 2.89 3.05 3.43 3.11 3.91  
Moderate G 7.75 7.22 9.65 7.44 8.41 10.26  
Moderate I 23.97 23.21 20.82 26.62 31.86 49.49  
High J 11.84 7.24 8.65 11.20 12.51 14.79  
High K 17.30 14.38 21.38 17.11 26.67 37.50  
High L 17.30 14.38 21.38 17.11 26.67 37.50  
Hyper-IgE M 38.83 35.23 36.89 36.15 42.69 46.07  
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ADDENDUM E   
 
